Datasets:

nnul
/

PubTables-1M_OTSL-v1.1-cleaned

Modalities:

Image

Text

Formats:

Size:

Libraries:

Dataset card Data Studio Files Files and versions

xet

Community

Dataset Viewer

Auto-converted to Parquet Duplicate

Split (1)

train · 5k rows

image imagewidth (px) 208 958	text stringlengths 122 8.5k
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Patient’s serum + :</td><td rowspan="2">Patient 1 (% of lysis)</td><td rowspan="2">Patient 2 (% of lysis)</td><td rowspan="2">Patient 3 (% of lysis)</td></tr><tr><td>C5 def serum</td><td>99</td><td>95</td><td>90</td></tr><tr><td>C6 def serum</td><td>94</td><td>95</td><td>79</td></tr><tr><td>C7 def serum</td><td>100</td><td>100</td><td>96</td></tr><tr><td>C8 alpha-gamma def serum</td><td>95</td><td>87</td><td>88</td></tr><tr><td>C8 beta def serum</td><td>0</td><td>0</td><td>0</td></tr><tr><td>C8 beta def serum + human C8</td><td>99</td><td>100</td><td>94</td></tr><tr><td>C9 def serum</td><td>100</td><td>100</td><td>100</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">All n (%)</td><td colspan="2">Douala</td><td colspan="2">Yaoundé</td></tr><tr><td></td><td>n (%)</td><td>Respondent Driven Sampling weighted % (95%CI)</td><td>n (%)</td><td>Respondent Driven Sampling weighted % (95%CI)</td></tr><tr><td>Total</td><td>511 (100)</td><td>272 (100)</td><td>-</td><td>239 (100)</td><td>-</td></tr><tr><td>Age, median (IQR) (yrs)</td><td>24 (21–28)</td><td>23 (21–27)</td><td>-</td><td>25 (21–28)</td><td>-</td></tr><tr><td>18–23</td><td>238 (46.6)</td><td>142 (52.2)</td><td>57.5 (50.4–64.6)</td><td>96 (40.2)</td><td>42.2 (34.1–50.3)</td></tr><tr><td>24–29</td><td>185 (36.2)</td><td>85 (31.3)</td><td>29.7 (23.3–36.1)</td><td>100 (41.8)</td><td>42.4 (43.3–50.4)</td></tr><tr><td>30+</td><td>88 (17.2)</td><td>45 (16.5)</td><td>12.8 (8.2–17.4)</td><td>43 (18.0)</td><td>15.4 (9.1–21.8)</td></tr><tr><td>NGO/CBO service access in the past 12 months</td><td>302 (59.1)</td><td>202 (74.3)</td><td>66.1 (57.5–74.7)</td><td>100 (41.8)</td><td>33.4 (26.3–40.6)</td></tr><tr><td>HIV status: HIV+</td><td>171 (37.0)</td><td>73 (28.6)</td><td>25.7 (19.2–32.1)</td><td>98 (47.3)</td><td>44.0 (35.2–52.8)</td></tr><tr><td>Previous history of HIV testing</td><td>413 (81.6)</td><td>216 (80.6)</td><td>77.5 (71.0–84.0)</td><td>197 (82.8)</td><td>79.7 (73.5–86.0)</td></tr><tr><td colspan="6">Education</td></tr><tr><td>Primary or less</td><td>26 (5.1)</td><td>20 (7.4)</td><td>7.6 (3.9–11.3)</td><td>6 (2.5)</td><td>2.7 (.3–7.0)</td></tr><tr><td>Secondary</td><td>341 (66.7)</td><td>183 (67.3)</td><td>70.1 (63.9–76.4)</td><td>158 (66.1)</td><td>70.1 (63.0–76.9)</td></tr><tr><td>Higher than secondary</td><td>144 (28.2)</td><td>69 (25.4)</td><td>22.3 (16.6–28.0)</td><td>75 (31.4)</td><td>27.3 (20.7–33.9)</td></tr><tr><td colspan="6">Occupational status</td></tr><tr><td>Student or Apprentice</td><td>204 (39.9)</td><td>116 (42.6)</td><td>46.6 (40.0–53.2)</td><td>88 (36.8)</td><td>36.9 (29.4–44.5)</td></tr><tr><td>Employed</td><td>248 (48.5)</td><td>126 (46.3)</td><td>44.4 (37.8–50.9)</td><td>122 (51.0)</td><td>48.7 (40.6–56.8)</td></tr><tr><td>Unemployed</td><td>59 (11.6)</td><td>30 (11.0)</td><td>9.1 (5.4–12.7)</td><td>29 (12.1)</td><td>14.4 (7.9–20.8)</td></tr><tr><td>MSM Network size, median (IQR)</td><td>12 (6–25)</td><td>13 (5–25)</td><td>-</td><td>12 (6–25)</td><td>-</td></tr><tr><td>Number of male partners in last 12 months</td><td>3 (2–5)</td><td>3 (2–5)</td><td>-</td><td>3 (2–5)</td><td>-</td></tr><tr><td colspan="6">Sexual identity</td></tr><tr><td>Gay/homosexual</td><td>144 (28.2)</td><td>71 (26.1)</td><td>23.3 (17.3–29.2)</td><td>73 (30.5)</td><td>27.8 (20.5–35.0)</td></tr><tr><td>Had male and female sexual partners in past 12 months</td><td>114 (22.3)</td><td>49 (18.0)</td><td>20.0 (14.2–25.8)</td><td>65 (27.2)</td><td>28.5 (21.1–36.0)</td></tr><tr><td colspan="6">Relationship status:</td></tr><tr><td>Single</td><td>425 (84.2)</td><td>226 (84.6)</td><td>85.6 (80.5–90.6)</td><td>194 (83.3)</td><td>87.3 (82.2–92.4)</td></tr><tr><td>In a relationship or married</td><td>80 (15.8)</td><td>41 (15.4)</td><td>14.4 (9.4–19.5)</td><td>39 (16.7)</td><td>12.7 (7.6–17.8)</td></tr><tr><td>Inconsistent condom use with casual partners in the past 12 months</td><td>207 (40.5)</td><td>112 (41.2)</td><td>38.8 (31.8–45.9)</td><td>96 (40.2)</td><td>38.4 (31.3–45.6)</td></tr><tr><td>STI symptoms in the past 12 months</td><td>175 (34.6)</td><td>80 (29.9)</td><td>31.0 (23.9–38.2)</td><td>95 (39.9)</td><td>39.2 (31.8–46.5)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Mn group</td><td>N</td><td>Semen volume (ml)</td><td>Sperm density (×106/ml)</td><td>Sperm viability (%)</td><td>Progressive motility (%)</td><td>Normal morphology (%)*</td></tr><tr><td><20%</td><td>234</td><td>2.6 (1.1)</td><td>70.9 (51.9)</td><td>71.4 (12.5)</td><td>49.1 (13.9)</td><td>46.2 (17.6)a</td></tr><tr><td>20–39%</td><td>232</td><td>2.5 (1.1)</td><td>69.9 (37.4)</td><td>69.2 (13.6)</td><td>47.0 (14.2)</td><td>41.9 (13.6)b</td></tr><tr><td>40–59%</td><td>241</td><td>2.4 (1.1)</td><td>77.0 (44.6)</td><td>69.3 (14.8)</td><td>47.6 (13.9)</td><td>43.0 (15.4)a,b</td></tr><tr><td>60–79%</td><td>236</td><td>2.4 (1.0)</td><td>73.1 (40.0)</td><td>69.8 (12.2)</td><td>47.0 (11.8)</td><td>43.0 (15.2)a,b</td></tr><tr><td>≥80%</td><td>236</td><td>2.5 (1.0)</td><td>69.9 (37.3)</td><td>69.9 (11.6)</td><td>45.7 (11.4)</td><td>42.6 (16.7)a,b</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>MO</td><td>MO Sequence (59-39)</td><td>RT-PCR primers (59-39)</td><td>Reference</td></tr><tr><td>ntn1a SBMO</td><td>ATGATGGACTTACCGACACATTCGT</td><td>ntn1a pre-mRNA (F1 X R1) ntn1a mRNA (F1 X R2) F1: CTTTCGGAGACGAAAACGAG R1: GTAGGCGCTTTCCAGAGATG R2: CTTTGCAGTAGTGGCAGTGG</td><td>Suli et al. 2007 [17]; Suli 2006 [26]</td></tr><tr><td>ntn1a TBMO</td><td>CGCCTTCCTCAGCCTCTCCTGTGCT</td><td>n/a</td><td>n/a</td></tr><tr><td>ntn1a 5-mispair MO</td><td>ATcATGcACTTAgCGACAgATTgGT (lower case letters are mismatches)</td><td>n/a</td><td>n/a</td></tr><tr><td>ntn1b SBMO</td><td>TAGTTTAGAAATGACTCACCGACAC</td><td>ntn1b pre-mRNA (F1 X R1) ntn1b mRNA (F1 X R2) F1: CCGACATCAAAGTGACCTTC R1: GAGCCATCCACACTTGTTGA R2: TGCACGTCGGTGTGATATAG</td><td>complementary to ntn1b exon 1/ intron 1–2 boundary</td></tr><tr><td>ntn2 SBMO</td><td>TTTCGTGACTTACGTAAGCACTCGT</td><td>net2E1F: TCCGGAGTGTGATCGATGTA net2E3R: CCTTTAGCACAGCGGTTACA</td><td>netrin2 SBMO3, Suli et al., 2007 [17]</td></tr><tr><td>dcc TBMO</td><td>GAATATCTCCAGTGACGCAGCCCAT</td><td>n/a</td><td>Suli et al., 2006 [26]</td></tr><tr><td>dscam SBMO</td><td>AAAGATCCTGAAATGCTCACCGGCC</td><td>dscam pre-mRNA (e2F X i2R) dscam mRNA (e2F X e3R) e2F: TTCTCAGTGAAGACCTACATTCC i2R: ATTCTGGGTAAGAGCTGTGA e3R: AATGCACTTGAAGACCGCTA</td><td>complementary to dscam exon2/ intron 2–3 boundary</td></tr><tr><td>dscam TBMO</td><td>CGCTCCTTTCAATCTCCAAACTAAG</td><td>n/a</td><td>DS2M, Yimlamai et al., 2005 [25]</td></tr><tr><td>standard control TBMO</td><td>CCTCTTACCTCAGTTACAATTTATA</td><td>n/a</td><td>Gene Tools https://store2.gene-tools.com/ node/7</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Bat species</td><td>Diet</td><td>Bacteria</td><td>Cavity</td><td>AMI</td><td>CAZ</td><td>CRO</td><td>CIP</td><td>CLO</td><td>DOX</td><td>GEN</td><td>IPM</td><td>AMC</td><td>AMP</td><td>CFL</td></tr><tr><td>Mimon bennetti</td><td>CAR</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Artibeus fimbriatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus fimbriatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus lituratus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus obscurus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>R</td><td>R</td></tr><tr><td>Platyrrhinus lineatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Diphylla ecaudata</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Molossus molossus</td><td>INS</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Anoura caudifer</td><td>NEC</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>shPlac1/Scr</td><td>shCxcl1/Scr</td></tr><tr><td>CD68</td><td>−4.2</td><td>−4.2</td></tr><tr><td>Cxcl1</td><td>−67</td><td>−4.0</td></tr><tr><td>Ly6a</td><td>−4.3</td><td>−3.1</td></tr><tr><td>Plau</td><td>−7.1</td><td>−7.3</td></tr><tr><td>Rgs16</td><td>−7.7</td><td>−3.2</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>WT infected/WT uninfected</td><td>t-test</td><td>wntD uninfected/WT uninfected</td><td>t-test</td><td>wntD infected/WT infected</td><td>t-test</td></tr><tr><td>Cecropin C</td><td>652.54</td><td>0.003</td><td>12.16</td><td>0.2</td><td>0.70</td><td>0.01</td></tr><tr><td>edin</td><td>394.73</td><td>0.008</td><td>15.36</td><td>0.02</td><td>5.14</td><td>0.00001</td></tr><tr><td>IM23</td><td>166.01</td><td>0.04</td><td>10.14</td><td>0.0009</td><td>0.98</td><td>0.9</td></tr><tr><td>CG6639</td><td>131.72</td><td>0.002</td><td>1.15</td><td>0.8</td><td>0.21</td><td>0.0002</td></tr><tr><td>Diptericin B</td><td>90.56</td><td>0.005</td><td>4.36</td><td>0.02</td><td>1.04</td><td>0.6</td></tr><tr><td>Attacin D</td><td>88.19</td><td>0.0004</td><td>3.65</td><td>0.008</td><td>1.87</td><td>0.004</td></tr><tr><td>Attacin B</td><td>57.37</td><td>0.0009</td><td>3.85</td><td>0.003</td><td>1.04</td><td>0.3</td></tr><tr><td>Attacin A</td><td>55.71</td><td>0.007</td><td>4.70</td><td>0.02</td><td>1.67</td><td>0.004</td></tr><tr><td>Defensin</td><td>44.85</td><td>0.001</td><td>2.92</td><td>0.008</td><td>1.30</td><td>0.01</td></tr><tr><td>Turandot M</td><td>41.93</td><td>0.03</td><td>1.40</td><td>0.5</td><td>1.68</td><td>0.04</td></tr><tr><td>CG30098</td><td>33.55</td><td>0.01</td><td>1.33</td><td>0.08</td><td>1.55</td><td>0.2</td></tr><tr><td>Cecropin B</td><td>23.08</td><td>0.01</td><td>1.21</td><td>0.2</td><td>0.97</td><td>0.8</td></tr><tr><td>Attacin C</td><td>20.70</td><td>0.008</td><td>1.90</td><td>0.09</td><td>1.09</td><td>0.4</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td>2/3</td><td>3/3</td><td>2/4</td><td>3/4</td><td>4/4</td></tr><tr><td rowspan="4">Frontal Plaque Density</td><td>None</td><td>0 (0%)</td><td>1 (0.4%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>1 (4.5%)</td><td>4 (1.7%)</td><td>0 (0%)</td><td>0 (0%)</td><td>1 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>28 (21.4%)</td><td>1 (7.7%)</td><td>11 (4.7%)</td><td>2 (3.3%)</td></tr><tr><td>Frequent</td><td>16 (72.7%)</td><td>198 (85.7%)</td><td>12 (92.3%)</td><td>224 (95.3%)</td><td>57 (96.7%)</td></tr><tr><td rowspan="4">Temporal Plaque Density</td><td>None</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>1 (4.5%)</td><td>6 (2.6%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>30 (13.1%)</td><td>1 (7.7%)</td><td>15 (6.4%)</td><td>1 (1.7%)</td></tr><tr><td>Frequent</td><td>16 (72.7%)</td><td>193 (84.3%)</td><td>12 (92.3%)</td><td>221 (93.6%)</td><td>59 (98.3%)</td></tr><tr><td rowspan="4">Parietal Plaque Density</td><td>None</td><td>0 (0%)</td><td>2 (0.9%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>0 (0%)</td><td>3 (1.3%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>22 (9.6%)</td><td>0 (0%)</td><td>6 (3%)</td><td>3 (5%)</td></tr><tr><td>Frequent</td><td>17 (77.3%)</td><td>201 (88.2%)</td><td>13 (100%)</td><td>229 (97%)</td><td>56 (95%)</td></tr><tr><td rowspan="4">Hippocampal Plaque Density</td><td>None</td><td>6 (27.3%)</td><td>20 (8.8%)</td><td>1 (7.7%)</td><td>4 (1.7%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>6 (27.3%)</td><td>54 (23.7%)</td><td>3 (23.1%)</td><td>28 (11.9%)</td><td>5 (8.3%)</td></tr><tr><td>Moderate</td><td>7 (31.8%)</td><td>81 (35.5%)</td><td>3 (23.1%)</td><td>108 (46%)</td><td>22 (36.7%)</td></tr><tr><td>Frequent</td><td>3 (13.6%)</td><td>73 (32%)</td><td>6 (46.1%)</td><td>95 (40.4%)</td><td>33 (55%)</td></tr><tr><td rowspan="4">Entorhinal Plaque Density</td><td>None</td><td>1 (4.5%)</td><td>8 (3.5%)</td><td>0 (0%)</td><td>3 (1.3%)</td><td>1 (1.7%)</td></tr><tr><td>Sparse</td><td>5 (22.7%)</td><td>14 (6.1%)</td><td>2 (15.4%)</td><td>3 (1.3%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>4 (18.2%)</td><td>75 (32.8%)</td><td>2 (15.4%)</td><td>59 (25%)</td><td>10 (16.7%)</td></tr><tr><td>Frequent</td><td>12 (54.5%)</td><td>132 (57.6%)</td><td>9 (69.2%)</td><td>171 (72.4%)</td><td>49 (81.7%)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="3">Sample 3</td><td colspan="3">Sample 4</td></tr><tr><td></td><td>Mean (SD)</td><td>Omega</td><td>Test-Retest</td><td>Mean (SD)</td><td>Omega</td><td>Test-Retest</td></tr><tr><td>Enhance</td><td>60.03 (8.38)</td><td>0.91</td><td>0.65</td><td>63.32 (6.81)</td><td>0.89</td><td>0.88</td></tr><tr><td>Divert</td><td>27.43 (4.10)</td><td>0.73</td><td>0.57</td><td>27.41 (4.06)</td><td>0.78</td><td>0.80</td></tr><tr><td>Worsen</td><td>30.80 (9.53)</td><td>0.90</td><td>0.70</td><td>25.76 (7.92)</td><td>0.87</td><td>0.78</td></tr><tr><td>Inauthentic</td><td>32.66 (7.03)</td><td>0.83</td><td>0.74</td><td>31.16 (6.95)</td><td>0.79</td><td>0.82</td></tr><tr><td>Conceal</td><td>23.26 (4.91)</td><td>0.80</td><td>0.69</td><td>24.37 (5.30)</td><td>0.82</td><td>0.84</td></tr><tr><td>Enhance-SF</td><td>23.83 (3.59)</td><td>0.82</td><td>0.55</td><td>25.45 (3.05)</td><td>0.84</td><td>0.82</td></tr><tr><td>Divert-SF</td><td>23.70 (3.70)</td><td>0.72</td><td>0.60</td><td>23.65 (3.63)</td><td>0.77</td><td>0.82</td></tr><tr><td>Worsen-SF</td><td>14.20 (4.67)</td><td>0.80</td><td>0.60</td><td>11.54 (3.92)</td><td>0.79</td><td>0.82</td></tr><tr><td>Inauthentic-SF</td><td>18.05 (4.18)</td><td>0.78</td><td>0.69</td><td>17.23 (4.09)</td><td>0.72</td><td>0.75</td></tr><tr><td>Conceal-SF</td><td>20.03 (4.50)</td><td>0.79</td><td>0.63</td><td>20.85 (4.74)</td><td>0.82</td><td>0.83</td></tr><tr><td>Enhance-VSF</td><td>15.83 (2.55)</td><td>0.80</td><td>0.50</td><td>16.91 (2.22)</td><td>0.82</td><td>0.78</td></tr><tr><td>Divert-VSF</td><td>15.79 (2.71)</td><td>0.66</td><td>0.63</td><td>15.53 (2.62)</td><td>0.70</td><td>0.78</td></tr><tr><td>Worsen-VSF</td><td>9.79 (3.26)</td><td>0.72</td><td>0.55</td><td>8.21 (2.89)</td><td>0.72</td><td>0.83</td></tr><tr><td>Inauthentic-VSF</td><td>11.77 (3.02)</td><td>0.77</td><td>0.65</td><td>11.45 (3.09)</td><td>0.74</td><td>0.68</td></tr><tr><td>Conceal-VSF</td><td>13.64 (3.29)</td><td>0.79</td><td>0.61</td><td>14.46 (3.43)</td><td>0.80</td><td>0.72</td></tr><tr><td>H</td><td>31.58 (6.16)</td><td>0.73</td><td></td><td>33.32 (6.42)</td><td>0.73</td><td></td></tr><tr><td>E</td><td>34.21 (6.34)</td><td>0.75</td><td></td><td>34.57 (6.45)</td><td>0.75</td><td></td></tr><tr><td>X</td><td>32.59 (6.86)</td><td>0.83</td><td></td><td>31.60 (7.56)</td><td>0.85</td><td></td></tr><tr><td>A</td><td>31.33 (6.50)</td><td>0.79</td><td></td><td>33.17 (6.87)</td><td>0.82</td><td></td></tr><tr><td>C</td><td>35.67 (6.45)</td><td>0.81</td><td></td><td>33.86 (6.86)</td><td>0.82</td><td></td></tr><tr><td>O</td><td>32.12 (6.76)</td><td>0.78</td><td></td><td>34.96 (6.64)</td><td>0.76</td><td></td></tr><tr><td>SEA</td><td>20.08 (5.06)</td><td>0.89</td><td></td><td>19.22 (4.85)</td><td>0.84</td><td></td></tr><tr><td>OEA</td><td>21.56 (4.28)</td><td>0.84</td><td></td><td>21.32 (4.19)</td><td>0.85</td><td></td></tr><tr><td>UOE</td><td>21.20 (4.78)</td><td>0.84</td><td></td><td>20.05 (4.52)</td><td>0.77</td><td></td></tr><tr><td>ROE</td><td>19.13 (5.76)</td><td>0.90</td><td></td><td>18.50 (4.72)</td><td>0.82</td><td></td></tr><tr><td>TEIQue-SF total score</td><td>141.78 (21.43)</td><td>0.87</td><td></td><td></td><td></td><td></td></tr><tr><td>Emotion Management</td><td></td><td></td><td></td><td>41.21 (7.24)</td><td>0.73</td><td></td></tr><tr><td>Relationship Skills</td><td></td><td></td><td></td><td>49.70 (6.86)</td><td>0.69</td><td></td></tr><tr><td>Social Competence</td><td></td><td></td><td></td><td>50.26 (10.32)</td><td>0.85</td><td></td></tr><tr><td>Empathy</td><td></td><td></td><td></td><td>47.31 (7.48)</td><td>0.80</td><td></td></tr><tr><td>Extrinsic Affect Improving</td><td>23.45 (3.56)</td><td>0.86</td><td>0.64</td><td>22.40 (4.44)</td><td>0.84</td><td></td></tr><tr><td>Extrinsic Affect Worsening</td><td>5.83 (2.49)</td><td>0.80</td><td>0.47</td><td>4.55 (1.86)</td><td>0.75</td><td></td></tr><tr><td>Intrinsic Affect Improving</td><td>20.08 (4.92)</td><td>0.84</td><td>0.61</td><td>19.52 (4.85)</td><td>0.79</td><td></td></tr><tr><td>Intrinsic Affect Worsening</td><td>9.48 (4.03)</td><td>0.89</td><td>0.62</td><td>8.99 (3.70)</td><td>0.85</td><td></td></tr><tr><td>PA</td><td>34.21 (7.60)</td><td>0.89</td><td>0.70</td><td>32.02 (7.09)</td><td>0.86</td><td></td></tr><tr><td>NA</td><td>23.41 (7.75)</td><td>0.87</td><td>0.55</td><td>26.00 (7.56)</td><td>0.85</td><td></td></tr><tr><td>Life Satisfaction</td><td>24.39 (6.59)</td><td>0.89</td><td>0.76</td><td>23.42 (6.55)</td><td>0.86</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Categorical</td><td>Control</td><td>Cases</td><td>OR (95% CI)</td><td>Chi-Square/Fisher</td></tr><tr><td>Excessive maternal weight gain (>30 lbs)</td><td>62/119 (52.1%)</td><td>31/44 (70.5%)</td><td>2.2 (1.05–4.6)</td><td>0.0356</td></tr><tr><td>Persistent fetal head malpresentation</td><td>15/128 (11.7%)</td><td>14/52 (26.9%)</td><td>2.8 (1.23–6.28)</td><td>0.0119</td></tr><tr><td>Gestational diabetes</td><td>6/123 (4.9%)</td><td>9/52 (17.3%)</td><td>4.1 (1.37–2.15)</td><td>0.0073</td></tr><tr><td>Maternal obesity at the beginning of pregnancy</td><td>29/119 (24.3%)</td><td>10/44 (22.7%)</td><td>0.9 (0.4–2.07)</td><td>0.8273</td></tr><tr><td>Maternal obesity at end of pregnancy</td><td>59/122 (48.4%)</td><td>27/47 (57.4%)</td><td>1.4 (0.73–0.84)</td><td>0.2897</td></tr><tr><td>Oxytocin administration</td><td>78/131 (59.5%)</td><td>41/52 (78.9%)</td><td>2.5 (1.19–5.37)</td><td>0.0135</td></tr><tr><td>Tachysystole</td><td>38/87 (43.7%)</td><td>37/50 (74%)</td><td>3.7 (1.71–7.85)</td><td>0.0006</td></tr><tr><td>Occiput anterior delivery position</td><td>106/129 (82.2%)</td><td>25/52 (48.1%)</td><td>4.9773</td><td>0.0001</td></tr><tr><td>Epidural administered</td><td>117/131 (89.3%)</td><td>50/52 (96.2%)</td><td>3 (0.66–13.65)</td><td>0.2434</td></tr><tr><td>Infant clavicle fracture</td><td>0/130 (0%)</td><td>5/52 (9.6%)</td><td>30.2 (1.64–557.01) </td><td>0.0033 </td></tr><tr><td>Infant humerus fracture</td><td>0/130 (0%)</td><td>2/52 (3.9%)</td><td>12.9 (0–273.83) </td><td>0.1610 </td></tr><tr><td>History of difﬁcult delivery</td><td>5/80 (6.3%)</td><td>3/27 (11.1%)</td><td>1.9 (0.42–8.43)</td><td>0.4133</td></tr><tr><td>History of fetal malpresentation</td><td>1/82 (1.2%)</td><td>1/27 (3.7%)</td><td>3.1 (0.19–51.58)</td><td>0.4358</td></tr><tr><td>Macrosomia</td><td>0/131 (0%)</td><td>4/52 (7.7%)</td><td>24.4 (1.29–461.7) *</td><td>0.0120</td></tr><tr><td>Pre-eclampsia</td><td>12/127 (9.5%)</td><td>1/52 (1.9%)</td><td>0.2 (0.02–1.48)</td><td>0.1123</td></tr><tr><td>Prostaglandin administration</td><td>19/126 (15.1%)</td><td>5/52 (9.6%)</td><td>0.6 (0.21–1.7)</td><td>0.4698</td></tr><tr><td>Shoulder Dystocia</td><td>3/132 (2.2%)</td><td>33/51 (64.7%)</td><td>78.8 (21.9–283.72)</td><td><0.0001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Variables</td><td>Mean</td><td>Median</td><td>Std. Deviation</td><td>25 Percentiles</td><td>75 Percentiles</td><td>Min</td><td>Max</td></tr><tr><td colspan="8">Dependent Variable</td></tr><tr><td>Log of IPO Net Proceeds</td><td>1.51</td><td>1.52</td><td>0.34</td><td>1.27</td><td>1.73</td><td>0.39</td><td>2.32</td></tr><tr><td colspan="8">Explanatory Variables</td></tr><tr><td>Healthcare</td><td>0.16</td><td>0.00</td><td>0.83</td><td>0.00</td><td>0.00</td><td>0.00</td><td>7.00</td></tr><tr><td>Genomic</td><td>0.21</td><td>0.00</td><td>0.79</td><td>0.00</td><td>0.00</td><td>0.00</td><td>6.00</td></tr><tr><td>Biotechnology</td><td>1.37</td><td>1.00</td><td>1.37</td><td>0.00</td><td>2.00</td><td>0.00</td><td>6.00</td></tr><tr><td>Regulatory</td><td>0.90</td><td>1.00</td><td>0.99</td><td>0.00</td><td>1.00</td><td>0.00</td><td>4.00</td></tr><tr><td colspan="8">Control Variables</td></tr><tr><td>Log of Number of Employees</td><td>2.11</td><td>2.00</td><td>0.63</td><td>1.73</td><td>2.42</td><td>0.00</td><td>3.97</td></tr><tr><td>Log of Number of Shares Locked Up</td><td>4.52</td><td>6.67</td><td>3.32</td><td>0.00</td><td>7.09</td><td>0.00</td><td>7.71</td></tr><tr><td>Log of Underwriter Reputation</td><td>0.86</td><td>0.91</td><td>0.17</td><td>0.85</td><td>0.96</td><td>0.04</td><td>0.96</td></tr><tr><td>Gross Spread</td><td>0.09</td><td>0.09</td><td>0.03</td><td>0.07</td><td>0.10</td><td>0.00</td><td>0.20</td></tr><tr><td>Hot Issue</td><td>0.35</td><td>0.00</td><td>0.48</td><td>0.00</td><td>1.00</td><td>0.00</td><td>1.00</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Samples Code</td><td>Characteristics</td><td>Merchandising</td></tr><tr><td>M1</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M2</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M3</td><td>Italy 100% (Sicily-Apulia)</td><td>packed</td></tr><tr><td>M4</td><td>EVOO-Extracted from Mediterranean Olives-Packed in Italy</td><td>packed</td></tr><tr><td>M5</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M6</td><td>Italy 100% (Sicily)</td><td>packed</td></tr><tr><td>M7</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M8</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M9</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M10</td><td>Italy 100%</td><td>unpacked</td></tr><tr><td>M11</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M12</td><td>Italy 100%</td><td>unpacked</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td rowspan="2">I Group n = 28</td><td rowspan="2">II Group n = 23</td><td rowspan="2">III Group n = 22</td><td rowspan="2">IV Group n = 22</td><td rowspan="2">Statistical signiﬁcance between groups</td></tr><tr><td>PC 20</td><td>IL-1β (pg/ml)</td><td>598±210</td><td>562±183</td><td>606±197</td><td>659±302</td><td>n.s</td></tr><tr><td rowspan="2">LPS</td><td>IL-6 (pg/ml)</td><td>807±219</td><td>730±87</td><td>797±84</td><td>946±41</td><td>n.s</td></tr><tr><td>TNFα (pg/ml)</td><td>770±391</td><td>387±259</td><td>444±44</td><td>954±79</td><td>n.s</td></tr><tr><td>PC 100</td><td>IL-1β (pg/ml)</td><td>710±210</td><td>597±95</td><td>434±45</td><td>702±220</td><td>I vs III; p<0.03</td></tr><tr><td rowspan="8">LPS</td><td>IL-6 (pg/ml)</td><td>824±188</td><td>670±77.3</td><td>795±48</td><td>934±44</td><td>n.s</td></tr><tr><td>TNFα (pg/ml)</td><td>831±378</td><td>420±379</td><td>596±423</td><td>966±28</td><td>n.s</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs III; p<0.001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs IV; p<0.0001</td></tr><tr><td>IL-1β (pg/ml)</td><td>1 399±85</td><td>1270±80.7</td><td>992±89</td><td>685±27.0</td><td>II vs III; p<0.0004</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II vs IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>III vs IV; p<0.0002</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs II; p<0.0002</td></tr><tr><td rowspan="6">LPS (C)</td><td>IL-6 (pg/ml)</td><td>1218±127.7</td><td>899±73.9</td><td>781.3±91.8</td><td>646±59.0</td><td>I vs III, IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II versus IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs III, IV; p< 0.0001</td></tr><tr><td>TNFα (pg/ml)</td><td>2 336.2±342</td><td>2075±164.4</td><td>1265±86.7</td><td>852.6±74.0</td><td>II vs III; p<0.0003</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II vs IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>III vs IV; p<0.04</td></tr><tr><td rowspan="3">PC100 (C)</td><td>IL-1β (pg/ml)</td><td><1</td><td><1</td><td><2</td><td><3</td><td></td></tr><tr><td>IL-6 (pg/ml)</td><td><2</td><td><2</td><td><3</td><td><3</td><td></td></tr><tr><td>TNFα (pg/ml)</td><td><20</td><td><10</td><td><20</td><td><4</td><td></td></tr><tr><td rowspan="3">Cells (C)</td><td>IL-1β (pg/ml)</td><td><2</td><td><2</td><td><2</td><td><2</td><td></td></tr><tr><td>IL-6 (pg/ml)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TNFα (pg/ml)</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Group</td><td colspan="2">Testis</td><td colspan="2">Ovary</td><td colspan="2">Testis-IP</td></tr><tr><td>miRs#</td><td>mirs#</td><td>miRs#</td><td>mirs#</td><td>miRs#</td><td>mirs#</td></tr><tr><td>gp1aa</td><td>238</td><td>169</td><td>341</td><td>212</td><td>195</td><td>157</td></tr><tr><td>gp1bb</td><td>18</td><td>12</td><td>32</td><td>22</td><td>20</td><td>13</td></tr><tr><td>gp2ac</td><td>11</td><td>11</td><td>28</td><td>26</td><td>4</td><td>4</td></tr><tr><td>gp2bd</td><td>69</td><td>53</td><td>122</td><td>111</td><td>66</td><td>64</td></tr><tr><td>gp3ae</td><td>220</td><td>192</td><td>490</td><td>397</td><td>282</td><td>251</td></tr><tr><td>gp3bf</td><td>375</td><td>340</td><td>261</td><td>218</td><td>93</td><td>84</td></tr><tr><td>gp4ag</td><td>951</td><td>844</td><td>1868</td><td>1735</td><td>2525</td><td>2415</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Age group (year)</td><td>Total no.</td><td>Positive no. (%)</td></tr><tr><td><0.5</td><td>92</td><td>86 (93.5)</td></tr><tr><td>0.5–1</td><td>94</td><td>69 (73.4)</td></tr><tr><td>2</td><td>94</td><td>78 (83.0)</td></tr><tr><td>3</td><td>94</td><td>77 (81.9)</td></tr><tr><td>4</td><td>93</td><td>75 (80.6)</td></tr><tr><td>5</td><td>91</td><td>75 (82.4)</td></tr><tr><td>6</td><td>90</td><td>77 (85.6)</td></tr><tr><td>7</td><td>94</td><td>77 (81.9)</td></tr><tr><td>8</td><td>95</td><td>76 (80.0)</td></tr><tr><td>Total</td><td>837</td><td>690 (82.4)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Substance</td><td>GothiaTek® ML</td><td>Average level 2009</td></tr><tr><td>Nitrite</td><td>7.0 ppm</td><td>2.0 ppm</td></tr><tr><td>TSNAs (total)</td><td>10.0 ppm</td><td>1.6 ppm</td></tr><tr><td>N-Nitrosodimethylamine (NDMA)</td><td>10.0 ppb</td><td>0.7 ppb</td></tr><tr><td>Benzo(a)pyrene (B(a)P)</td><td>20.0 ppb</td><td>1.1 ppb</td></tr><tr><td>Lead</td><td>2.0 ppm</td><td>0.3 ppm</td></tr><tr><td>Cadmium</td><td>1 ppm</td><td>0.6 ppm</td></tr><tr><td>Arsenic</td><td>0.5 ppm</td><td>0.1 ppm</td></tr><tr><td>Nickel</td><td>4.5 ppm</td><td>1.3 ppm</td></tr><tr><td>Chromium</td><td>3.0 ppm</td><td>0.8 ppm</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Line</td><td>Cells/mm2</td><td>P (line)</td><td>P (type)</td><td>Cell layers</td><td>P (line)</td><td>P (type)</td></tr><tr><td>Wild type</td><td>6.192</td><td></td><td></td><td>27.53</td><td></td><td></td></tr><tr><td>SlARF9-OE-4</td><td>5.676</td><td>ns</td><td rowspan="2">ns</td><td>24.39</td><td></td><td rowspan="2"></td></tr><tr><td>SlARF9-OE-5</td><td>5.395</td><td>ns</td><td>23.96</td><td></td></tr><tr><td>SlARF9-RNAi-1</td><td>7.391</td><td>ns</td><td rowspan="4"></td><td>36.03</td><td></td><td rowspan="4"></td></tr><tr><td>SlARF9-RNAi-6</td><td>7.307</td><td>ns</td><td>32.85</td><td></td></tr><tr><td>SlARF9-RNAi-9</td><td>7.241</td><td>ns</td><td>34.40</td><td></td></tr><tr><td>SlARF9-RNAi-12</td><td>9.755</td><td></td><td>34.13</td><td>*</td></tr><tr><td>Maximum SED</td><td>1.1514</td><td></td><td></td><td>2.034</td><td></td><td></td></tr><tr><td>Degrees of freedom</td><td>49</td><td></td><td></td><td>50</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Biomarker</td><td>RR</td><td>95 % CI</td><td>Hedges’g</td><td>95% CrI</td><td>PPPV</td><td>Rank</td></tr><tr><td>AVC</td><td>1.19</td><td>1.05–1.36</td><td>0.08</td><td>0.01 to 0.13</td><td>0.010</td><td>2</td></tr><tr><td>Midwall ﬁbrosis</td><td>2.88</td><td>1.12–7.39</td><td>0.11</td><td>−0.34 to 0.67</td><td>0.456</td><td>4</td></tr><tr><td>LGE%</td><td>1.05</td><td>1.01–1.10</td><td>0.016</td><td>0.01 to 0.02</td><td><0.0001</td><td>1</td></tr><tr><td>ECV</td><td>1.68</td><td>1.17–2.41</td><td>0.15</td><td>−0.06 to 0.44</td><td>0.134</td><td>3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Group</td><td colspan="3">Resistive Index before sildenafil</td><td colspan="3">Resistive Index after sildenafil</td></tr><tr><td>Control</td><td>Breath hold</td><td>Hyperventilation</td><td>Control</td><td>Breath hold</td><td>Hyperventilation</td></tr><tr><td>Normal</td><td>0.56 ± 0.02</td><td>0.51 ± 0.02</td><td>0.7 ± 0.03</td><td>0.58 ± 0.02</td><td>0.49 ± 0.02</td><td>0.7 ± 0.02</td></tr><tr><td>DM</td><td>0.6 ± 0.02</td><td>0.53 ± .02</td><td>0.71 ± 0.02</td><td>0.6 ± .015</td><td>0.53 ± .02</td><td>0.72 ± .018</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Diagnostic criteria</td><td colspan="2">Total (5959)</td><td colspan="2">Male (2451)</td><td colspan="2">Female (3508)</td><td rowspan="2">χ2</td><td rowspan="2">P</td></tr><tr><td></td><td>Prevalence</td><td>Prevalence rate</td><td>Prevalence</td><td>Prevalence rate</td><td>Prevalence</td><td>Prevalence rate</td></tr><tr><td>Overweight or obese</td><td>CDS</td><td>1685</td><td>28.28%</td><td>747</td><td>30.48%</td><td>938</td><td>26.74%</td><td>9.89</td><td><0.01</td></tr><tr><td>Central obesity</td><td>IDF/ ATPⅢ</td><td>2249</td><td>37.74%</td><td>609</td><td>24.85%</td><td>1640</td><td>46.75%</td><td>294.01</td><td><0.01</td></tr><tr><td>Hypertriglyceridemia</td><td>IDF/ ATPⅢ</td><td>1432</td><td>24.03%</td><td>655</td><td>26.72%</td><td>777</td><td>22.15%</td><td>16.48</td><td><0.01</td></tr><tr><td rowspan="2">Reduced HDL-C</td><td>IDF</td><td>2071</td><td>34.75%</td><td>618</td><td>25.21%</td><td>1453</td><td>41.42%</td><td>167.62</td><td><0.01</td></tr><tr><td>ATPⅢ</td><td>2117</td><td>35.53%</td><td>618</td><td>25.21%</td><td>1499</td><td>42.73%</td><td>193.88</td><td><0.01</td></tr><tr><td rowspan="2">Elevated blood pressure</td><td>IDF/ ATPⅢ</td><td>2483</td><td>41.67%</td><td>1154</td><td>47.08%</td><td>1329</td><td>37.88%</td><td>51.26</td><td><0.01</td></tr><tr><td>CDS</td><td>1656</td><td>27.79%</td><td>744</td><td>30.35%</td><td>912</td><td>26.00%</td><td>14.01</td><td><0.01</td></tr><tr><td rowspan="3">Hyperglycemia</td><td>IDF</td><td>1918</td><td>32.19%</td><td>834</td><td>34.03%</td><td>1084</td><td>30.90%</td><td>6.31</td><td>0.01</td></tr><tr><td>ATPⅢ</td><td>1912</td><td>32.09%</td><td>833</td><td>33.99%</td><td>1079</td><td>30.76%</td><td>6.74</td><td>0.01</td></tr><tr><td>CDS</td><td>1346</td><td>22.59%</td><td>591</td><td>24.11%</td><td>755</td><td>21.52%</td><td>5.73</td><td>0.02</td></tr><tr><td>Dyslipidemia</td><td>CDS</td><td>1524</td><td>25.57%</td><td>670</td><td>27.34%</td><td>854</td><td>24.34%</td><td>6.74</td><td>0.01</td></tr><tr><td rowspan="3">MS</td><td>IDF</td><td>1327</td><td>22.27%</td><td>412</td><td>16.81%</td><td>915</td><td>26.08%</td><td>71.69</td><td><0.01</td></tr><tr><td>ATPⅢ</td><td>1670</td><td>28.02%</td><td>594</td><td>24.24%</td><td>1076</td><td>30.67%</td><td>29.65</td><td><0.01</td></tr><tr><td>CDS</td><td>698</td><td>11.71%</td><td>320</td><td>13.06%</td><td>378</td><td>10.78%</td><td>7.26</td><td>0.01</td></tr><tr><td rowspan="3">MS**</td><td>IDF</td><td>—</td><td>19.85%</td><td>—</td><td>16.98%</td><td>—</td><td>22.11%</td><td>—</td><td>—</td></tr><tr><td>ATPⅢ</td><td>—</td><td>24.77%</td><td>—</td><td>23.86%</td><td>—</td><td>25.76%</td><td>—</td><td>—</td></tr><tr><td>CDS</td><td>—</td><td>9.95%</td><td>—</td><td>12.31%</td><td>—</td><td>8.50%</td><td>—</td><td>—</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">Age</td></tr><tr><td>10–14</td><td>109</td><td>20.2</td></tr><tr><td>15–19</td><td>429</td><td>79.4</td></tr><tr><td>20–24</td><td>2</td><td>0.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Sex</td></tr><tr><td>Male</td><td>213</td><td>39.4</td></tr><tr><td>Female</td><td>327</td><td>60.6</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Ethnic group</td></tr><tr><td>Yoruba</td><td>468</td><td>86.7</td></tr><tr><td>Igbo</td><td>47</td><td>8.7</td></tr><tr><td>Hausa</td><td>10</td><td>1.9</td></tr><tr><td>Others</td><td>15</td><td>2.8</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Class</td></tr><tr><td>SSS 1</td><td>128</td><td>23.7</td></tr><tr><td>SSS 2</td><td>253</td><td>46.9</td></tr><tr><td>SSS 3</td><td>159</td><td>29.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">School type</td></tr><tr><td>Public</td><td>482</td><td>89.3</td></tr><tr><td>Private</td><td>58</td><td>10.7</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Religion</td></tr><tr><td>Christianity</td><td>511</td><td>94.6</td></tr><tr><td>Islam</td><td>29</td><td>5.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Ethnicity</td></tr><tr><td>Yoruba</td><td>468</td><td>86.7</td></tr><tr><td>Ibo</td><td>47</td><td>8.7</td></tr><tr><td>Hausa</td><td>10</td><td>1.9</td></tr><tr><td>Others</td><td>15</td><td>2.8</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Dimension of performance</td><td colspan="3">Number of written concerns/comments</td></tr><tr><td></td><td>First cycle</td><td>Second cycle</td><td>Third cycle</td></tr><tr><td>1</td><td>Communication with patients and their families</td><td>Five</td><td>Two</td><td>Zero</td></tr><tr><td>2</td><td>Courtesy and professionalism</td><td>Nine</td><td>Zero</td><td>Two</td></tr><tr><td>3</td><td>Temper</td><td>Four</td><td>Three</td><td>One</td></tr><tr><td>4</td><td>Approachability</td><td>Six</td><td>One</td><td>Zero</td></tr><tr><td>5</td><td>Responsiveness to concerns</td><td>Five</td><td>Zero</td><td>Zero</td></tr><tr><td>6</td><td>Non-clinical quality of care</td><td>Six</td><td>Zero</td><td>Zero</td></tr><tr><td>7</td><td>Overall Management of ED patients</td><td>Fifteen</td><td>One</td><td>Three</td></tr><tr><td>8</td><td>Initiative and responsibility in conflict resolution</td><td>Nine</td><td>One</td><td>One</td></tr><tr><td>9</td><td>Availability in ED</td><td>Six</td><td>Zero</td><td>One</td></tr><tr><td>10</td><td>Engaging the nurses in plan of care</td><td>Seven</td><td>Zero</td><td>One</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Reads (M)</td><td>Data (MB)</td><td>Alignment (%)</td><td>Coverage (%)</td><td>Depth</td></tr><tr><td>MO-1</td><td>3.05</td><td>0.27</td><td>91.39</td><td>93.57</td><td>135.92</td></tr><tr><td>FA-1</td><td>2.37</td><td>0.21</td><td>88.77</td><td>95.30</td><td>104.15</td></tr><tr><td>FT-1</td><td>2.71</td><td>0.24</td><td>89.05</td><td>93.23</td><td>124.62</td></tr><tr><td>MP-1</td><td>128.89</td><td>11.59</td><td>93.58</td><td>95.63</td><td>203.21</td></tr><tr><td>MP-1(Duo-index)</td><td>128.89</td><td>11.59</td><td>93.58</td><td>95.66</td><td>279.91</td></tr><tr><td>MO-2</td><td>30.35</td><td>2.73</td><td>92.10</td><td>98.36</td><td>174.87</td></tr><tr><td>FA-2</td><td>22.09</td><td>1.99</td><td>92.90</td><td>97.14</td><td>135.81</td></tr><tr><td>FT-2</td><td>33.92</td><td>3.05</td><td>89.36</td><td>98.51</td><td>176.90</td></tr><tr><td>MP-2</td><td>141.91</td><td>12.78</td><td>95.34</td><td>98.61</td><td>62.28</td></tr><tr><td>MO-3</td><td>30.83</td><td>2.77</td><td>93.14</td><td>98.36</td><td>131.22</td></tr><tr><td>FA-3</td><td>33.04</td><td>2.97</td><td>93.31</td><td>97.43</td><td>148.44</td></tr><tr><td>FT-3</td><td>22.66</td><td>2.04</td><td>92.99</td><td>98.32</td><td>104.64</td></tr><tr><td>MP-3</td><td>145.86</td><td>13.12</td><td>95.28</td><td>98.68</td><td>44.75</td></tr><tr><td>MO-4</td><td>39.81</td><td>3.58</td><td>91.82</td><td>98.67</td><td>226.32</td></tr><tr><td>FA-4</td><td>28.02</td><td>2.52</td><td>92.19</td><td>97.30</td><td>176.12</td></tr><tr><td>FT-4</td><td>28.75</td><td>2.59</td><td>89.97</td><td>97.34</td><td>117.40</td></tr><tr><td>MP-4</td><td>188.27</td><td>16.94</td><td>89.16</td><td>97.56</td><td>93.81</td></tr><tr><td>MO-5</td><td>34.61</td><td>3.46</td><td>94.65</td><td>98.61</td><td>174.67</td></tr><tr><td>FA-5</td><td>43.09</td><td>4.31</td><td>94.20</td><td>97.27</td><td>180.79</td></tr><tr><td>FT-5</td><td>41.39</td><td>4.14</td><td>91.54</td><td>97.46</td><td>176.58</td></tr><tr><td>MP-5</td><td>134.99</td><td>12.14</td><td>95.24</td><td>97.11</td><td>28.91</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Comparison</td><td>Hazard ratio for death</td><td>95% CI</td><td>p-value</td></tr><tr><td>(Adjuvant treated, miR-21 negative) vs. rest</td><td>0.316</td><td>0.166–0.600</td><td>0.0004</td></tr><tr><td>CXCR3 status: positive vs. negative</td><td>4.177</td><td>1.775–9.831</td><td>0.0011</td></tr><tr><td>AJCC stage: IIB vs. IIA</td><td>2.092</td><td>1.078–4.058</td><td>0.0290</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td>Initial range</td><td>Case 1</td><td>Case 2</td><td>Case 3</td><td>Case 4</td><td>Case 5</td></tr><tr><td colspan="2">aon</td><td>(0.001, 0.04)</td><td>0.019</td><td>0.020</td><td>0.028</td><td>0.024</td><td>0.021</td></tr><tr><td colspan="2">aoff</td><td>(100, 1,000)</td><td>211</td><td>348</td><td>309</td><td>460</td><td>206</td></tr><tr><td rowspan="2">Ck</td><td>xi > 0</td><td>(0, 2,100)</td><td>1,544</td><td>1,735</td><td>1,885</td><td>2,085</td><td>2,015</td></tr><tr><td>xi < 0</td><td>(0, 2,100)</td><td>264</td><td>1,345</td><td>1,166</td><td>1,113</td><td>529</td></tr><tr><td rowspan="2">kd</td><td>xi > 0</td><td>(0, 400)</td><td>293</td><td>343</td><td>280</td><td>190</td><td>247</td></tr><tr><td>xi < 0</td><td>(0, 400)</td><td>195</td><td>74</td><td>51</td><td>290</td><td>267</td></tr><tr><td rowspan="4">kdb</td><td>xi > 0</td><td>(0, 50)</td><td>26</td><td>49</td><td>47</td><td>42</td><td>36</td></tr><tr><td>xi < 0</td><td>(0, 50)</td><td>47</td><td>19</td><td>28</td><td>18</td><td>19</td></tr><tr><td>kplus</td><td>(0, 100)</td><td>54</td><td>50</td><td>40</td><td>72</td><td>35</td></tr><tr><td>kminus</td><td>(0, 20)</td><td>12</td><td>14</td><td>19</td><td>18</td><td>13</td></tr><tr><td colspan="2">�/element (strain)</td><td>N/A</td><td>0.077</td><td>0.078</td><td>0.055</td><td>0.080</td><td>0.076</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Database</td><td>common carp hits</td><td>Unique protein</td><td>% of total unique proteins</td></tr><tr><td>NR</td><td>28,055</td><td>19,165</td><td></td></tr><tr><td colspan="4">Refseq/Ensembl</td></tr><tr><td>Zebrafish</td><td>27,693</td><td>14,554</td><td>53.4% of 27,271</td></tr><tr><td>Medaka</td><td>24,501</td><td>12,471</td><td>50.6% of 24,661</td></tr><tr><td>Tetraodon</td><td>24,371</td><td>12,536</td><td>54.2% of 23,118</td></tr><tr><td>Three-spined stickleback</td><td>25,025</td><td>13,147</td><td>47.7% of 27,576</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Medium</td><td>icorr (μA cm−2)</td><td>Ecorr (mV)</td><td>βa (mV/dec)</td><td>βc (mV/dec)</td></tr><tr><td>Sterile</td><td>0.087</td><td>− 472</td><td>286.4</td><td>− 237.8</td></tr><tr><td>P. aeruginosa inoculated</td><td>0.328</td><td>− 277</td><td>121.2</td><td>− 153.6</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Village/Strata</td><td colspan="2">Examined for nodules (REMO)</td><td rowspan="2">Nodules No. positive (%)</td><td colspan="3">OV16 tests</td></tr><tr><td>N</td><td>Median age (IQR)</td><td>Number screened (%)</td><td>Positive percentage (95% CI)</td><td>χ2-test (P-value)δ</td></tr><tr><td colspan="7">Village</td></tr><tr><td>Matumbala</td><td>35</td><td>38.5 (28.0–47.0)</td><td>1 (2.9)</td><td>34 (97.1)</td><td>32.3 (15.8–48.9)</td><td></td></tr><tr><td>Vigoi</td><td>54</td><td>43.8 (33.5–55.5)</td><td>1 (1.9)</td><td>53 (98.1)</td><td>62.3 (48.8–75.8)</td><td>7.41 (0.006)</td></tr><tr><td>Mdindo</td><td>54</td><td>43.2 (30.8–53.5)</td><td>3 (5.6)</td><td>50 (92.6)</td><td>80.0 (68.5–91.5)</td><td>19.26 ( < 0.001)</td></tr><tr><td>Msogezi</td><td>72</td><td>35.7 (28.6–50.2)</td><td>0 (0)</td><td>69 (95.8)</td><td>73.9 (63.3–84.5)</td><td>16.42 (< 0.001)</td></tr><tr><td colspan="7">Strata</td></tr><tr><td>Suburban</td><td>126</td><td>42.5 (31.9–53.6)</td><td>2 (1.6)</td><td>119 (94.4)</td><td>50.6 (39.9–61.3)</td><td></td></tr><tr><td>Rural</td><td>89</td><td>39.0 (28.9–51.9)</td><td>3 (3.4)</td><td>87 (97.6)</td><td>76.5 (68.7–84.2)</td><td>14.9 (< 0.001)</td></tr><tr><td>Total/Average</td><td>215</td><td>40.2 (29.6–52.9)</td><td>5 (2.3)</td><td>206 (95.8)</td><td>65.5 (59.0–72.1)</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Length (μm)</td><td>Diameter (μm)</td></tr><tr><td>Proboscis</td><td>L1 = 1560 (n = 8)</td><td>D1 = 25</td></tr><tr><td>Pharynx</td><td>L2 = 200 (n = 4)</td><td>D2 = 25</td></tr><tr><td>Pharyngeal valve (closed)</td><td>l2 = 20</td><td>d2 = 5</td></tr><tr><td>Esophagus</td><td>L3 = 100</td><td>D3 = 50</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Indicator</td><td>Short name</td><td>Units/ Range</td><td>Associated population feature</td><td>Description</td></tr><tr><td>Centre of Gravity</td><td>CG</td><td>Degree</td><td>Location</td><td>Mean location of the population</td></tr><tr><td>Number of Patches</td><td>NP</td><td>>0</td><td>Patchiness</td><td>Patchiness, biomass hotspots</td></tr><tr><td>Inertia</td><td>I</td><td>nmi2</td><td>Dispersion</td><td>Dispersion of the individuals around the GC of the population</td></tr><tr><td>Isotropy</td><td>I</td><td>0 to 1</td><td>Dispersion</td><td>Elongation of the population</td></tr><tr><td>Positive Area</td><td>PA</td><td>nmi2</td><td>Occupation</td><td>Area of presence</td></tr><tr><td>Spreading Area</td><td>SA</td><td>nmi2</td><td>Aggregation</td><td>Area occupied by the population accounting for density values</td></tr><tr><td>Equivalent Area</td><td>EA</td><td>nmi2</td><td>Aggregation</td><td>Individual-based measure of the area occupied by the stock</td></tr><tr><td>Global Index of Collocation</td><td>GIC</td><td>0 to 1</td><td>Overlap</td><td>Overlapping degree of two populations</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Response: Predictor</td><td colspan="4">Probability of reproduction (0,1)</td><td></td><td colspan="4">Reproductive success (N offspring)</td><td></td></tr><tr><td rowspan="2">Estimate</td><td colspan="2">95% CI</td><td rowspan="2">z</td><td></td><td rowspan="2">Estimate</td><td colspan="2">95% CI</td><td rowspan="2">z</td><td></td></tr><tr><td>lower</td><td>upper</td><td></td><td>lower</td><td>upper</td><td></td></tr><tr><td>Intercept</td><td>-0.068</td><td>-0.596</td><td>0.461</td><td>-0.17</td><td></td><td>-0.403</td><td>-0.762</td><td>-0.044</td><td>-2.41</td><td></td></tr><tr><td>Trap effort (TE)</td><td>0.167</td><td>-0.196</td><td>0.530</td><td>0.94</td><td></td><td>0.106</td><td>-0.114</td><td>0.326</td><td>0.93</td><td></td></tr><tr><td>Maternal age (mmage)</td><td>2.278</td><td>-0.599</td><td>5.154</td><td>2.17</td><td></td><td>1.228</td><td>-0.366</td><td>2.822</td><td>2.01</td><td></td></tr><tr><td>mmage2</td><td>-0.642</td><td>-1.206</td><td>-0.079</td><td>-2.44</td><td></td><td>-0.335</td><td>-0.638</td><td>-0.031</td><td>-2.27</td><td></td></tr><tr><td>rain</td><td>-0.513</td><td>-0.889</td><td>-0.136</td><td>-2.71</td><td></td><td>-0.324</td><td>-0.551</td><td>-0.097</td><td>-2.86</td><td></td></tr><tr><td>RPY</td><td>0.084</td><td>-0.690</td><td>0.857</td><td></td><td></td><td>-0.048</td><td>-0.501</td><td>0.405</td><td></td><td></td></tr><tr><td>TQ4</td><td>0.746</td><td>0.290</td><td>1.201</td><td>3.26</td><td></td><td>0.338</td><td>0.021</td><td>0.656</td><td>2.42</td><td></td></tr><tr><td>maxage</td><td>-0.075</td><td>-0.736</td><td>0.586</td><td></td><td></td><td>0.111</td><td>-0.277</td><td>0.499</td><td></td><td></td></tr><tr><td>mmage × rain</td><td>-0.112</td><td>-0.653</td><td>0.429</td><td></td><td></td><td>-0.031</td><td>-0.351</td><td>0.288</td><td></td><td></td></tr><tr><td>mmage × RPY</td><td>-0.624</td><td>-1.591</td><td>0.344</td><td></td><td></td><td>-0.457</td><td>-1.049</td><td>0.135</td><td></td><td></td></tr><tr><td>mmage × TQ4</td><td>0.660</td><td>0.094</td><td>1.226</td><td>2.34</td><td></td><td>0.286</td><td>-0.056</td><td>0.627</td><td>1.60</td><td></td></tr><tr><td>mmage × maxage</td><td>-0.578</td><td>-1.301</td><td>0.144</td><td></td><td></td><td>-0.262</td><td>-0.723</td><td>0.199</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>1QF6</td><td>BaThrRS</td></tr><tr><td>Cys334</td><td>Cys343</td></tr><tr><td>Arg363</td><td>Arg372</td></tr><tr><td>Glu365</td><td>Glu374</td></tr><tr><td>Met374</td><td>Met383</td></tr><tr><td>Arg375</td><td>Arg384</td></tr><tr><td>Val376</td><td>Val385</td></tr><tr><td>Phe379</td><td>Phe388</td></tr><tr><td>Gln381</td><td>Gln390</td></tr><tr><td>His385</td><td>His394</td></tr><tr><td>Gln479</td><td>Gln493</td></tr><tr><td>Cys480</td><td>Cys494</td></tr><tr><td>Thr482</td><td>Thr496</td></tr><tr><td>His511</td><td>His525</td></tr><tr><td>Gly516</td><td>Gly530</td></tr><tr><td>Ser517</td><td>Ser531</td></tr><tr><td>Arg520</td><td>Arg534</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Subcategory</td><td colspan="2">Farmers</td><td colspan="2">Advisors</td><td colspan="2">Technicians</td><td colspan="2">Veterinarians</td></tr><tr><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td></tr><tr><td>Reproduction or number of lambs or kids born</td><td>9.5</td><td>5–10</td><td>8.4</td><td>6–10</td><td>7.7</td><td>0–10</td><td>8.2</td><td>0–10</td></tr><tr><td>Number of sheep sold per year</td><td>8.2</td><td>4–10</td><td>7.0</td><td>5–9</td><td>6.4</td><td>0–10</td><td>6.9</td><td>0–10</td></tr><tr><td>Number of goats sold per year</td><td>8.2</td><td>4–10</td><td>6.2</td><td>59</td><td>5.9</td><td>0–10</td><td>6.0</td><td>0–10</td></tr><tr><td>Amount of wool sold per year</td><td>8.3</td><td>2–10</td><td>8.3</td><td>6–10</td><td>7.5</td><td>0–10</td><td>6.7</td><td>0–10</td></tr><tr><td>Quality of wool sold</td><td>8.5</td><td>3–10</td><td>8.1</td><td>6–10</td><td>7.2</td><td>0–10</td><td>6.7</td><td>0–10</td></tr><tr><td>Others (specify income source)</td><td>0.0</td><td>0–0</td><td>1.9</td><td>0–10</td><td>0.4</td><td>0–8</td><td>0.0</td><td>0–0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>C27H32O</td><td>F000 = 4040</td></tr><tr><td>Mr = 372.53</td><td>Dx = 1.111 Mg m−3</td></tr><tr><td>Monoclinic, C2/c</td><td>Mo Kα radiation λ = 0.71073 Å</td></tr><tr><td>Hall symbol: -C 2yc</td><td>Cell parameters from 2156 reflections</td></tr><tr><td>a = 41.246 (7) Å</td><td>θ = 5.3–40.8º</td></tr><tr><td>b = 6.2930 (10) Å</td><td>µ = 0.07 mm−1</td></tr><tr><td>c = 43.001 (7) Å</td><td>T = 293 (2) K</td></tr><tr><td>β = 94.243 (4)º</td><td>Prism, yellow</td></tr><tr><td>V = 11131 (3) Å3</td><td>0.50 × 0.41 × 0.18 mm</td></tr><tr><td>Z = 20</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="2">Gender</td></tr><tr><td>(i) Male</td><td>51</td></tr><tr><td>(ii) Female</td><td>29</td></tr><tr><td>Age</td><td>47.65 (SD = 7.1)</td></tr><tr><td colspan="2">Ethnicity</td></tr><tr><td>(i) Black, non-Hispanic</td><td>77</td></tr><tr><td>(ii) Hispanic</td><td>2</td></tr><tr><td>(iii) White</td><td>1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Characteristic</td><td></td><td colspan="2">Study Cohort</td></tr><tr><td></td><td>N</td><td>%</td></tr><tr><td>Total</td><td></td><td>8,711</td><td>100</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>3,733</td><td>42.9</td></tr><tr><td>Female</td><td>4,978</td><td>57.1</td></tr><tr><td>Age (years)</td><td>Mean (SD)</td><td>65.9</td><td>10.5</td></tr><tr><td rowspan="5">Age category (years)</td><td>45–54</td><td>1,474</td><td>16.9</td></tr><tr><td>55–64</td><td>2,780</td><td>31.9</td></tr><tr><td>65–74</td><td>2,573</td><td>29.5</td></tr><tr><td>75–84</td><td>1,583</td><td>18.2</td></tr><tr><td>≥85</td><td>302</td><td>3.5</td></tr><tr><td rowspan="3">SES</td><td>High</td><td>1,651</td><td>19.2</td></tr><tr><td>Intermediate</td><td>3,597</td><td>41.9</td></tr><tr><td>Low</td><td>3,346</td><td>38.9</td></tr><tr><td>BMI (kg/m²)</td><td>Mean (SD)</td><td>27.1</td><td>4.1</td></tr><tr><td rowspan="3">Smoking</td><td>Current</td><td>1,734</td><td>20.2</td></tr><tr><td>Former</td><td>4,288</td><td>49.9</td></tr><tr><td>Never</td><td>2,570</td><td>29.9</td></tr><tr><td>Diabetes Status</td><td></td><td>952</td><td>10.9</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Location2</td><td>size (kb)</td><td>classification</td><td>genes in the region1</td></tr><tr><td>Ger1</td><td>chr10 12719281–13144281</td><td>425</td><td>coding, imprinted, disease related</td><td>Phactr2 (phosphatase and actin regulator 2 isoform A), Plagl1 (pleiomorphic adenoma gene-like 1), Zac1 (zinc finger protein)</td></tr><tr><td>Ger2</td><td>chr14 35,222,025–35,451,7633</td><td>230</td><td>coding, disease related</td><td>Bmpr1a (bone morphogenetic protein receptor type-1A), Ldb3 (LIM domain-binding protein 3 isoform), Opn4 (melanopsin isoform 1)</td></tr><tr><td>Ger3</td><td>chr17 11,520,278–12,071,811</td><td>550</td><td>coding, disease related</td><td>Park2 (parkinson protein 2 - E3 ubiquitin-protein ligase parkin)</td></tr><tr><td>Fra1</td><td>chr12 59,560,813–59,710,943</td><td>150</td><td>non-coding</td><td>center of 680 kb non-coding region</td></tr><tr><td>Fra2</td><td>chr15 38,059,935–38,210,538</td><td>150</td><td>coding</td><td>Odf1, main protein of sperm tail outer dense fibers</td></tr><tr><td>Cze1</td><td>chr3 112,689,523–115,078,986</td><td>2,390</td><td>coding, disease related</td><td>Amy2b (amylase 2b isoform 1), Amy2a5 (pancreatic alpha- amylase), Amy1 (alpha-amylase 1), Col11a1 (collagen alpha-1(XI) chain), Olfm3 (olfactomedin 3)</td></tr><tr><td>Cze2</td><td>chr7 29571436–30171436</td><td>600</td><td>coding</td><td>ca 35 partially overlapping genes</td></tr><tr><td>Cze3</td><td>chr8 6013855–6933855</td><td>920</td><td>non-coding</td><td>center of an approx 3 Mb non- coding region</td></tr><tr><td>Kaz1</td><td>chr14 109933747–111553747</td><td>1,620</td><td>coding (mostly non-coding)</td><td>Slitrk6 (SLIT and NTRK-like protein 6)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>EV</td><td>Concentration (particles/mL)</td><td>Size (nm)</td></tr><tr><td rowspan="2">HS.5</td><td rowspan="2">3,29 × 1011 ± 2,4 × 1010</td><td>Mean – 125.6</td></tr><tr><td>SD – 49.8</td></tr><tr><td rowspan="2">hTERT</td><td rowspan="2">7,64 × 1011 ± 4,62 × 1010</td><td>Mean – 159,7</td></tr><tr><td>SD – 130,4</td></tr><tr><td rowspan="2">K562</td><td rowspan="2">3,36 × 1011 ± 5,05 × 1010</td><td>Mean – 122</td></tr><tr><td>SD – 65,9</td></tr><tr><td rowspan="2">hMSC</td><td rowspan="2">6,40 × 1011 ± 1 × 1010</td><td>Mean – 136,6</td></tr><tr><td>SD – 86,8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Motif No.</td><td>Consensus sequences</td></tr><tr><td>1</td><td>KCGDQAQLSCCNKATYAQDVTDIDEFILAGTLKNLIGGGSG{T, S}EGLGLF{D, N}Q</td></tr><tr><td>2</td><td>{D, G}L{V, G}{G, N}Q{K, S}C{K, S}{Q, A}{Q, N}{I, T}{V, A}CCQN{S, N}{P{F, S}{D, N}{G, A}</td></tr><tr><td>3</td><td>{S, Q}{Q, C}{C, S}{N, Q}{T, G}{G, Q}{T, S}{L, V, A}{Q, K}CCNS</td></tr><tr><td>4</td><td>VQS{A, S}S{S, D, N}PX{V, A}{A, G}{G, L}LLGLLG{I, V}V{L, V}G</td></tr><tr><td>5</td><td>L{V, I}{G, N}LTC{S, T}PI{S, T}V</td></tr><tr><td>6</td><td>SX{T, V}A{A, L}VLALAA{A, L}{A, L}{A, V}{A, V}AXPXPX</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>n</td><td>%</td></tr><tr><td colspan="3">Predominant site of gastric lymphoma</td></tr><tr><td>Corpus</td><td>28</td><td>35</td></tr><tr><td>Antrum</td><td>26</td><td>33</td></tr><tr><td>Cardia</td><td>7</td><td>9</td></tr><tr><td>Fundus</td><td>2</td><td>3</td></tr><tr><td>Multiple site</td><td>5</td><td>6</td></tr><tr><td>Unknown</td><td>11</td><td>14</td></tr><tr><td colspan="3">Symptoms</td></tr><tr><td>Abdominal pain and dyspepsia</td><td>55</td><td>70</td></tr><tr><td>Weight loss, fever, night sweat</td><td>42</td><td>53</td></tr><tr><td>Nausea and vomiting</td><td>13</td><td>17</td></tr><tr><td>Weakness</td><td>11</td><td>14</td></tr><tr><td>Gastrointestinal bleeding</td><td>8</td><td>10</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Type of response provided</td><td>Number (22 total)a</td><td>Percentage of total</td></tr><tr><td>Favorable</td><td>11</td><td>50 %</td></tr><tr><td>Neutral</td><td>1</td><td>4.5 %</td></tr><tr><td>Unfavorable</td><td>2</td><td>9.1 %</td></tr><tr><td>Both favorable and unfavorable</td><td>6</td><td>27.3 %</td></tr><tr><td>Prefer not to answer</td><td>2</td><td>9.1 %</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="5">Men (n = 68)</td><td colspan="5">Women (n = 71)</td></tr><tr><td></td><td colspan="2">Crude intake</td><td colspan="3">Energy-adjusted intake</td><td colspan="2">Crude intake</td><td colspan="3">Energy-adjusted intake</td></tr><tr><td></td><td>CC</td><td>95% conﬁdence interval</td><td>CC</td><td>95% conﬁdence interval</td><td>De- attenuated CC</td><td>CC</td><td>95% conﬁdence interval</td><td>CC</td><td>95% conﬁdence interval</td><td>De- attenuated CC</td></tr><tr><td>Protein</td><td>0.35</td><td>(0.12, 0.54)</td><td>0.54</td><td>(0.35, 0.69)</td><td>0.67</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.39</td><td>(0.18, 0.57)</td><td>0.47</td></tr><tr><td>Isoleucine</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.59</td><td>(0.41, 0.73)</td><td>0.75</td><td>0.58</td><td>(0.40, 0.71)</td><td>0.43</td><td>(0.22, 0.60)</td><td>0.52</td></tr><tr><td>Leucine</td><td>0.38</td><td>(0.15, 0.56)</td><td>0.58</td><td>(0.39, 0.72)</td><td>0.73</td><td>0.58</td><td>(0.40, 0.71)</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.46</td></tr><tr><td>Lysine</td><td>0.37</td><td>(0.14, 0.56)</td><td>0.57</td><td>(0.38, 0.71)</td><td>0.73</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.42</td><td>(0.20, 0.59)</td><td>0.52</td></tr><tr><td>Methionine</td><td>0.36</td><td>(0.13, 0.55)</td><td>0.54</td><td>(0.34, 0.69)</td><td>0.69</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.39</td><td>(0.18, 0.58)</td><td>0.49</td></tr><tr><td>Phenylalanine</td><td>0.40</td><td>(0.18, 0.58)</td><td>0.59</td><td>(0.41, 0.72)</td><td>0.73</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.42</td><td>(0.21, 0.60)</td><td>0.52</td></tr><tr><td>Threonine</td><td>0.36</td><td>(0.13, 0.55)</td><td>0.56</td><td>(0.37, 0.70)</td><td>0.70</td><td>0.56</td><td>(0.38, 0.70)</td><td>0.43</td><td>(0.21, 0.60)</td><td>0.52</td></tr><tr><td>Tryptophan</td><td>0.40</td><td>(0.18, 0.58)</td><td>0.61</td><td>(0.43, 0.74)</td><td>0.74</td><td>0.60</td><td>(0.43, 0.73)</td><td>0.44</td><td>(0.23, 0.61)</td><td>0.54</td></tr><tr><td>Valine</td><td>0.39</td><td>(0.17, 0.57)</td><td>0.59</td><td>(0.41, 0.73)</td><td>0.73</td><td>0.58</td><td>(0.40, 0.72)</td><td>0.42</td><td>(0.20, 0.59)</td><td>0.50</td></tr><tr><td>Histidine</td><td>0.32</td><td>(0.09, 0.52)</td><td>0.40</td><td>(0.18, 0.59)</td><td>0.60</td><td>0.63</td><td>(0.47, 0.76)</td><td>0.46</td><td>(0.26, 0.63)</td><td>0.61</td></tr><tr><td>Arginine</td><td>0.44</td><td>(0.22, 0.61)</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.69</td><td>0.49</td><td>(0.29, 0.65)</td><td>0.38</td><td>(0.17, 0.57)</td><td>0.48</td></tr><tr><td>Cystine</td><td>0.45</td><td>(0.23, 0.62)</td><td>0.51</td><td>(0.31, 0.67)</td><td>0.60</td><td>0.51</td><td>(0.31, 0.66)</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.45</td></tr><tr><td>Tyrosine</td><td>0.40</td><td>(0.17, 0.58)</td><td>0.58</td><td>(0.39, 0.72)</td><td>0.72</td><td>0.62</td><td>(0.45, 0.74)</td><td>0.46</td><td>(0.25, 0.63)</td><td>0.57</td></tr><tr><td>Alanine</td><td>0.39</td><td>(0.17, 0.58)</td><td>0.61</td><td>(0.43, 0.74)</td><td>0.75</td><td>0.53</td><td>(0.33, 0.68)</td><td>0.39</td><td>(0.17, 0.57)</td><td>0.47</td></tr><tr><td>Aspartic acid</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.65</td><td>(0.49, 0.77)</td><td>0.78</td><td>0.54</td><td>(0.35, 0.69)</td><td>0.43</td><td>(0.22, 0.60)</td><td>0.52</td></tr><tr><td>Glutamic acid</td><td>0.30</td><td>(0.07, 0.50)</td><td>0.56</td><td>(0.37, 0.71)</td><td>0.72</td><td>0.51</td><td>(0.31, 0.66)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.43</td></tr><tr><td>Glycine</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.48</td><td>(0.27, 0.64)</td><td>0.61</td><td>0.53</td><td>(0.33, 0.68)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.42</td></tr><tr><td>Proline</td><td>0.28</td><td>(0.05, 0.49)</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.75</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.42</td></tr><tr><td>Serine</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.55</td><td>(0.36, 0.70)</td><td>0.67</td><td>0.53</td><td>(0.34, 0.68)</td><td>0.36</td><td>(0.13, 0.54)</td><td>0.43</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>References</td><td>Pts. (N)</td><td>Age of treated GHD patients (years)</td><td>GHD testing</td><td>Study design</td><td>GH dose/ day*</td><td>Follow-up</td><td>Parameters</td><td>Key results</td></tr><tr><td>High et al. (16)</td><td>12 treated/ 11 controls</td><td>36.1 ± 10</td><td>Glucagon stimulation test</td><td>Open, prospective, randomized study</td><td>0.6 mg (or uptitrated)</td><td>12 months</td><td>Cognition: neuropsych. battery</td><td>Improvements in Dominant Hand Finger Tapping Test, WAIS III–PSI, CVLT II, WCST (executive functioning)</td></tr><tr><td>Maric et al. (19)</td><td>4 treated/ 2 controls (≥3 yrs after TBI)</td><td>39.3 ± 11</td><td>GHRH + GH releasing peptide-6</td><td>Open, prospective, study</td><td>0.3 mg (males), 0.4 mg (females)</td><td>6 months</td><td>Cognition: semi-structured interviews, SCL-90-R, ZDI, neuropsych. battery</td><td>Improvements in cognition, particularly of memory, and psychiatric functioning; worsening of memory and symptoms in 3 SCL dimensions after discontinuing GH therapy for 12 months (n = 3)</td></tr><tr><td>Reimunde et al. (17)</td><td>11/19 GHD, 8/19 controls w/o GHD</td><td>53.4 ± 17.4</td><td>GHRH-arginine</td><td>Open, prospective study, placebo-controlled study</td><td>1 mg</td><td>3 months</td><td>Cognition WAIS test</td><td>GHD: significant improvements in understanding, digits, numbers, incomplete figures, similarities, vocabulary, verbal and total IQ; GHD vs. controls: significant improvements in similarities, vocabulary, verbal and total IQ</td></tr><tr><td>Moreau et al. (15)</td><td>23 (27 controls)</td><td>37.9 ± 11.7</td><td>ITT or GHRH-arginine</td><td>Open, prospective, controlled study</td><td>0.2–0.6 mg</td><td>12 months</td><td>Cognition, HrQoL, ADL</td><td>Significant cognitive improvements, in particular for the ROCF, and in 2/6 QoL domains (personal, functional); greatest improvements if lower pre-treatment performance; modest correlation with ADL</td></tr><tr><td>Devesa et al. (20)</td><td>5/13 GHD (2.5 months−11 years after TBI)</td><td>24.6 ± 9.6</td><td>GHRH-arginine</td><td>Open, prospective study</td><td>0.8–1 mg/ 5 days/week, resting 15 days every 2 months</td><td>max. 8 months</td><td>Cognition, motor symptoms</td><td>Significant improvements in all patients; cognitive improvements appeared earlier and were more important than motor improvements; visual performance ameliorated in a patient with amaurosis</td></tr><tr><td>Gardner et al. (18)</td><td>161</td><td>42.6 [40.8; 44.5]</td><td>ITT or glucagon stimulation or GHRH-arginine or IGF-1 SDS</td><td>Retrospective database analysis</td><td>0.37 mg (95% CI, 0.35, 0.40)</td><td>8 years</td><td>HrQoL: QoL-AGHDA</td><td>Significant improvement of QoL-AGHDA score was sustained over 8 years; normalization of socialization after 1 year, self-confidence and tenseness after 6 years; no normalization of tiredness and memory</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Substrate and coatings</td><td>AZ91D</td><td>Ni-P</td><td>Ni-P-Al2O3 (1.7%)</td><td>Ni-P-Al2O3 (3.6%)</td><td>Ni-P-Al2O3 (4.2%)</td></tr><tr><td>icorr (A/cm2)</td><td>1.4 × 10−4</td><td>3.1 × 10−6</td><td>1.6 × 10−6</td><td>4.5 × 10−7</td><td>1.0 × 10−6</td></tr><tr><td>Ecorr (V)</td><td>− 1.46</td><td>− 0.51</td><td>− 0.47</td><td>− 0.35</td><td>− 0.41</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>N</td><td>Frequency%</td></tr><tr><td colspan="3">Exon 1 allele</td></tr><tr><td>A normal</td><td>587</td><td>80</td></tr><tr><td>B(A>G)</td><td>3</td><td>0.4</td></tr><tr><td>C(G>A)</td><td>141</td><td>20</td></tr><tr><td>D(C>T)</td><td>1</td><td>0.1</td></tr><tr><td colspan="3">Promoter alleles</td></tr><tr><td>-550H</td><td>38</td><td>5</td></tr><tr><td>-550L</td><td>694</td><td>95</td></tr><tr><td>-221X</td><td>134</td><td>18</td></tr><tr><td>-221Y</td><td>598</td><td>82</td></tr><tr><td>+4P</td><td>343</td><td>47</td></tr><tr><td>+4Q</td><td>389</td><td>53</td></tr><tr><td colspan="3">MBL2 Exon 1 genotype</td></tr><tr><td>AA wild-type</td><td>233</td><td>64</td></tr><tr><td>AB (A>G)</td><td>3</td><td>0.8</td></tr><tr><td>AC(G>A)</td><td>117</td><td>32</td></tr><tr><td>AD (C>T)</td><td>1</td><td>0.2</td></tr><tr><td>CC (C>T)</td><td>12</td><td>3</td></tr><tr><td colspan="3">Promoter region genotypes</td></tr><tr><td>-550HH</td><td>1</td><td>0.3</td></tr><tr><td>-550HL</td><td>37</td><td>10.1</td></tr><tr><td>-550LL</td><td>328</td><td>89.6</td></tr><tr><td>-221YY</td><td>242</td><td>66.1</td></tr><tr><td>-221XY</td><td>112</td><td>30.0</td></tr><tr><td>-221XX</td><td>12</td><td>3.2</td></tr><tr><td>+4PP</td><td>74</td><td>20.2</td></tr><tr><td>+4QQ</td><td>97</td><td>26.5</td></tr><tr><td>+4PQ</td><td>195</td><td>53.3</td></tr><tr><td colspan="3">MBL2 Haplotypes</td></tr><tr><td>1. MBL2LYPA</td><td>260</td><td>35.5</td></tr><tr><td>2. MBL2LYQA</td><td>183</td><td>25.0</td></tr><tr><td>3. MBL2LYQC</td><td>108</td><td>14.6</td></tr><tr><td>4. MBL2LXPA</td><td>58</td><td>7.9</td></tr><tr><td>5. MBL2LXQA</td><td>45</td><td>6.1</td></tr><tr><td>6. MBL2HYPA</td><td>41</td><td>5.6</td></tr><tr><td>7. MBL2LXQC</td><td>31</td><td>4.2</td></tr><tr><td>8. MBL2LXPC</td><td>2</td><td>0.3</td></tr><tr><td>9. MBL2LYQB</td><td>2</td><td>0.3</td></tr><tr><td>10. MBL2HYPD</td><td>1</td><td>0.1</td></tr><tr><td>11. MBL2*LYPB</td><td>1</td><td>0.1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>LTG (n = 30)</td><td>VPA (n = 30)</td><td>Control (n = 30)</td></tr><tr><td>Age (year)a</td><td>27.2±8.4</td><td>24.4±8.9</td><td>26.1±3.9</td></tr><tr><td>Gender (female;male)</td><td>15;15</td><td>15;15</td><td>15;15</td></tr><tr><td>Duration of AED therapy (month)b</td><td>17(6,30)</td><td>22.5(12.25,59.5)</td><td></td></tr><tr><td>Dosage of AED (mg/day)b</td><td>112.5(100,181.25)</td><td>750(625,1000)</td><td></td></tr><tr><td>AED concentration (μg/ml)a</td><td>2.89±1.33</td><td>64.22±29.52</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Case ID</td><td>Age (Years)</td><td>Sex</td><td>Cause of Death</td><td>Smoking *</td><td>Classification</td></tr><tr><td>ME0503</td><td>54</td><td>Male</td><td>Cardiac arrest</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0501</td><td>69</td><td>Female</td><td>Head trauma</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0105</td><td>78</td><td>Male</td><td>Cardiac arrest</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0505</td><td>59</td><td>Female</td><td>Cardiovascular</td><td>Unknown</td><td>Control</td></tr><tr><td>ELM0065</td><td>77</td><td>Male</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0038</td><td>65</td><td>Female</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0056</td><td>61</td><td>Male</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0060</td><td>77</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr><tr><td>ELM0041</td><td>62</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr><tr><td>ELM0063</td><td>71</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Strain</td><td>Period of isolation</td><td>Source</td><td>References</td></tr><tr><td>1</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>2</td><td>2009–2010</td><td>Ground, Farm E</td><td>Polifroni et al., 2012</td></tr><tr><td>3</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>4</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>5</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>6</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>7</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>8</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>9</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>10</td><td>2002–2009</td><td>Human with diarrhea</td><td>Rivero et al., 2010</td></tr><tr><td>11</td><td>2002–2009</td><td>Human with diarrhea</td><td>Rivero et al., 2010</td></tr><tr><td>12</td><td>2009</td><td>Milk-fed calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>13</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>14</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>15</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>16</td><td>2010</td><td>Newborn calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>17</td><td>2009–2010</td><td>Cow, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>18</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>19</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>20</td><td>2010</td><td>Newborn calf, Farm B</td><td>Fernández et al., 2012</td></tr><tr><td>21</td><td>2010</td><td>Newborn calf, Farm B</td><td>Fernández et al., 2012</td></tr><tr><td>22</td><td>2009</td><td>Growing calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>23</td><td>2010</td><td>Human with diarrhea</td><td>This study</td></tr><tr><td>24</td><td>2009</td><td>Human with diarrhea</td><td>This study</td></tr><tr><td>25</td><td>2009</td><td>Cow</td><td>This study</td></tr><tr><td>26</td><td>2013</td><td>Beef</td><td>This study</td></tr><tr><td>27</td><td>2013</td><td>Beef</td><td>This study</td></tr><tr><td>28</td><td>2013</td><td>Ground meat</td><td>This study</td></tr><tr><td>29</td><td>2009</td><td>Calf feed, Farm E</td><td>This study</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="4">Liver 21 days</td></tr><tr><td>Fatty acid</td><td>Corn oil diet</td><td>Canola diet</td><td>p value</td></tr><tr><td>18:2 LA</td><td>17.35 ± 1.22</td><td>12.10 ± 0.90</td><td><0.0001</td></tr><tr><td>18:1+18:3 ALA</td><td>9.59 ± 2.16</td><td>20.29 ± 2.04</td><td><0.0001</td></tr><tr><td>20:4 AA</td><td>18.40 ± 1.60</td><td>10.08 ± 0.57</td><td><0.0001</td></tr><tr><td>20:5 EPA</td><td>0.09 ± 0.02</td><td>1.39 ± 0.20</td><td><0.0001</td></tr><tr><td>22:6 DHA</td><td>5.04 ± 0.81</td><td>11.22 ± 0.46</td><td><0.0001</td></tr><tr><td>22:5 DPA</td><td>0.64 ± 0.08</td><td>0.53 ± 0.06</td><td>0.023</td></tr><tr><td colspan="4">Liver 130 days</td></tr><tr><td>18:2 LA</td><td>23.96 ± 2.74</td><td>22.91 ± 0.93</td><td>0.5565</td></tr><tr><td>18:1+18:3 ALA</td><td>18.19 ± 2.47</td><td>24.14 ± 1.01</td><td>0.0289</td></tr><tr><td>20:4 AA</td><td>13.82 ± 0.46</td><td>10.33 ± 0.49</td><td>0.0041</td></tr><tr><td>20:5 EPA</td><td>0.045 ± 0.04</td><td>0.10 ± 0.04</td><td>0.2382</td></tr><tr><td>22:6 DHA</td><td>5.37 ± 0.49</td><td>3.83 ± 0.17</td><td>0.0127</td></tr><tr><td>22:5 DPA</td><td>0.315 ± 0.04</td><td>0.24 ± 0.03</td><td>0.0817</td></tr><tr><td colspan="4">Mammary gland 21 days</td></tr><tr><td>18:2 LA</td><td>26.25 ± 1.32</td><td>6.74 ± 1.99</td><td>0.0000</td></tr><tr><td>18:1+18:3 ALA</td><td>29.26 ± 0.70</td><td>50.99 ± 1.98</td><td>0.0000</td></tr><tr><td>20:4 AA</td><td>0.67 ± 0.12</td><td>0.31 ± 0.11</td><td>0.0043</td></tr><tr><td>20:5 EPA</td><td>0.06 ± 0.01</td><td>0.08 ± 0.05</td><td>0.4050</td></tr><tr><td>22:6 DHA</td><td>0.08 ± 0.02</td><td>0.02 ± 0.01</td><td>0.0008</td></tr><tr><td>22:5 DPA</td><td>0.01 ± 0.01</td><td>0.06 ± 0.03</td><td>0.0124</td></tr><tr><td colspan="4">Mammary gland 130 days</td></tr><tr><td>18:2 LA</td><td>37.15 ± 0.78</td><td>35.77 ± 2.30</td><td>0.2879</td></tr><tr><td>18:1+18:3 ALA</td><td>0.40 ± 0.01</td><td>0.38 ± 0.03</td><td>0.1996</td></tr><tr><td>20:4 AA</td><td>0.13 ± 0.01</td><td>0.11 ± 0.03</td><td>0.3218</td></tr><tr><td>20:5 EPA</td><td>0.02 ± 0.01</td><td>0.00 ± 0.00</td><td>0.0000</td></tr><tr><td>22:6 DHA</td><td>0.01 ± 0.00</td><td>0.01 ± 0.01</td><td>0.2415</td></tr><tr><td>22:5 DPA</td><td>0.02 ± 0.00</td><td>0.00 ± 0.00</td><td>0.0000</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Independent variable</td><td>F for set</td><td>R2</td><td>t for predictors</td><td>df</td><td>Semipartial correlation (sr)</td><td>P</td></tr><tr><td>1</td><td>.179</td><td>.002</td><td></td><td>2,160</td><td></td><td>.836</td></tr><tr><td>Age</td><td></td><td></td><td>2.109</td><td></td><td>2.009</td><td>.913</td></tr><tr><td>Gender</td><td></td><td></td><td>.591</td><td></td><td>.047</td><td>.555</td></tr><tr><td>2</td><td>34.008</td><td>.463</td><td></td><td>4,158</td><td></td><td>.001</td></tr><tr><td>Depression</td><td></td><td></td><td>8.443</td><td></td><td>.492</td><td>.001</td></tr><tr><td>Autistic traits</td><td></td><td></td><td>4.745</td><td></td><td>.277</td><td>.001</td></tr><tr><td>3</td><td>28.904</td><td>.479</td><td></td><td>5,157</td><td></td><td>.001</td></tr><tr><td>Autistic traits 3 depression</td><td></td><td></td><td>22.241</td><td></td><td>2.129</td><td>.026</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Hes6</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>93</td><td>252</td><td>1534</td><td>2.74E-014</td><td>[26, 38]</td></tr><tr><td>Uterus</td><td>39</td><td>94</td><td>1692</td><td>3.24E-008</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>12</td><td>27</td><td>1759</td><td>0.00043528</td><td>-</td></tr><tr><td>Rectum</td><td>12</td><td>32</td><td>1754</td><td>0.00303994</td><td>-</td></tr><tr><td>Hes6/DDC</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>197</td><td>252</td><td>1534</td><td>0</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>21</td><td>27</td><td>1759</td><td>1.42E-009</td><td>-</td></tr><tr><td>Rectum</td><td>23</td><td>32</td><td>1754</td><td>5.03E-009</td><td>-</td></tr><tr><td>Liver</td><td>24</td><td>38</td><td>1748</td><td>1.65E-007</td><td>-</td></tr><tr><td>Kidney</td><td>75</td><td>214</td><td>1572</td><td>0.00040486</td><td>-</td></tr><tr><td>Stomach</td><td>5</td><td>8</td><td>1778</td><td>0.00476289</td><td>-</td></tr><tr><td>Hes6/CHGA</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>89</td><td>252</td><td>1534</td><td>0</td><td>-</td></tr><tr><td>Uterus</td><td>42</td><td>94</td><td>1692</td><td>6.80E-013</td><td>-</td></tr><tr><td>Endometrium</td><td>30</td><td>71</td><td>1715</td><td>6.50E-009</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>13</td><td>27</td><td>1759</td><td>1.02E-005</td><td>-</td></tr><tr><td>Rectum</td><td>13</td><td>32</td><td>1754</td><td>0.00011383</td><td>-</td></tr><tr><td>Stomach</td><td>4</td><td>8</td><td>1778</td><td>0.00324489</td><td>-</td></tr><tr><td>NTS</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Lung</td><td>36</td><td>108</td><td>1678</td><td>1.29E-010</td><td>[39]</td></tr><tr><td>Ovary</td><td>32</td><td>170</td><td>1616</td><td>0.00143643</td><td>[40]</td></tr><tr><td>Small intestine</td><td>3</td><td>6</td><td>1780</td><td>0.00226141</td><td>[41]</td></tr><tr><td>Ascl1</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Breast</td><td>40</td><td>317</td><td>1469</td><td>8.27E-008</td><td>-</td></tr><tr><td>Lung</td><td>20</td><td>108</td><td>1678</td><td>3.76E-007</td><td>[42, 43]</td></tr><tr><td>Ascl1/Hes6/NTS/DDC</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Lung</td><td>15</td><td>108</td><td>1678</td><td>3.79E-006</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>4</td><td>27</td><td>1759</td><td>0.00421239</td><td>-</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Factor</td><td>Meditation practitioners∗</td></tr><tr><td>Number of responses</td><td>343</td></tr><tr><td>% Male</td><td>39.6</td></tr><tr><td>Mean age and age range</td><td>44, (SD 13.4), range 18 yrs to 82 yrs</td></tr><tr><td>% Caucasian</td><td>77.2</td></tr><tr><td>% Asian</td><td>21.9</td></tr><tr><td>% Single/never married/divorced/widow</td><td>27</td></tr><tr><td>% Married/de facto</td><td>73</td></tr><tr><td>High school, highest level</td><td>25.9</td></tr><tr><td>Undergraduate, highest level</td><td>49.4</td></tr><tr><td>Postgraduate, highest level</td><td>21.2</td></tr><tr><td>No history of mental illness</td><td>87.9</td></tr><tr><td>History of minor mental illness</td><td>10.4</td></tr><tr><td>History of major mental illness</td><td>1.7</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Variables</td><td colspan="2">TdIF1 expression</td><td rowspan="2">Total</td><td rowspan="2">Χ2</td><td rowspan="2">P value</td></tr><tr><td></td><td>High</td><td>Low</td></tr><tr><td rowspan="3">Age (year)</td><td></td><td></td><td></td><td></td><td>1.298</td><td>0.254</td></tr><tr><td>≤60</td><td>24</td><td>17</td><td>41</td><td></td><td></td></tr><tr><td>>60</td><td>35</td><td>15</td><td>50</td><td></td><td></td></tr><tr><td rowspan="3">Sex</td><td></td><td></td><td></td><td></td><td>1.298</td><td>0.254</td></tr><tr><td>Female</td><td>24</td><td>17</td><td>41</td><td></td><td></td></tr><tr><td>Male</td><td>35</td><td>15</td><td>50</td><td></td><td></td></tr><tr><td rowspan="4">TNM stage</td><td></td><td></td><td></td><td></td><td>3.613</td><td>0.057</td></tr><tr><td>I/II</td><td>24</td><td>21</td><td>45</td><td></td><td></td></tr><tr><td>III/IV</td><td>30</td><td>11</td><td>41</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td>5</td><td></td><td></td></tr><tr><td rowspan="4">T stage</td><td></td><td></td><td></td><td></td><td>5.129</td><td>0.024*</td></tr><tr><td>N0</td><td>20</td><td>18</td><td>38</td><td></td><td></td></tr><tr><td>N1/N2/N3</td><td>28</td><td>8</td><td>36</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td>17</td><td></td><td></td></tr><tr><td rowspan="4">M stage</td><td></td><td></td><td></td><td></td><td>0.558</td><td>0.455</td></tr><tr><td>M0</td><td>57</td><td>32</td><td>89</td><td></td><td></td></tr><tr><td>M1</td><td>1</td><td>0</td><td>1</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Error rate (%)</td><td>Raw reads</td><td>Clean reads</td><td>Ave overall mapping rate to virus</td><td>Ave overall mapping rate to host</td></tr><tr><td colspan="6">RNA-seq</td></tr><tr><td>dcl1-9_M</td><td>0.03</td><td>47155365</td><td>46712485</td><td>0.00%</td><td>78.33%</td></tr><tr><td>dcl1-9_T</td><td>0.03</td><td>47105814</td><td>47086893</td><td>1.73%</td><td>80.17%</td></tr><tr><td>WT_M</td><td>0.03</td><td>47249649</td><td>47027652</td><td>0.19%</td><td>86.60%</td></tr><tr><td>WT_T</td><td>0.03</td><td>46493706</td><td>46186167</td><td>7.19%</td><td>85.73%</td></tr><tr><td colspan="6">sRNA-seq</td></tr><tr><td>dcl1-9_M</td><td>0.01</td><td>23404642</td><td>22422124</td><td>0.54%</td><td>63.12%</td></tr><tr><td>dcl1-9_T</td><td>0.01</td><td>22075148</td><td>21033182</td><td>52.63%</td><td>52.27%</td></tr><tr><td>WT_M</td><td>0.01</td><td>22873226</td><td>22026042</td><td>0.19%</td><td>58.76%</td></tr><tr><td>WT_T</td><td>0.01</td><td>22645661</td><td>21997229</td><td>87.46%</td><td>22.37%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>SNP id</td><td>Position</td><td>MAFa</td><td>Odds ratiob</td><td>P-valueb</td><td>PC1c</td><td>PC2c</td></tr><tr><td>rs1394371</td><td>76511524</td><td>0.32</td><td>1.110685</td><td>7.34E-02</td><td>0.238102</td><td>0.289431</td></tr><tr><td>rs12903150</td><td>76511700</td><td>0.22</td><td>0.916667</td><td>1.89E-01</td><td>20.22088</td><td>0.066403</td></tr><tr><td>rs12899131</td><td>76513940</td><td>0.38</td><td>0.973222</td><td>6.27E-01</td><td>20.36255</td><td>0.013854</td></tr><tr><td>rs2656069</td><td>76532762</td><td>0.23</td><td>0.760253</td><td>7.67E-05</td><td>0.110054</td><td>20.40066</td></tr><tr><td>rs13180</td><td>76576543</td><td>0.39</td><td>0.873685</td><td>1.75E-02</td><td>20.08845</td><td>20.374</td></tr><tr><td>rs3743079</td><td>76578116</td><td>0.17</td><td>1.075484</td><td>3.13E-01</td><td>20.2273</td><td>20.05414</td></tr><tr><td>rs3885951</td><td>76612972</td><td>0.12</td><td>1.279568</td><td>2.30E-03</td><td>0.158959</td><td>0.186958</td></tr><tr><td>rs2036534</td><td>76614003</td><td>0.24</td><td>0.698668</td><td>1.23E-07</td><td>0.120671</td><td>20.42301</td></tr><tr><td>rs2292117</td><td>76621744</td><td>0.36</td><td>0.908155</td><td>8.78E-02</td><td>20.39076</td><td>0.034655</td></tr><tr><td>rs680244</td><td>76658343</td><td>0.37</td><td>0.911216</td><td>1.03E-01</td><td>20.39566</td><td>0.037326</td></tr><tr><td>rs578776</td><td>76675455</td><td>0.29</td><td>0.738028</td><td>1.45E-06</td><td>0.085806</td><td>20.39304</td></tr><tr><td>rs12914385</td><td>76685778</td><td>0.41</td><td>1.416705</td><td>3.68E-10</td><td>0.258519</td><td>0.31863</td></tr><tr><td>rs1948</td><td>76704454</td><td>0.3</td><td>0.878962</td><td>3.10E-02</td><td>20.36327</td><td>0.013799</td></tr><tr><td>rs11636753</td><td>76716001</td><td>0.35</td><td>0.89959</td><td>6.74E-02</td><td>20.35628</td><td>0.025404</td></tr><tr><td>rs12441998</td><td>76716427</td><td>0.24</td><td>0.725298</td><td>2.24E-06</td><td>0.096535</td><td>20.36738</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Safety margin</td><td>Total prediction accuracy</td><td>Class 1 (< 25% activity)</td><td>Class 2 (> 25% activity)</td><td>Unknown</td><td>MCC</td></tr><tr><td>0</td><td>76.6</td><td>78.7</td><td>73.6</td><td>0</td><td>0.52</td></tr><tr><td>5</td><td>78.3</td><td>80.4</td><td>75.3</td><td>11.4</td><td>0.55</td></tr><tr><td>10</td><td>80.2</td><td>83.4</td><td>75.8</td><td>23.3</td><td>0.59</td></tr><tr><td>15</td><td>82.6</td><td>85.6</td><td>78.3</td><td>34.9</td><td>0.64</td></tr><tr><td>20</td><td>85.5</td><td>89.1</td><td>80.5</td><td>46.0</td><td>0.70</td></tr><tr><td>25</td><td>87.6</td><td>91.1</td><td>82.6</td><td>54.9</td><td>0.74</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Country</td><td rowspan="3">Locality</td><td rowspan="3">Coordinates (Lat; Long)</td><td rowspan="3">Source</td><td colspan="2">N</td><td rowspan="3">Molecular form</td><td colspan="6">2L arrangements and 2L PCR genotypes</td></tr><tr><td rowspan="2">Ag</td><td rowspan="2">Aa</td><td colspan="2">2L+a/2L+a</td><td colspan="2">2La/2L+a</td><td rowspan="2">2La/2La 492/492</td><td rowspan="2">HWE: χ2; P values</td></tr><tr><td>207/207</td><td>207/687</td><td>207/492</td><td>687/492</td></tr><tr><td>Cameroon</td><td>Loum</td><td>-4.100; 11.500</td><td>Colony</td><td>30</td><td>0</td><td>M</td><td>0</td><td>0</td><td>16</td><td>0</td><td>14</td><td>P = 0.6</td></tr><tr><td>Mali</td><td>Banambani</td><td>-8.050; 12.800</td><td>Colony</td><td>30</td><td>0</td><td>M</td><td>1</td><td>0</td><td>12</td><td>0</td><td>17</td><td>P = 0.9</td></tr><tr><td>Kenya</td><td>Kisumu</td><td>-0.583; 34.466</td><td>Colony</td><td>37</td><td>0</td><td>S</td><td>6</td><td>0</td><td>22</td><td>0</td><td>9</td><td>P = 0.9</td></tr><tr><td>Tanzania</td><td>Njage</td><td>-8.133; 36.683</td><td>Colony</td><td>79</td><td>0</td><td>S</td><td>2</td><td>3</td><td>23</td><td>37</td><td>14</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Lupiro</td><td>-8.377 36.667</td><td>Field</td><td>45</td><td>101</td><td>S</td><td>10</td><td>1</td><td>7</td><td>8</td><td>19</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Mkamba</td><td>-8.033; 37.767</td><td>Field</td><td>51</td><td>23</td><td>S</td><td>18</td><td>0</td><td>1</td><td>2</td><td>30</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Mikeregemb e</td><td>-8.036; 37.967</td><td>Field</td><td>1</td><td>138</td><td>S</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Ukindu</td><td>-8.277; 36.667</td><td>Field</td><td>0</td><td>76</td><td>N/A</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Malinyi</td><td>-8.933; 36.133</td><td>Field</td><td>1</td><td>122</td><td>S</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Ilonga</td><td>-9.067; 36.855</td><td>Field</td><td>15</td><td>15</td><td>S</td><td>3</td><td>0</td><td>3</td><td>2</td><td>7</td><td>P = 0.5</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Factor</td><td colspan="2">mRNA expression</td><td colspan="2">Protein localization</td></tr><tr><td>Oocytes</td><td>Ovary</td><td>Oocyte</td><td>Ovary</td></tr><tr><td>Oct-4</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>Figα</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>NoBox</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>TAFII 105</td><td>—</td><td>+++</td><td>n/d</td><td>n/d</td></tr><tr><td>FOXL2</td><td>+</td><td>+++</td><td>—</td><td>+++</td></tr><tr><td>Oogenesin 1</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>Sox 3</td><td>+</td><td>++</td><td>—</td><td>—</td></tr><tr><td>Obox 1,2,3,4,5,6</td><td>++</td><td>—</td><td>n/d</td><td>n/d</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Testing set</td><td>ACC(%)</td><td>SN(%)</td><td>Spec(%)</td><td>PPV(%)</td><td>NPV(%)</td><td>F1(%)</td><td>MCC(%)</td></tr><tr><td>1</td><td>95.41</td><td>93.15</td><td>97.60</td><td>97.46</td><td>93.54</td><td>92.26</td><td>90.88</td></tr><tr><td>2</td><td>94.99</td><td>92.03</td><td>97.82</td><td>97.57</td><td>92.80</td><td>94.72</td><td>90.11</td></tr><tr><td>3</td><td>94.28</td><td>92.31</td><td>96.29</td><td>96.23</td><td>92.44</td><td>94.23</td><td>88.64</td></tr><tr><td>4</td><td>94.95</td><td>92.69</td><td>97.22</td><td>97.10</td><td>92.97</td><td>94.84</td><td>89.99</td></tr><tr><td>5</td><td>95.40</td><td>93.15</td><td>97.60</td><td>97.46</td><td>93.54</td><td>95.26</td><td>90.88</td></tr><tr><td>Average</td><td>95.01±0.46</td><td>92.67±0.5</td><td>97.31±0.61</td><td>97.16±0.55</td><td>93.06±0.48</td><td>94.26±1.18</td><td>90.1±0.92</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>conformer</td><td>E 1 (a) [kJ/mol]</td><td>E 1 (b) [kJ/mol]</td><td>conformer</td><td>E 2 (a) [kJ/mol]</td><td>E 2 (b) [kJ/mol]</td></tr><tr><td>g+ g+</td><td>7.7</td><td>0.3</td><td>g− g−</td><td>9.8</td><td>0</td></tr><tr><td>g+ t</td><td>4.7</td><td>0.8</td><td>g− t</td><td>5.3</td><td>1.4</td></tr><tr><td>t t</td><td>0</td><td>0</td><td>t t</td><td>0</td><td>0.1</td></tr><tr><td>g+ g−</td><td>13.3</td><td>3.2</td><td>g− g+</td><td>16.4</td><td>3.6</td></tr><tr><td>g− t</td><td>9.6</td><td>2.5</td><td>g+ t</td><td>10.8</td><td>1.8</td></tr><tr><td>g− g−</td><td>18.2</td><td>3.4</td><td>g+ g+</td><td>22.5</td><td>6.8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>Ka</td><td>Ks</td><td>Ka/Ks</td></tr><tr><td>nd6</td><td>0.056</td><td>1.248</td><td>0.045</td></tr><tr><td>atp6</td><td>0.040</td><td>0.598</td><td>0.067</td></tr><tr><td>atp8</td><td>0.162</td><td>0.557</td><td>0.290</td></tr><tr><td>cox1</td><td>0.009</td><td>0.866</td><td>0.010</td></tr><tr><td>cox2</td><td>0.024</td><td>1.123</td><td>0.021</td></tr><tr><td>cox3</td><td>0.026</td><td>1.601</td><td>0.016</td></tr><tr><td>cytb</td><td>0.051</td><td>1.271</td><td>0.040</td></tr><tr><td>nd1</td><td>0.023</td><td>1.847</td><td>0.012</td></tr><tr><td>nd2</td><td>0.043</td><td>0.665</td><td>0.064</td></tr><tr><td>nd3</td><td>0.063</td><td>0.929</td><td>0.068</td></tr><tr><td>nd4</td><td>0.028</td><td>1.008</td><td>0.028</td></tr><tr><td>nd4l</td><td>0.040</td><td>0.874</td><td>0.046</td></tr><tr><td>nd5</td><td>0.056</td><td>1.123</td><td>0.050</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">T0</td><td colspan="2">T1</td><td colspan="2">T2</td></tr><tr><td></td><td>Mean</td><td>S.D.</td><td>Mean</td><td>S.D.</td><td>Mean</td><td>S.D.</td></tr><tr><td>A-angle(group A)</td><td>20.63</td><td>5.98</td><td>22.93</td><td>7.16</td><td>20.80</td><td>6.72</td></tr><tr><td>A-angle(group B)</td><td>18.13</td><td>8.09</td><td>20.33</td><td>7.87</td><td>18.23</td><td>7.71</td></tr><tr><td>Total</td><td>19.38</td><td>7.11</td><td>21.63</td><td>7.51</td><td>19.52</td><td>7.23</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Name</td><td>Definition</td></tr><tr><td>TAF1 [GenBank:NP004597.2]</td><td>TBP-associated factor 1 isoform 1</td></tr><tr><td>ATF2 [GenBank:NP001871.2]</td><td>activating transcription factor 2</td></tr><tr><td>GTF2B [GenBank:NP001505.1]</td><td>general transcription factor IIB</td></tr><tr><td>CCND1 [GenBank:NP444284.1]</td><td>cyclin D1</td></tr><tr><td>STAT1 [GenBank:NP009330.1]</td><td>signal transducer and activator of transcription 1 isoform alpha</td></tr><tr><td>TBP [GenBank:NP003185.1]</td><td>TATA box binding protein</td></tr><tr><td>CDKN1A [GenBank:NP000380.1]</td><td>cyclin-dependent kinase inhibitor 1A</td></tr><tr><td>CEBPB [GenBank:NP005185.2]</td><td>CCAAT/enhancer binding protein beta</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Catechins</td><td>Tea Leaves a</td><td>Tea Flowers b</td></tr><tr><td>EGCG</td><td>6.81–8.58</td><td>0.27–1.97</td></tr><tr><td>ECG</td><td>1.11–2.07</td><td>0.21–0.85</td></tr><tr><td>EGC</td><td>1.15–1.58</td><td>0.03–1.96</td></tr><tr><td>EC</td><td>0.50–0.69</td><td>0.04–0.41</td></tr><tr><td>C</td><td>0.02–0.11</td><td>0.00–0.31</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="5">Caregivers of patients with</td></tr><tr><td></td><td rowspan="3">Eating Disordersa (n=251) Mean C-index</td><td rowspan="3">Depressionb (n=252) Mean C-index</td><td rowspan="3">Schizophreniaa (n=151) Mean C-index*</td><td rowspan="3">P-value</td></tr><tr><td colspan="5">IE Q-EU scales</td></tr><tr><td>Tension</td><td>0.18 (0.19)b,c</td><td>0.17 (0.21)c,ab,ac,a</td><td>0.11 (0.17)b,ab,c</td><td>0.0002</td></tr><tr><td>Supervision</td><td>0.10 (0.19)c</td><td>0.07 (0.14)</td><td>0.06 (0.15)a</td><td>0.06</td></tr><tr><td>Worrying</td><td>0.56 (0.29)b,c</td><td>0.32 (0.31)a</td><td>0.37 (0.31)a</td><td><0.0001</td></tr><tr><td>Urging</td><td>0.21 (0.17)b,c</td><td>0.16 (0.20)a</td><td>0.21 (0.25)a</td><td><0.0001</td></tr><tr><td>Total score</td><td>0.26 (0.15)b,c</td><td>0.17 (0.16)a</td><td>0.18 (0.17)a</td><td><0.0001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Autism Group</td><td>Neurotypical Group</td></tr><tr><td>Total Participants</td><td>55</td><td>44</td></tr><tr><td>Male</td><td>49 (89%)</td><td>39 (89%)</td></tr><tr><td>Female</td><td>6 (11%)</td><td>5(11%)</td></tr><tr><td>Age (years)</td><td>10.0 +/- 3.1</td><td>11.0 +/- 3.1</td></tr><tr><td>Diagnosis</td><td>85% autism, 4% PDD/ NOS, 11% Asperger’s</td><td>In good mental and physical health</td></tr><tr><td>Medications</td><td>55% no medications 29% psycho- pharmaceuticals - primarily risperidone and clonidine; 9% on CNS stimulants (primarily Concerta); 4% on anti-convulsants 5% on GI medications; 7% on asthma/allergy medicine; 2% on insulin</td><td>89% no medications; 9% on anti-inflammatories (asthma/allergies); 2% on anti-incontinence medication</td></tr><tr><td>Special Diets</td><td>84% on regular diet; 3 gluten-free, casein-free diet; 1 gluten-free; 3 reduced dairy/gluten; 2 low sugar</td><td>1 child on dairy-free diet</td></tr><tr><td>Nutritional Supplements</td><td>1 on fish oil; 2 on melatonin</td><td>none</td></tr><tr><td>PDD-BI (modified autism composite)</td><td>-63 +/- 54</td><td>n/a</td></tr><tr><td>ATEC</td><td>64 +/- 25</td><td>n/a</td></tr><tr><td>SAS</td><td>4.9 +/- 2.4</td><td>n/a</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Parameters</td><td>Meaning</td><td>Value</td><td>Unit</td><td>Reference</td></tr><tr><td>π</td><td>Bee daily birth rate</td><td>2500</td><td>bees × day−1</td><td>[13]</td></tr><tr><td>δ</td><td>Maturation rate</td><td>0.05</td><td>day−1</td><td>[13]</td></tr><tr><td>H</td><td>Generic hygienic behavior</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>Hi</td><td>Hygienic behavior towards infested brood</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>g</td><td>Grooming</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>μ</td><td>Mortality rate</td><td>0.04</td><td>day−1</td><td>[14]</td></tr><tr><td>γ</td><td>Mite induced mortality</td><td>10−7</td><td>day−1</td><td>[11]</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">No. of the at-risk area (full name of the area)</td><td>P1 (2012–2013 and 2013–2014) Culture</td><td>P2 (2015–2016 and 2016–2017) PCR</td></tr><tr><td colspan="2">Apparent prevalence (No. of infected wild</td></tr><tr><td>rates [95% CI] boar/no. analyzed)</td><td>1 (Brotonne-Mauny forest)</td><td>1.5% [0.6–3.2%] (6/401)</td></tr><tr><td>1.3% [0.4–2.9%] (5/394)</td><td>2 (Côte-d’Or)</td><td>3.1% [1.7–5.1%] (15/483)</td></tr><tr><td>2.2% [1.0–4.2%] (9/404)</td><td>3 (Dordogne/Charente/ Charente-Maritime/Haute- Vienne/Corrèze/Gironde)</td><td>4.1% [2.4–6.4%] (17/419)</td></tr><tr><td>2.7% [1.7–4.1%] (21/770)</td><td>4 (Dordogne/Lot)</td><td>4.3% [1.9–8.2%] (8/188)</td></tr><tr><td>3.2% [1.6–5.7%] (11/341)</td><td>5 (Béarn)</td><td>2.1% [0.9–4.2%] (8/373)</td></tr><tr><td>4.4% [2.4–7.4%] (13/295)</td><td>9 (Lot-et-Garonne)</td><td>/</td></tr><tr><td>4.2% [1.6–8.9%] (6/143)</td><td>11 (Ariège/Haute-Garonne)</td><td>/</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Kdr mutation status</td><td colspan="4">2010</td><td colspan="4">2011</td></tr><tr><td rowspan="2">LLIN only arm n (%)</td><td rowspan="2">IRS-LLIN arm n (%)</td><td rowspan="2">OR (95% CI) (adjusted for clustering)</td><td rowspan="2">p value</td><td rowspan="2">LLIN only arm n (%)</td><td rowspan="2">IRS-LLIN arm n (%)</td><td rowspan="2">OR (95% CI) (adjusted for clustering)</td><td rowspan="2">p value</td></tr><tr><td>Wild type</td><td>1761 (70.3%)</td><td>1015 (58.5%)</td><td></td><td></td><td>461 (53.9%)</td><td>250 (39.6%)</td><td></td><td></td></tr><tr><td>Any Vgsc‑1014 muta‑ tion</td><td>695 (27.7%)</td><td>693 (39.9%)</td><td>1.54 (1.07–2.22)</td><td>0.02</td><td>370 (43.2%)</td><td>344 (54.4%)</td><td>2.26 (1.24–4.11)</td><td>0.01</td></tr><tr><td>Heterozygous Vgsc‑ 1014F</td><td>70 (2.8%)</td><td>103 (5.9%)</td><td>2.17 (1.28–3.68)</td><td>0.004</td><td>34 (4.0%)</td><td>31 (4.9%)</td><td>1.32 (0.75–2.33)</td><td>0.34</td></tr><tr><td>Homozygous Vgsc‑ 1014F</td><td>167 (6.7%)</td><td>290 (16.7%)</td><td>2.24 (1.12–4.49)</td><td>0.02</td><td>169 (19.7%)</td><td>196 (31.0%)</td><td>2.52 (1.20–5.29)</td><td>0.01</td></tr><tr><td>Heterozygous Vgsc‑ 1014S</td><td>412 (16.4%)</td><td>262 (15.1%)</td><td>0.86 (0.67–1.11)</td><td>0.26</td><td>149 (17.4%)</td><td>95 (15.0%)</td><td>0.71 (0.41–1.23)</td><td>0.22</td></tr><tr><td>Homozygous Vgsc‑ 1014S</td><td>46 (1.8%)</td><td>38 (2.2%)</td><td>1.09 (0.60–1.99)</td><td>0.78</td><td>18 (2.1%)</td><td>22 (3.5%)</td><td>1.34 (0.53–3.36)</td><td>0.54</td></tr><tr><td>N</td><td>2506</td><td>1736</td><td></td><td></td><td>856</td><td>632</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Median</td><td>Mean</td><td>Range</td></tr><tr><td>Age (years)</td><td>77</td><td>76.5</td><td>53-95</td></tr><tr><td>Follow-up period (months)</td><td>49</td><td>52.0</td><td>12-143</td></tr><tr><td>PSA level at diagnosis (ng/mL)</td><td>15</td><td>28.9</td><td>1.4-200</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Label</td><td>Size (Mb)</td><td>Topology</td><td>INSDC identifier</td><td>RefSeq ID</td></tr><tr><td>Chromosome 1</td><td>2.74</td><td>circular</td><td>CP001365.1</td><td>NC012029.1</td></tr><tr><td>Chromosome 2 (pHL500)</td><td>0.53</td><td>circular</td><td>CP001366.1</td><td>NC012028.1</td></tr><tr><td>Plasmid (pHL400)</td><td>0.43</td><td>circular</td><td>CP001367.1</td><td>NC012030.1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Variable</td><td rowspan="2">Patients, n/n</td><td rowspan="2">Patients with Variable when Increased ECFCs Frequency is Present, n</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td>Unadjusted Odds Ratio for Increased ECFCs Frequency (95% CI)</td><td>P value</td><td>Adjusted Odds Ratio for Increased ECFCs Frequency (95% CI)</td><td>P value</td></tr><tr><td>Female sex</td><td>102/214</td><td>29</td><td>2.24 (1.09–4.69)</td><td>0.026</td><td></td><td></td></tr><tr><td>Age lower than 50 years</td><td>99/214</td><td>17</td><td>2.72 (1.28–5.68)</td><td>0.008</td><td></td><td></td></tr><tr><td>Diagnosis of prefibrotic myelofibrosis</td><td>56/214</td><td>21</td><td>2.84 (1.36–5.81)</td><td>0.005</td><td></td><td></td></tr><tr><td>Phenotype of non-active disease</td><td>27/214</td><td>13</td><td>4.67 (1.81–11.94)</td><td>0.001</td><td>4.43 (1.45–13.49)</td><td>0.008</td></tr><tr><td>History of splanchnic vein thrombosis</td><td>35/214</td><td>20</td><td>7.63 (3.34–17.91)</td><td>,0.001</td><td>6.61 (2.54–17.16)</td><td>,0.001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Inhibitor</td><td>Other name(s)</td><td>IC50/Ki</td><td>IC50/Ki for PARP-1</td><td>IC50/Ki for PARP-2</td><td>Trial status</td><td>Type of cancer(s)</td></tr><tr><td>Olaparib</td><td>AZD2281 KU0059436</td><td>IC50</td><td>5 nM</td><td>1 nM</td><td>Phase I/II singly or combination</td><td>Breast, ovarian, colorectal, solid tumors, pancreatic, prostate, carcinoma of esophagus, head and neck squamous cells carcinoma, gastric, NSCLC, brain, CNS, Ewing’s sarcoma, uterine, fallopian tube, etc.</td></tr><tr><td>Veliparib</td><td>ABT-888</td><td>Ki</td><td>5.2 nM</td><td>2.9 nM</td><td>Phase I/II singly or combination</td><td>Breast, colorectal, GBM, melanoma, solid tumors, pancreatic, fallopian tube, peritoneal cavity, pancreatic, brain, CNS, lymphoma, multiple myeloma, etc.</td></tr><tr><td>Rucaparib</td><td>AG014699 PF01367338</td><td>Ki</td><td>1.4 nM</td><td>–</td><td>Phase I combined with chemotherapy/phase II singly in BRCA associated status</td><td>Breast, ovarian, solid tumors (also diabetes mellitus)</td></tr><tr><td>INO-1001</td><td>–</td><td>IC50</td><td>50 nM</td><td>–</td><td>Phase I/II</td><td>Cardiovascular disease/combination with TMZ in melanoma</td></tr><tr><td>MK-4827</td><td>–</td><td>IC50</td><td>3.8 nM</td><td>2.1 nM</td><td>Phase I singly or with chemotherapy/phase II</td><td>Ovarian, solid tumors, glioblastoma multiform, melanoma, lymphoma, chronic lymphocytic leukemia, T-cell-pro-lymphocytic leukemia</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>Least-squares matrix: full</td><td>H-atom parameters constrained</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.038</td><td>w = 1/[σ2(Fo 2) + (0.0379P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>wR(F2) = 0.084</td><td>(Δ/σ)max = 0.001</td></tr><tr><td>S = 0.84</td><td>Δρmax = 0.28 e Å−3</td></tr><tr><td>4303 reflections</td><td>Δρmin = −0.30 e Å−3</td></tr><tr><td>229 parameters</td><td>Extinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4</td></tr><tr><td>1 restraint</td><td>Extinction coefficient: 0.046 (2)</td></tr><tr><td>Primary atom site location: structure-invariant direct methods</td><td>Absolute structure: Flack (1983), 1878 Friedel pairs</td></tr><tr><td>Secondary atom site location: difference Fourier map</td><td>Flack parameter: 0.05 (7)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Mesh</td><td># of fly genes</td><td># of fly genes with human ortholog(s)</td><td># of fly genes shared disease categories with their human ortholog</td><td>% fly genes with human ortholog(s)</td><td>% fly genes shared disease categories with their human ortholog</td></tr><tr><td>Neoplasms</td><td>681</td><td>636</td><td>592</td><td>93%</td><td>93%</td></tr><tr><td>Pathological Conditions, Signs and Symptoms</td><td>2105</td><td>1713</td><td>1566</td><td>81%</td><td>91%</td></tr><tr><td>Nervous System Diseases</td><td>1179</td><td>1004</td><td>878</td><td>85%</td><td>87%</td></tr><tr><td>Digestive System Diseases</td><td>105</td><td>94</td><td>81</td><td>90%</td><td>86%</td></tr><tr><td>Otorhinolaryngologic Diseases</td><td>18</td><td>14</td><td>12</td><td>78%</td><td>86%</td></tr><tr><td>Mental Disorders</td><td>470</td><td>448</td><td>378</td><td>95%</td><td>84%</td></tr><tr><td>Congenital, Hereditary, and Neonatal Diseases and Abnormalities</td><td>1234</td><td>1100</td><td>900</td><td>89%</td><td>82%</td></tr><tr><td>Cardiovascular Diseases</td><td>139</td><td>126</td><td>103</td><td>91%</td><td>82%</td></tr><tr><td>Stomatognathic Diseases</td><td>20</td><td>20</td><td>16</td><td>100%</td><td>80%</td></tr><tr><td>Skin and Connective Tissue Diseases</td><td>148</td><td>123</td><td>98</td><td>83%</td><td>80%</td></tr><tr><td>Immune System Diseases</td><td>112</td><td>84</td><td>64</td><td>75%</td><td>76%</td></tr><tr><td>Respiratory Tract Diseases</td><td>8</td><td>8</td><td>6</td><td>100%</td><td>75%</td></tr><tr><td>Disorders of Environmental Origin</td><td>760</td><td>642</td><td>466</td><td>84%</td><td>73%</td></tr><tr><td>Hemic and Lymphatic Diseases</td><td>100</td><td>96</td><td>69</td><td>96%</td><td>72%</td></tr><tr><td>Endocrine System Diseases</td><td>163</td><td>144</td><td>103</td><td>88%</td><td>72%</td></tr><tr><td>Nutritional and Metabolic Diseases</td><td>577</td><td>452</td><td>310</td><td>78%</td><td>69%</td></tr><tr><td>Female Urogenital Diseases and Pregnancy Complications</td><td>558</td><td>413</td><td>276</td><td>74%</td><td>67%</td></tr><tr><td>Virus Diseases</td><td>38</td><td>32</td><td>21</td><td>84%</td><td>66%</td></tr><tr><td>Musculoskeletal Diseases</td><td>211</td><td>165</td><td>106</td><td>78%</td><td>64%</td></tr><tr><td>Male Urogenital Diseases</td><td>468</td><td>355</td><td>221</td><td>76%</td><td>62%</td></tr><tr><td>Bacterial Infections and Mycoses</td><td>325</td><td>233</td><td>99</td><td>72%</td><td>42%</td></tr><tr><td>Eye Diseases</td><td>699</td><td>590</td><td>221</td><td>84%</td><td>37%</td></tr><tr><td>Parasitic Diseases</td><td>229</td><td>187</td><td>21</td><td>82%</td><td>11%</td></tr><tr><td>All Categories</td><td>3557</td><td>2739</td><td>2283</td><td>77%</td><td>83%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Genotypes qGL3aqGL7</td><td colspan="4">qGW5aqGW9b</td></tr><tr><td>NNNN</td><td>NNCC</td><td>CCNN</td><td>CCCC</td></tr><tr><td>NNNN</td><td>3.36</td><td>3.43</td><td>3.64</td><td>3.86</td></tr><tr><td>NNCC</td><td>2.83</td><td>2.89</td><td>3.06</td><td>3.25</td></tr><tr><td>CCNN</td><td>2.48</td><td>2.53</td><td>2.68</td><td>2.84</td></tr><tr><td>CCCC</td><td>2.26</td><td>2.30</td><td>2.44</td><td>2.59</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Rank</td><td colspan="2">FD</td><td colspan="2">XS</td><td colspan="2">QH</td><td colspan="2">Total</td></tr><tr><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td></tr><tr><td>1</td><td>PP2A</td><td>1.42 ± 0.34</td><td>UBC</td><td>0.60 ± 0.10</td><td>CYP</td><td>1.70 ± 0.50</td><td>UBC</td><td>2.03 ± 0.48</td></tr><tr><td>2</td><td>α-TUB</td><td>1.96 ± 0.45</td><td>GAPDH</td><td>1.00 ± 0.20</td><td>UBC</td><td>2.40 ± 0.60</td><td>EF-1α</td><td>2.22 ± 0.52</td></tr><tr><td>3</td><td>TIP41</td><td>1.75 ± 0.45</td><td>TIP41</td><td>1.00 ± 0.30</td><td>EF-1α</td><td>2.60 ± 0.60</td><td>TIP41</td><td>2.16 ± 0.56</td></tr><tr><td>4</td><td>GAPDH</td><td>2.25± 0.48</td><td>PP2A</td><td>1.50 ± 0.40</td><td>TIP41</td><td>2.30 ± 0.60</td><td>CYP</td><td>2.37 ± 0.62</td></tr><tr><td>5</td><td>UBC</td><td>2.28 ± 0.53</td><td>EF-1α</td><td>1.70 ± 0.40</td><td>α-TUB</td><td>3.10 ± 0.80</td><td>PP2A</td><td>2.64 ± 0.66</td></tr><tr><td>6</td><td>ACTIN</td><td>2.04± 0.53</td><td>ACTIN</td><td>2.10 ± 0.60</td><td>GAPDH</td><td>3.50 ± 0.80</td><td>GAPDH</td><td>3.34 ± 0.74</td></tr><tr><td>7</td><td>EF-1α</td><td>2.46 ± 0.58</td><td>α-TUB</td><td>2.40 ± 0.60</td><td>β-TUB</td><td>3.30 ± 0.80</td><td>α-TUB</td><td>3.55 ± 0.85</td></tr><tr><td>8</td><td>CYP</td><td>2.77 ± 0.71</td><td>CYP</td><td>2.20 ± 0.60</td><td>PP2A</td><td>3.30 ± 0.80</td><td>ACTIN</td><td>3.17 ± 0.85</td></tr><tr><td>9</td><td>SAMS</td><td>3.67 ± 0.76</td><td>β-TUB</td><td>2.60 ± 0.70</td><td>ACTIN</td><td>3.70 ± 1.00</td><td>β-TUB</td><td>3.53 ± 0.86</td></tr><tr><td>10</td><td>β-TUB</td><td>3.84 ± 0.90</td><td>SAMS</td><td>3.20 ± 0.70</td><td>SAMS</td><td>5.70 ± 1.20</td><td>SAMS</td><td>4.37 ± 0.91</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Modality</td><td>Model</td><td>Test sample(s)</td><td>Axon Dice similarity</td><td>Myelin Dice similarity</td><td>Pixel-wise accuracy</td><td>Sensitivity</td><td>Precision</td></tr><tr><td rowspan="3">SEM</td><td rowspan="3">Trained on rat samples</td><td>Rat 1</td><td>0.9089</td><td>0.8193</td><td>0.8510</td><td>0.9699</td><td>0.8468</td></tr><tr><td>Rat 2</td><td>0.9244</td><td>0.8389</td><td>0.8822</td><td>0.9876</td><td>0.7987</td></tr><tr><td>Human</td><td>0.8089</td><td>0.7629</td><td>0.8114</td><td>0.9300</td><td>0.7306</td></tr><tr><td rowspan="2">TEM</td><td rowspan="2">Trained on mice samples</td><td>Mice</td><td>0.9493</td><td>0.8552</td><td>0.9451</td><td>0.9597</td><td>0.9647</td></tr><tr><td>Macaque</td><td>0.9069</td><td>0.7519</td><td>0.8438</td><td>0.9429</td><td>0.8129</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Bimatoprost 0.03%, 2.5 mL</td><td>Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL)</td><td>Latanoprost 0.005%, 2.5 mL</td><td>Travoprost 0.004%, 2.5 mL</td></tr><tr><td>Walgreens</td><td>$54.99</td><td>$52.50</td><td>$53.99</td><td>--</td></tr><tr><td>Park Pharmacy</td><td>$51.95</td><td>$50.98</td><td>$49.95</td><td>$49.95</td></tr><tr><td>WalMart</td><td>$51.46</td><td>$51.89</td><td>$40.98</td><td>$48.62</td></tr><tr><td>Winn Dixie</td><td>$44.50</td><td>$44.50</td><td>$46.00</td><td>$47.00</td></tr><tr><td>K-Mart</td><td>$56.97</td><td>$51.99</td><td>$49.99</td><td>$53.97</td></tr><tr><td>Target</td><td>$56.39</td><td>$51.35</td><td>$41.99</td><td>$53.69</td></tr><tr><td>DrugStore.Com</td><td>$50.10</td><td>$50.10</td><td>$46.90</td><td>$47.40</td></tr><tr><td>Average</td><td>$52.34</td><td>$50.47</td><td>$47.11</td><td>$50.11</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Primary atom site location: structure-invariant direct methods</td></tr><tr><td>Least-squares matrix: full</td><td>Secondary atom site location: difference Fourier map</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.041</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>wR(F2) = 0.140</td><td>H-atom parameters constrained</td></tr><tr><td>S = 1.11</td><td>w = 1/[σ2(Fo 2) + (0.0893P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>15185 reflections</td><td>(Δ/σ)max < 0.001</td></tr><tr><td>582 parameters</td><td>Δρmax = 0.83 e Å−3</td></tr><tr><td>1 restraint</td><td>Δρmin = −0.88 e Å−3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">COG ID</td><td rowspan="2">Estimated No. of truly existing CDSs</td><td colspan="2">Read Counts</td></tr><tr><td></td><td>By BLAST</td><td>By RPS-BLAST</td></tr><tr><td rowspan="3">Step 1</td><td>COG0454</td><td>0</td><td>362</td><td>0</td></tr><tr><td>COG0500</td><td>2</td><td>658</td><td>0</td></tr><tr><td>COG0477</td><td>0</td><td>2283</td><td>85</td></tr><tr><td rowspan="2">Step 2</td><td>COG0457</td><td>0</td><td>101</td><td>0</td></tr><tr><td>COG0639</td><td>2</td><td>58</td><td>0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Electron donor</td><td rowspan="3">Concentration (mM)</td><td colspan="4">Specific activity (U mg21)a</td></tr><tr><td colspan="2">FepB</td><td colspan="2">HRP</td></tr><tr><td>pH 3.3</td><td>pH 4.7</td><td>pH 3.3</td><td>pH 4.7</td></tr><tr><td>Catechol</td><td>10</td><td>0.3060.04</td><td>nd</td><td>179.165.0</td><td>413.1635.6</td></tr><tr><td>ABTS</td><td>1.5</td><td>39.466.3</td><td>0.7060.05</td><td>1.3260.12</td><td>42066.6</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">Ocln</td><td colspan="2">ZO-1</td><td colspan="2">Cldn-1</td><td colspan="2">Cldn-4</td></tr><tr><td></td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td></tr><tr><td colspan="9">Tumor grading</td></tr><tr><td>I</td><td>57.1%</td><td>25.9%</td><td>27.3%</td><td>25.0%</td><td>32.5%</td><td>50%</td><td>20.8%</td><td>40%</td></tr><tr><td>II</td><td>28.6%</td><td>40.7%</td><td>45.4%</td><td>37.5%</td><td>42.5%</td><td>25%</td><td>50%</td><td>20%</td></tr><tr><td>III</td><td>14.3%</td><td>33.4%</td><td>27.3%</td><td>37.5%</td><td>25%</td><td>25%</td><td>29.2%</td><td>40%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="8">A) Toxicogenomics study</td></tr><tr><td rowspan="2">GO category</td><td rowspan="2">Original Annotation</td><td rowspan="2">Non redundant Annotations</td><td colspan="3">SELECTIONS</td><td rowspan="2">STEM</td><td rowspan="2">Pair-wise</td></tr><tr><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td></tr><tr><td>BP</td><td>1828</td><td>967</td><td>7</td><td>33</td><td>15</td><td></td><td></td></tr><tr><td>MF</td><td>992</td><td>534</td><td>8</td><td>15</td><td>20</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>398</td><td>243</td><td>0</td><td>10</td><td>8</td><td></td><td></td></tr><tr><td></td><td>total</td><td>15</td><td>58</td><td>43</td><td>0</td><td>49</td></tr><tr><td colspan="8">B) Potato Stress study</td></tr><tr><td></td><td></td><td></td><td colspan="3">SELECTIONS</td><td></td><td></td></tr><tr><td>GO category</td><td>Original Annotation</td><td>Non redundant Annotations</td><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td><td>STEM</td><td>Pair-wise</td></tr><tr><td>BP</td><td>2444</td><td>780</td><td>23</td><td>258</td><td>116</td><td></td><td></td></tr><tr><td>MF</td><td>943</td><td>431</td><td>21</td><td>141</td><td>29</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>369</td><td>203</td><td>14</td><td>48</td><td>46</td><td></td><td></td></tr><tr><td></td><td>total</td><td>58</td><td>447</td><td>191</td><td>0</td><td>46</td></tr><tr><td colspan="8">C) Arabidopsis IAA study</td></tr><tr><td></td><td></td><td></td><td colspan="3">SELECTIONS</td><td></td><td></td></tr><tr><td>GO category</td><td>Original Annotation</td><td>Non redundant Annotations</td><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td><td>STEM</td><td>Pair-wise</td></tr><tr><td>BP</td><td>2640</td><td>1120</td><td>3</td><td>60</td><td>201</td><td></td><td></td></tr><tr><td>MF</td><td>1769</td><td>694</td><td>8</td><td>24</td><td>45</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>499</td><td>260</td><td>0</td><td>8</td><td>61</td><td></td><td></td></tr><tr><td></td><td>total</td><td>11</td><td>92</td><td>307</td><td>46</td><td>284</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Plasmid</td><td>Size (bp)</td><td>Characteristics</td><td>Reference</td></tr><tr><td>pCD256</td><td>4790</td><td>pUC19 containing origin from p256, AmpR, CmR</td><td>[19]</td></tr><tr><td>pCDWV01</td><td>3514</td><td>pUC19 containing origin from pWV01, AmpR, CmR</td><td>[19]</td></tr><tr><td>pCD256_hTFF1</td><td>5362</td><td>pCD256 containing hTFF1 expression cassette</td><td></td></tr><tr><td>pCD256ΔEc</td><td>1690</td><td>pCD256 lacking E. coli sequences</td><td rowspan="2">this study</td></tr><tr><td>pCD256ΔEc_hTFF1</td><td>2302</td><td>pCD256ΔEc containing hTFF1 expression cassette</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Counts Prior Filtering</td><td>Counts after Filtering</td></tr><tr><td>Blank</td><td>3824</td><td>NA</td></tr><tr><td>FI3</td><td>78,903</td><td>78,881</td></tr><tr><td>FI9</td><td>24,956</td><td>24,495</td></tr><tr><td>FI12</td><td>56,971</td><td>56,846</td></tr><tr><td>NASD3</td><td>32,086</td><td>14,768</td></tr><tr><td>NASD14</td><td>44,255</td><td>24,740</td></tr><tr><td>NASD22</td><td>60,266</td><td>55,727</td></tr><tr><td>NASD27</td><td>24,633</td><td>13,392</td></tr><tr><td>NASD29</td><td>101,517</td><td>100,028</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Acetylase/ Deacetylase</td><td>Loss/Gain of function</td><td>Physiological roles</td><td>References</td></tr><tr><td>CBP</td><td>Loss</td><td>Increased insulin sensitivity and glucose tolerance</td><td>Yamauchi et al. (2002)</td></tr><tr><td>CBP/p300</td><td>Loss</td><td>Improved insulin sensitivity with reduction in body mass Decreased glucose production</td><td>Bedford et al. (2011) He et al. (2012)</td></tr><tr><td>p300</td><td>Gain</td><td>Impaired insulin sensitivity and glucose tolerance</td><td>Bricambert et al. (2010)</td></tr><tr><td rowspan="2">SIRT1</td><td>Loss</td><td>Impaired insulin sensitivity and glucose tolerance Increased fatty liver development</td><td>Chalkiadaki and Guarente (2012) Xu et al. (2010)</td></tr><tr><td>Gain</td><td>Improved insulin sensitivity and glucose tolerance</td><td>Banks et al. (2008), Li et al. (2011)</td></tr><tr><td>HDAC3</td><td>Loss</td><td>Improved insulin sensitivity and glucose tolerance, despite of increased lipid accumulation</td><td>Sun et al. (2012)</td></tr><tr><td>Class IIa HDAC</td><td>Loss</td><td>Improved glucose tolerance by inhibiting gluconeogenesis</td><td>Mihaylova et al. (2011)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Time/group</td><td>3h</td><td>24h</td><td>72h</td></tr><tr><td>100%CL</td><td>10.13 (0.89)Bab</td><td>8.7 (0.45)Cab</td><td>7.35 (0.08)Aa</td></tr><tr><td>100%PG</td><td>10.19 (0.4)Ab</td><td>9.44 (0.72)Ac</td><td>7.4 (0.09)Bab</td></tr><tr><td>50% CL+50% PG</td><td>8.54 (0.63)Ac</td><td>8.54 (0.14)Aa</td><td>7.39 (0.22)Bab</td></tr><tr><td>80% CL+20% PG</td><td>9.42 (0.51)Aa</td><td>9.08 (0.16)Abc</td><td>7.56 (0.2)Bb</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Clinical parameter</td><td>Negative Tau expression</td><td>Positive Tau expression</td><td>p value</td></tr><tr><td colspan="4">Age</td></tr><tr><td>o < 65</td><td>16</td><td>44</td><td rowspan="2">p= ,8496</td></tr><tr><td>o ≥ 65</td><td>4</td><td>10</td></tr><tr><td colspan="4">FIGO stage at diagnosis</td></tr><tr><td>o Early (I,II)</td><td>7</td><td>10</td><td rowspan="2">p= ,1345</td></tr><tr><td>o Advanced (III,IV)</td><td>13</td><td>44</td></tr><tr><td colspan="4">Histopathologic cell type</td></tr><tr><td>o Serous</td><td>8</td><td>29</td><td rowspan="2">p= ,2951</td></tr><tr><td>o others</td><td>12</td><td>25</td></tr><tr><td colspan="4">Performance status (ECOG)</td></tr><tr><td>o 0-1</td><td>19</td><td>50</td><td rowspan="2">p= ,8768</td></tr><tr><td>o 2</td><td>1</td><td>4</td></tr><tr><td colspan="4">Tumor grade</td></tr><tr><td>o G1,G2</td><td>12</td><td>19</td><td rowspan="2">p= ,0547</td></tr><tr><td>o G3, unknown</td><td>8</td><td>35</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Age (years)</td><td>Min</td><td>18</td></tr><tr><td>Mean</td><td>52</td></tr><tr><td>Max</td><td>83</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>81 (21.5 %)</td></tr><tr><td>Female</td><td>296 (78.5 %)</td></tr><tr><td rowspan="3">Disease duration (years)</td><td>Min</td><td>0.3</td></tr><tr><td>Mean</td><td>7.3</td></tr><tr><td>Max</td><td>39.7</td></tr><tr><td rowspan="3">DAS28-CRP score</td><td>Min</td><td>3.6</td></tr><tr><td>Mean</td><td>5.9</td></tr><tr><td>Max</td><td>7.9</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Primary atom site location: structure-invariant direct methods</td></tr><tr><td>Least-squares matrix: full</td><td>Secondary atom site location: difference Fourier map</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.051</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>wR(F2) = 0.167</td><td>H-atom parameters constrained</td></tr><tr><td>S = 1.05</td><td>w = 1/[σ2(Fo 2) + (0.0656P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>5479 reflections</td><td>(Δ/σ)max = 0.001</td></tr><tr><td>290 parameters</td><td>Δρmax = 1.26 e Å−3</td></tr><tr><td>42 restraints</td><td>Δρmin = −1.31 e Å−3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Generator</td><td>Power (MW)</td></tr><tr><td>1</td><td>110.802</td></tr><tr><td>2</td><td>110.800</td></tr><tr><td>3</td><td>97.400</td></tr><tr><td>4</td><td>179.733</td></tr><tr><td>5</td><td>87.800</td></tr><tr><td>6</td><td>140.000</td></tr><tr><td>7</td><td>259.600</td></tr><tr><td>8</td><td>284.601</td></tr><tr><td>9</td><td>284.599</td></tr><tr><td>10</td><td>130.000</td></tr><tr><td>11</td><td>94.000</td></tr><tr><td>12</td><td>94.001</td></tr><tr><td>13</td><td>214.760</td></tr><tr><td>14</td><td>394.279</td></tr><tr><td>15</td><td>394.279</td></tr><tr><td>16</td><td>394.278</td></tr><tr><td>17</td><td>489.280</td></tr><tr><td>18</td><td>489.279</td></tr><tr><td>19</td><td>511.279</td></tr><tr><td>20</td><td>511.279</td></tr><tr><td>21</td><td>523.280</td></tr><tr><td>22</td><td>523.279</td></tr><tr><td>23</td><td>523.278</td></tr><tr><td>24</td><td>523.279</td></tr><tr><td>25</td><td>523.279</td></tr><tr><td>26</td><td>523.280</td></tr><tr><td>27</td><td>10.000</td></tr><tr><td>28</td><td>10.000</td></tr><tr><td>29</td><td>10.000</td></tr><tr><td>30</td><td>87.800</td></tr><tr><td>31</td><td>189.999</td></tr><tr><td>32</td><td>190.000</td></tr><tr><td>33</td><td>190.000</td></tr><tr><td>34</td><td>164.800</td></tr><tr><td>35</td><td>199.996</td></tr><tr><td>36</td><td>194.401</td></tr><tr><td>37</td><td>110.000</td></tr><tr><td>38</td><td>110.000</td></tr><tr><td>39</td><td>110.000</td></tr><tr><td>40</td><td>511.279</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Group</td><td>Pooled Effect Estimate 95% CI</td><td>I2%</td><td>Number of Observations</td></tr><tr><td>All citations</td><td>1.65 (1.47, 1.85)</td><td>89.9</td><td>51</td></tr><tr><td>Case-control citations</td><td>1.70 (1.42, 2.03)</td><td>88.7</td><td>37</td></tr><tr><td>Cohort citations</td><td>1.64 (1.30, 2.08)</td><td>87.8</td><td>14</td></tr><tr><td>Asia</td><td>3.26(1.91, 5.58)</td><td>0.0</td><td>3</td></tr><tr><td>Canada</td><td>1.22 (1.09, 1.37)</td><td>82.1</td><td>14</td></tr><tr><td>Europe</td><td>1.90 (1.35, 2.66)</td><td>75.5</td><td>10</td></tr><tr><td>USA</td><td>1.70 (1.41, 2.04)</td><td>73.3</td><td>24</td></tr><tr><td>Studies reported adjusted effect estimates</td><td>1.78 (1.56, 2.02)</td><td>92.2</td><td>37</td></tr><tr><td>Studies reported unadjusted effect estimates</td><td>1.27 (0.93, 1.71)</td><td>59.4</td><td>14</td></tr><tr><td>PPI ascertainment method (Chart){</td><td>1.89 (1.45, 2.45)</td><td>93.6</td><td>20</td></tr><tr><td>PPI ascertainment method (Interview){</td><td>1.17 (0.91, 1.51)</td><td>79.0</td><td>8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Pathogen</td><td colspan="4">Geographical location</td><td colspan="2">Sepsis severitya,b</td><td colspan="3">Clinical diagnosis</td><td rowspan="2">Overall urosepsis</td></tr><tr><td>Europe n (%)</td><td>Asia n (%)</td><td>Africa n (%)</td><td>Americas n (%)</td><td>Simple urosepsis n (%)</td><td>Severe urosepsis and uroseptic shock n (%)</td><td>MAGI n (%)</td><td>Pyelone- phritis n (%)</td><td>Cystitis n (%)</td></tr><tr><td colspan="11">Gram negative</td></tr><tr><td>E. coli</td><td>127 (41 %)</td><td>34 (52 %)</td><td>8 (38 %)</td><td>5 (50 %)</td><td>121 (46.9 %)</td><td>29 (37.2 %)</td><td>77 (37 %)</td><td>190 (45 %)</td><td>240 (43 %)</td><td>174 (43 %)</td></tr><tr><td>Klebsiella spp.</td><td>25 (8 %)</td><td>8 (11 %)</td><td>6 (29 %)</td><td>3 (30 %)</td><td>24 (9.3 %)</td><td>9 (11.5 %)</td><td>17 (8 %)</td><td>54 (13 %)</td><td>73 (13 %)</td><td>42 (10 %)</td></tr><tr><td>P. aeruginosa</td><td>39 (13 %)</td><td>3 (5 %)</td><td>0</td><td>0</td><td>24 (9.3 %)</td><td>11 (14. %1)</td><td>25 (12 %)</td><td>34 (8 %)</td><td>48 (9 %)</td><td>42 (10 %)</td></tr><tr><td>Enterobacter spp.</td><td>19 (6 %)</td><td>2 (3 %)</td><td>0</td><td>2 (20 %)</td><td>14 (5.4 %)</td><td>6 (7.7 %)</td><td>13 (6 %)</td><td>20 (5 %)</td><td>42 (7 %)</td><td>23 (6 %)</td></tr><tr><td>Proteus spp.</td><td>14 (4 %)</td><td>0</td><td>2 (10 %)</td><td>0</td><td>7 (2.7)</td><td>4 (5.1)</td><td>7 (3 %)</td><td>27 (6 %)</td><td>34 (6 %)</td><td>16 (4 %)</td></tr><tr><td>Acinetobacter spp.</td><td>2 (1 %)</td><td>5 (8 %)</td><td>0</td><td></td><td>3 (1.2 %)</td><td>3 (3.8 %)</td><td>1 (1 %)</td><td>6 (1 %)</td><td>9 (2 %)</td><td>7 (2 %)</td></tr><tr><td>Citrobacter spp.</td><td>3 (1 %)</td><td>1 (2 %)</td><td>0</td><td>0</td><td>2 (0.8 %)</td><td>0</td><td>2 (1 %)</td><td>7 (2 %)</td><td>8 (1 %)</td><td>4 (1 %)</td></tr><tr><td colspan="11">Gram positive</td></tr><tr><td>Enterococcus.</td><td>37 (12 %)</td><td>5 (8 %)</td><td>4 (19 %)</td><td>0</td><td>27 (10.5 %)</td><td>9 (11.5 %)</td><td>23 (11 %)</td><td>41 (10 %)</td><td>55 (10 %)</td><td>46 (11 %)</td></tr><tr><td>S. aureus</td><td>12 (4 %)</td><td>3 (5 %)</td><td>0</td><td>0</td><td>12 (4.7 %)</td><td>2 (2.6 %)</td><td>7 (3 %)</td><td>7 (2 %)</td><td>18 (3 %)</td><td>15 (4 %)</td></tr><tr><td>CoNS</td><td>8 (3 %)</td><td>1 (2 %)</td><td>0</td><td>0</td><td>7 (2.7 %)</td><td>0</td><td>11 (5 %)</td><td>6 (1 %)</td><td>9 (2 %)</td><td>9 (2 %)</td></tr><tr><td>Other gram (+) cocci</td><td>4 (1 %)</td><td>0</td><td>1 (5 %)</td><td>0</td><td>3 (1.2)</td><td>0 (0.0)</td><td>4 (2 %)</td><td>0</td><td>4 (1 %)</td><td>5 (1 %)</td></tr><tr><td>Other bacteria</td><td>13 (4 %)</td><td>0</td><td>0</td><td>0</td><td>9 (3.5 %)</td><td>3 (3.8 %)</td><td>18 (9 %)</td><td>21 (5 %)</td><td>17 (3 %)</td><td>13 (3 %)</td></tr><tr><td>Fungi</td><td>8 (3 %)</td><td>4 (6 %)</td><td>0</td><td>0</td><td>5 (1.9 %)</td><td>2 (2.6 %)</td><td>2 (1 %)</td><td>14 (3 %)</td><td>7 (1 %)</td><td>12 (3 %)</td></tr><tr><td>Total</td><td>311</td><td>66</td><td>21</td><td>10</td><td>258</td><td>78</td><td>207</td><td>427</td><td>564</td><td>408</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Partial Correlation Coefficient</td><td>t Value</td><td>Significance</td></tr><tr><td colspan="4">Dependent variable: Pimax</td></tr><tr><td>cACE activity</td><td>0.262</td><td>2.899</td><td>0.0045</td></tr><tr><td>Weight at measurement</td><td>0.244</td><td>2.697</td><td>0.0081</td></tr><tr><td>ACE genotypes</td><td></td><td>0.317</td><td>0.752</td></tr><tr><td>Postmenstrual age</td><td></td><td>0.283</td><td>0.778</td></tr><tr><td>Gender</td><td></td><td>0.077</td><td>0.939</td></tr><tr><td>Duration of mechanicalventilation</td><td></td><td>1.451</td><td>0.150</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>miRNA ID</td><td>Control Average</td><td>FM Average</td><td>Ratio C/FM Average</td></tr><tr><td>hsa-miR-223-3p</td><td>66736.98</td><td>10577.74</td><td>6.31</td></tr><tr><td>hsa-miR-451a</td><td>4830.07</td><td>358.62</td><td>13.47</td></tr><tr><td>hsa-miR-338-3p</td><td>374.20</td><td>32.22</td><td>11.62</td></tr><tr><td>hsa-miR-143-3p</td><td>506.26</td><td>45.42</td><td>11.15</td></tr><tr><td>hsa-miR-145-5p</td><td>546.05</td><td>52.58</td><td>10.39</td></tr><tr><td>hsa-miR-21-5p</td><td>5470.04</td><td>1409.50</td><td>3.88</td></tr><tr><td>hsa-miR-1908-5p</td><td>762.60</td><td>660.45</td><td>1.15</td></tr><tr><td>hsa-miR-1260b</td><td>23676.19</td><td>17356.79</td><td>1.36</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Laxative type</td><td>Examples</td><td>Proposed mode of action</td><td>Potential limitations</td></tr><tr><td>Dietary ﬁber/bulking agents</td><td>Wheat bran Psyllium seed husk Methylcellulose</td><td>Luminal water binding increases stool bulk and reduces consistency</td><td>Flatulence and abdominal distension Stool impaction (rarely) Not recommended in frail, immobile, or palliative care patients</td></tr><tr><td colspan="4">Osmotic laxatives</td></tr><tr><td>Undigestible disaccharides and sugar alcohols</td><td>Lactulose Sorbitol</td><td>Luminal water binding by creating an osmotic gradient</td><td>Bloating, ﬂatulence</td></tr><tr><td>Synthetic macromolecules</td><td>PEG Polycarbophil</td><td>Luminal water binding</td><td>Bloating</td></tr><tr><td>Salinic laxatives</td><td>Magnesium hydroxide (e.g., milk of magnesia) Magnesium citrate Magnesium sulfate Sodium phosfate</td><td>Luminal water binding Increases ﬂuid excretion</td><td>Electrolyte imbalance (must be used with caution in patients with compromised renal or cardiac function)</td></tr><tr><td colspan="4">Stimulant laxatives</td></tr><tr><td>Diphenylmethane derivatives</td><td>Bisacodyl, sodium picosulfate</td><td>Act locally to stimulate colonic motility, decrease water absorption from large intestine</td><td>Abdominal discomfort and cramps</td></tr><tr><td>Anthraquinones</td><td>Senna, aloe, cascara</td><td>Act locally to stimulate colonic motility, decrease water absorption from large intestine</td><td>Abdominal discomfort and cramps</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">Intervention Group (n = 212)</td><td colspan="4">Control Group (n = 217)</td></tr><tr><td></td><td>At Admission</td><td>At Discharge</td><td>p-Value b</td><td>At Admission</td><td>At Discharge</td><td>p-Value b</td></tr><tr><td>Anticholinergic drugs, n (%)</td><td>15 (7.1)</td><td>7 (3.3)</td><td>0.005</td><td>12 (5.5)</td><td>9 (4.1)</td><td>0.083</td></tr><tr><td>Propiomazine, n (%)</td><td>6 (2.8)</td><td>5 (2.4)</td><td>0.317</td><td>6 (2.8)</td><td>6 (2.8)</td><td>-</td></tr><tr><td>Tramadol, n (%)</td><td>4 (1.9)</td><td>3 (1.4)</td><td>0.317</td><td>5 (2.3)</td><td>4 (1.8)</td><td>0.317</td></tr><tr><td>Long-acting benzodiazepines, n (%)</td><td>1 (0.5)</td><td>1 (0.5)</td><td>-</td><td>6 (2.8)</td><td>6 (2.8)</td><td>-</td></tr><tr><td>Antipsychotic drug use, n (%)</td><td>16 (7.5)</td><td>16 (7.5)</td><td>-</td><td>12 (5.5)</td><td>13 (6.0)</td><td>0.317</td></tr><tr><td>NSAID, n (%)</td><td>7 (3.3)</td><td>2 (0.9)</td><td>0.025</td><td>11 (5.1)</td><td>9 (4.1)</td><td>0.157</td></tr><tr><td>Potentially inappropriate medication a, n (%)</td><td>43 (20.3)</td><td>30 (14.2)</td><td>0.002</td><td>45 (20.7)</td><td>40 (18.4)</td><td>0.025</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Likely</td><td>Possible</td></tr><tr><td>Diﬀuse cutaneous subtype</td><td rowspan="5">Anti-topoisomerase antibodies</td></tr><tr><td>Anti-centromere antibodies</td></tr><tr><td>Current smoking</td></tr><tr><td>Anti-beta2-glycoprotein I antibodies</td></tr><tr><td>Anti-granzyme B antibodies</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Characteristics</td><td rowspan="2">All patients (n = 763)</td><td rowspan="2">MACE (n = 254)</td><td rowspan="2">No MACE (n = 509)</td><td rowspan="2">P value</td></tr><tr><td>Age in years, μ (σ)</td><td>60.49 (13.33)</td><td>61.75 (11.86)</td><td>59.86 (13.97)</td><td>0.001</td></tr><tr><td>Men</td><td>496 (64.9)</td><td>185 (72.8)</td><td>310 (60.9)</td><td>0.001</td></tr><tr><td>Race</td><td></td><td></td><td></td><td>0.647</td></tr><tr><td>Chinese</td><td>489 (64.1)</td><td>168 (66.1)</td><td>321 (63.1)</td><td></td></tr><tr><td>Malay</td><td>144 (18.9)</td><td>47 (18.5)</td><td>97 (19.1)</td><td></td></tr><tr><td>Indian</td><td>106 (13.9)</td><td>30 (11.8)</td><td>76 (14.9)</td><td></td></tr><tr><td>Other</td><td>24 (3.1)</td><td>9 (3.5)</td><td>15 (2.9)</td><td></td></tr><tr><td colspan="5">Medical history</td></tr><tr><td>IHD</td><td>336 (44.0)</td><td>115 (45.3)</td><td>221 (43.4)</td><td>0.643</td></tr><tr><td>DM</td><td>275 (36.0)</td><td>113 (44.5)</td><td>162 (31.8)</td><td>0.001</td></tr><tr><td>Hypertension</td><td>492 (64.5)</td><td>173 (68.1)</td><td>319 (62.7)</td><td>0.149</td></tr><tr><td>Hyperlipidemia</td><td>456 (59.8)</td><td>148 (58.3)</td><td>308 (60.5)</td><td>0.584</td></tr><tr><td>Previous stroke</td><td>60 (7.9)</td><td>19 (7.5)</td><td>41 (8.1)</td><td>0.887</td></tr><tr><td>Cancer</td><td>32 (4.2)</td><td>8 (3.1)</td><td>24 (4.7)</td><td>0.345</td></tr><tr><td>Respiratory disease</td><td>31 (4.1)</td><td>4 (1.6)</td><td>27 (5.3)</td><td>0.012</td></tr><tr><td>Renal disease</td><td>96 (12.6)</td><td>34 (13.4)</td><td>62 (12.2)</td><td>0.644</td></tr><tr><td>CHF</td><td>39 (5.1)</td><td>10 (3.9)</td><td>29 (5.7)</td><td>0.383</td></tr><tr><td>Previous PCI</td><td>175 (22.9)</td><td>64 (25.2)</td><td>111 (21.8)</td><td>0.315</td></tr><tr><td>Previous CABG</td><td>70 (9.2)</td><td>25 (9.8)</td><td>45 (8.8)</td><td>0.690</td></tr><tr><td>Previous MI</td><td>114 (14.9)</td><td>41 (16.1)</td><td>73 (14.3)</td><td>0.519</td></tr><tr><td>Disposition from ED</td><td></td><td></td><td></td><td><0.001</td></tr><tr><td>Admission to GW</td><td>354 (46.4)</td><td>96 (37.8)</td><td>258 (50.7)</td><td></td></tr><tr><td>Admission to ICW</td><td>176 (23.1)</td><td>141 (55.5)</td><td>35 (6.9)</td><td></td></tr><tr><td>No admission</td><td>233 (30.5)</td><td>17 (6.7)</td><td>216 (42.4)</td><td></td></tr></tbody></table> <\|md_end\|>

End of preview. Expand in Data Studio

README.md exists but content is empty.

Downloads last month: 10

Size of downloaded dataset files:

163 MB

Size of the auto-converted Parquet files:

163 MB

Number of rows:

5,000

image imagewidth (px) 208 958	text stringlengths 122 8.5k
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Patient’s serum + :</td><td rowspan="2">Patient 1 (% of lysis)</td><td rowspan="2">Patient 2 (% of lysis)</td><td rowspan="2">Patient 3 (% of lysis)</td></tr><tr><td>C5 def serum</td><td>99</td><td>95</td><td>90</td></tr><tr><td>C6 def serum</td><td>94</td><td>95</td><td>79</td></tr><tr><td>C7 def serum</td><td>100</td><td>100</td><td>96</td></tr><tr><td>C8 alpha-gamma def serum</td><td>95</td><td>87</td><td>88</td></tr><tr><td>C8 beta def serum</td><td>0</td><td>0</td><td>0</td></tr><tr><td>C8 beta def serum + human C8</td><td>99</td><td>100</td><td>94</td></tr><tr><td>C9 def serum</td><td>100</td><td>100</td><td>100</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">All n (%)</td><td colspan="2">Douala</td><td colspan="2">Yaoundé</td></tr><tr><td></td><td>n (%)</td><td>Respondent Driven Sampling weighted % (95%CI)</td><td>n (%)</td><td>Respondent Driven Sampling weighted % (95%CI)</td></tr><tr><td>Total</td><td>511 (100)</td><td>272 (100)</td><td>-</td><td>239 (100)</td><td>-</td></tr><tr><td>Age, median (IQR) (yrs)</td><td>24 (21–28)</td><td>23 (21–27)</td><td>-</td><td>25 (21–28)</td><td>-</td></tr><tr><td>18–23</td><td>238 (46.6)</td><td>142 (52.2)</td><td>57.5 (50.4–64.6)</td><td>96 (40.2)</td><td>42.2 (34.1–50.3)</td></tr><tr><td>24–29</td><td>185 (36.2)</td><td>85 (31.3)</td><td>29.7 (23.3–36.1)</td><td>100 (41.8)</td><td>42.4 (43.3–50.4)</td></tr><tr><td>30+</td><td>88 (17.2)</td><td>45 (16.5)</td><td>12.8 (8.2–17.4)</td><td>43 (18.0)</td><td>15.4 (9.1–21.8)</td></tr><tr><td>NGO/CBO service access in the past 12 months</td><td>302 (59.1)</td><td>202 (74.3)</td><td>66.1 (57.5–74.7)</td><td>100 (41.8)</td><td>33.4 (26.3–40.6)</td></tr><tr><td>HIV status: HIV+</td><td>171 (37.0)</td><td>73 (28.6)</td><td>25.7 (19.2–32.1)</td><td>98 (47.3)</td><td>44.0 (35.2–52.8)</td></tr><tr><td>Previous history of HIV testing</td><td>413 (81.6)</td><td>216 (80.6)</td><td>77.5 (71.0–84.0)</td><td>197 (82.8)</td><td>79.7 (73.5–86.0)</td></tr><tr><td colspan="6">Education</td></tr><tr><td>Primary or less</td><td>26 (5.1)</td><td>20 (7.4)</td><td>7.6 (3.9–11.3)</td><td>6 (2.5)</td><td>2.7 (.3–7.0)</td></tr><tr><td>Secondary</td><td>341 (66.7)</td><td>183 (67.3)</td><td>70.1 (63.9–76.4)</td><td>158 (66.1)</td><td>70.1 (63.0–76.9)</td></tr><tr><td>Higher than secondary</td><td>144 (28.2)</td><td>69 (25.4)</td><td>22.3 (16.6–28.0)</td><td>75 (31.4)</td><td>27.3 (20.7–33.9)</td></tr><tr><td colspan="6">Occupational status</td></tr><tr><td>Student or Apprentice</td><td>204 (39.9)</td><td>116 (42.6)</td><td>46.6 (40.0–53.2)</td><td>88 (36.8)</td><td>36.9 (29.4–44.5)</td></tr><tr><td>Employed</td><td>248 (48.5)</td><td>126 (46.3)</td><td>44.4 (37.8–50.9)</td><td>122 (51.0)</td><td>48.7 (40.6–56.8)</td></tr><tr><td>Unemployed</td><td>59 (11.6)</td><td>30 (11.0)</td><td>9.1 (5.4–12.7)</td><td>29 (12.1)</td><td>14.4 (7.9–20.8)</td></tr><tr><td>MSM Network size, median (IQR)</td><td>12 (6–25)</td><td>13 (5–25)</td><td>-</td><td>12 (6–25)</td><td>-</td></tr><tr><td>Number of male partners in last 12 months</td><td>3 (2–5)</td><td>3 (2–5)</td><td>-</td><td>3 (2–5)</td><td>-</td></tr><tr><td colspan="6">Sexual identity</td></tr><tr><td>Gay/homosexual</td><td>144 (28.2)</td><td>71 (26.1)</td><td>23.3 (17.3–29.2)</td><td>73 (30.5)</td><td>27.8 (20.5–35.0)</td></tr><tr><td>Had male and female sexual partners in past 12 months</td><td>114 (22.3)</td><td>49 (18.0)</td><td>20.0 (14.2–25.8)</td><td>65 (27.2)</td><td>28.5 (21.1–36.0)</td></tr><tr><td colspan="6">Relationship status:</td></tr><tr><td>Single</td><td>425 (84.2)</td><td>226 (84.6)</td><td>85.6 (80.5–90.6)</td><td>194 (83.3)</td><td>87.3 (82.2–92.4)</td></tr><tr><td>In a relationship or married</td><td>80 (15.8)</td><td>41 (15.4)</td><td>14.4 (9.4–19.5)</td><td>39 (16.7)</td><td>12.7 (7.6–17.8)</td></tr><tr><td>Inconsistent condom use with casual partners in the past 12 months</td><td>207 (40.5)</td><td>112 (41.2)</td><td>38.8 (31.8–45.9)</td><td>96 (40.2)</td><td>38.4 (31.3–45.6)</td></tr><tr><td>STI symptoms in the past 12 months</td><td>175 (34.6)</td><td>80 (29.9)</td><td>31.0 (23.9–38.2)</td><td>95 (39.9)</td><td>39.2 (31.8–46.5)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Mn group</td><td>N</td><td>Semen volume (ml)</td><td>Sperm density (×106/ml)</td><td>Sperm viability (%)</td><td>Progressive motility (%)</td><td>Normal morphology (%)*</td></tr><tr><td><20%</td><td>234</td><td>2.6 (1.1)</td><td>70.9 (51.9)</td><td>71.4 (12.5)</td><td>49.1 (13.9)</td><td>46.2 (17.6)a</td></tr><tr><td>20–39%</td><td>232</td><td>2.5 (1.1)</td><td>69.9 (37.4)</td><td>69.2 (13.6)</td><td>47.0 (14.2)</td><td>41.9 (13.6)b</td></tr><tr><td>40–59%</td><td>241</td><td>2.4 (1.1)</td><td>77.0 (44.6)</td><td>69.3 (14.8)</td><td>47.6 (13.9)</td><td>43.0 (15.4)a,b</td></tr><tr><td>60–79%</td><td>236</td><td>2.4 (1.0)</td><td>73.1 (40.0)</td><td>69.8 (12.2)</td><td>47.0 (11.8)</td><td>43.0 (15.2)a,b</td></tr><tr><td>≥80%</td><td>236</td><td>2.5 (1.0)</td><td>69.9 (37.3)</td><td>69.9 (11.6)</td><td>45.7 (11.4)</td><td>42.6 (16.7)a,b</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>MO</td><td>MO Sequence (59-39)</td><td>RT-PCR primers (59-39)</td><td>Reference</td></tr><tr><td>ntn1a SBMO</td><td>ATGATGGACTTACCGACACATTCGT</td><td>ntn1a pre-mRNA (F1 X R1) ntn1a mRNA (F1 X R2) F1: CTTTCGGAGACGAAAACGAG R1: GTAGGCGCTTTCCAGAGATG R2: CTTTGCAGTAGTGGCAGTGG</td><td>Suli et al. 2007 [17]; Suli 2006 [26]</td></tr><tr><td>ntn1a TBMO</td><td>CGCCTTCCTCAGCCTCTCCTGTGCT</td><td>n/a</td><td>n/a</td></tr><tr><td>ntn1a 5-mispair MO</td><td>ATcATGcACTTAgCGACAgATTgGT (lower case letters are mismatches)</td><td>n/a</td><td>n/a</td></tr><tr><td>ntn1b SBMO</td><td>TAGTTTAGAAATGACTCACCGACAC</td><td>ntn1b pre-mRNA (F1 X R1) ntn1b mRNA (F1 X R2) F1: CCGACATCAAAGTGACCTTC R1: GAGCCATCCACACTTGTTGA R2: TGCACGTCGGTGTGATATAG</td><td>complementary to ntn1b exon 1/ intron 1–2 boundary</td></tr><tr><td>ntn2 SBMO</td><td>TTTCGTGACTTACGTAAGCACTCGT</td><td>net2E1F: TCCGGAGTGTGATCGATGTA net2E3R: CCTTTAGCACAGCGGTTACA</td><td>netrin2 SBMO3, Suli et al., 2007 [17]</td></tr><tr><td>dcc TBMO</td><td>GAATATCTCCAGTGACGCAGCCCAT</td><td>n/a</td><td>Suli et al., 2006 [26]</td></tr><tr><td>dscam SBMO</td><td>AAAGATCCTGAAATGCTCACCGGCC</td><td>dscam pre-mRNA (e2F X i2R) dscam mRNA (e2F X e3R) e2F: TTCTCAGTGAAGACCTACATTCC i2R: ATTCTGGGTAAGAGCTGTGA e3R: AATGCACTTGAAGACCGCTA</td><td>complementary to dscam exon2/ intron 2–3 boundary</td></tr><tr><td>dscam TBMO</td><td>CGCTCCTTTCAATCTCCAAACTAAG</td><td>n/a</td><td>DS2M, Yimlamai et al., 2005 [25]</td></tr><tr><td>standard control TBMO</td><td>CCTCTTACCTCAGTTACAATTTATA</td><td>n/a</td><td>Gene Tools https://store2.gene-tools.com/ node/7</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Bat species</td><td>Diet</td><td>Bacteria</td><td>Cavity</td><td>AMI</td><td>CAZ</td><td>CRO</td><td>CIP</td><td>CLO</td><td>DOX</td><td>GEN</td><td>IPM</td><td>AMC</td><td>AMP</td><td>CFL</td></tr><tr><td>Mimon bennetti</td><td>CAR</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Artibeus fimbriatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus fimbriatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus lituratus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Artibeus obscurus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>R</td><td>R</td></tr><tr><td>Platyrrhinus lineatus</td><td>FRU</td><td>Klebsiella oxytoca</td><td>Oral</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Desmodus rotundus</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Diphylla ecaudata</td><td>SAN</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>I</td><td>S</td></tr><tr><td>Molossus molossus</td><td>INS</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr><tr><td>Anoura caudifer</td><td>NEC</td><td>Klebsiella oxytoca</td><td>Rectal</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>shPlac1/Scr</td><td>shCxcl1/Scr</td></tr><tr><td>CD68</td><td>−4.2</td><td>−4.2</td></tr><tr><td>Cxcl1</td><td>−67</td><td>−4.0</td></tr><tr><td>Ly6a</td><td>−4.3</td><td>−3.1</td></tr><tr><td>Plau</td><td>−7.1</td><td>−7.3</td></tr><tr><td>Rgs16</td><td>−7.7</td><td>−3.2</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>WT infected/WT uninfected</td><td>t-test</td><td>wntD uninfected/WT uninfected</td><td>t-test</td><td>wntD infected/WT infected</td><td>t-test</td></tr><tr><td>Cecropin C</td><td>652.54</td><td>0.003</td><td>12.16</td><td>0.2</td><td>0.70</td><td>0.01</td></tr><tr><td>edin</td><td>394.73</td><td>0.008</td><td>15.36</td><td>0.02</td><td>5.14</td><td>0.00001</td></tr><tr><td>IM23</td><td>166.01</td><td>0.04</td><td>10.14</td><td>0.0009</td><td>0.98</td><td>0.9</td></tr><tr><td>CG6639</td><td>131.72</td><td>0.002</td><td>1.15</td><td>0.8</td><td>0.21</td><td>0.0002</td></tr><tr><td>Diptericin B</td><td>90.56</td><td>0.005</td><td>4.36</td><td>0.02</td><td>1.04</td><td>0.6</td></tr><tr><td>Attacin D</td><td>88.19</td><td>0.0004</td><td>3.65</td><td>0.008</td><td>1.87</td><td>0.004</td></tr><tr><td>Attacin B</td><td>57.37</td><td>0.0009</td><td>3.85</td><td>0.003</td><td>1.04</td><td>0.3</td></tr><tr><td>Attacin A</td><td>55.71</td><td>0.007</td><td>4.70</td><td>0.02</td><td>1.67</td><td>0.004</td></tr><tr><td>Defensin</td><td>44.85</td><td>0.001</td><td>2.92</td><td>0.008</td><td>1.30</td><td>0.01</td></tr><tr><td>Turandot M</td><td>41.93</td><td>0.03</td><td>1.40</td><td>0.5</td><td>1.68</td><td>0.04</td></tr><tr><td>CG30098</td><td>33.55</td><td>0.01</td><td>1.33</td><td>0.08</td><td>1.55</td><td>0.2</td></tr><tr><td>Cecropin B</td><td>23.08</td><td>0.01</td><td>1.21</td><td>0.2</td><td>0.97</td><td>0.8</td></tr><tr><td>Attacin C</td><td>20.70</td><td>0.008</td><td>1.90</td><td>0.09</td><td>1.09</td><td>0.4</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td>2/3</td><td>3/3</td><td>2/4</td><td>3/4</td><td>4/4</td></tr><tr><td rowspan="4">Frontal Plaque Density</td><td>None</td><td>0 (0%)</td><td>1 (0.4%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>1 (4.5%)</td><td>4 (1.7%)</td><td>0 (0%)</td><td>0 (0%)</td><td>1 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>28 (21.4%)</td><td>1 (7.7%)</td><td>11 (4.7%)</td><td>2 (3.3%)</td></tr><tr><td>Frequent</td><td>16 (72.7%)</td><td>198 (85.7%)</td><td>12 (92.3%)</td><td>224 (95.3%)</td><td>57 (96.7%)</td></tr><tr><td rowspan="4">Temporal Plaque Density</td><td>None</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>1 (4.5%)</td><td>6 (2.6%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>30 (13.1%)</td><td>1 (7.7%)</td><td>15 (6.4%)</td><td>1 (1.7%)</td></tr><tr><td>Frequent</td><td>16 (72.7%)</td><td>193 (84.3%)</td><td>12 (92.3%)</td><td>221 (93.6%)</td><td>59 (98.3%)</td></tr><tr><td rowspan="4">Parietal Plaque Density</td><td>None</td><td>0 (0%)</td><td>2 (0.9%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>0 (0%)</td><td>3 (1.3%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>5 (22.7%)</td><td>22 (9.6%)</td><td>0 (0%)</td><td>6 (3%)</td><td>3 (5%)</td></tr><tr><td>Frequent</td><td>17 (77.3%)</td><td>201 (88.2%)</td><td>13 (100%)</td><td>229 (97%)</td><td>56 (95%)</td></tr><tr><td rowspan="4">Hippocampal Plaque Density</td><td>None</td><td>6 (27.3%)</td><td>20 (8.8%)</td><td>1 (7.7%)</td><td>4 (1.7%)</td><td>0 (0%)</td></tr><tr><td>Sparse</td><td>6 (27.3%)</td><td>54 (23.7%)</td><td>3 (23.1%)</td><td>28 (11.9%)</td><td>5 (8.3%)</td></tr><tr><td>Moderate</td><td>7 (31.8%)</td><td>81 (35.5%)</td><td>3 (23.1%)</td><td>108 (46%)</td><td>22 (36.7%)</td></tr><tr><td>Frequent</td><td>3 (13.6%)</td><td>73 (32%)</td><td>6 (46.1%)</td><td>95 (40.4%)</td><td>33 (55%)</td></tr><tr><td rowspan="4">Entorhinal Plaque Density</td><td>None</td><td>1 (4.5%)</td><td>8 (3.5%)</td><td>0 (0%)</td><td>3 (1.3%)</td><td>1 (1.7%)</td></tr><tr><td>Sparse</td><td>5 (22.7%)</td><td>14 (6.1%)</td><td>2 (15.4%)</td><td>3 (1.3%)</td><td>0 (0%)</td></tr><tr><td>Moderate</td><td>4 (18.2%)</td><td>75 (32.8%)</td><td>2 (15.4%)</td><td>59 (25%)</td><td>10 (16.7%)</td></tr><tr><td>Frequent</td><td>12 (54.5%)</td><td>132 (57.6%)</td><td>9 (69.2%)</td><td>171 (72.4%)</td><td>49 (81.7%)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="3">Sample 3</td><td colspan="3">Sample 4</td></tr><tr><td></td><td>Mean (SD)</td><td>Omega</td><td>Test-Retest</td><td>Mean (SD)</td><td>Omega</td><td>Test-Retest</td></tr><tr><td>Enhance</td><td>60.03 (8.38)</td><td>0.91</td><td>0.65</td><td>63.32 (6.81)</td><td>0.89</td><td>0.88</td></tr><tr><td>Divert</td><td>27.43 (4.10)</td><td>0.73</td><td>0.57</td><td>27.41 (4.06)</td><td>0.78</td><td>0.80</td></tr><tr><td>Worsen</td><td>30.80 (9.53)</td><td>0.90</td><td>0.70</td><td>25.76 (7.92)</td><td>0.87</td><td>0.78</td></tr><tr><td>Inauthentic</td><td>32.66 (7.03)</td><td>0.83</td><td>0.74</td><td>31.16 (6.95)</td><td>0.79</td><td>0.82</td></tr><tr><td>Conceal</td><td>23.26 (4.91)</td><td>0.80</td><td>0.69</td><td>24.37 (5.30)</td><td>0.82</td><td>0.84</td></tr><tr><td>Enhance-SF</td><td>23.83 (3.59)</td><td>0.82</td><td>0.55</td><td>25.45 (3.05)</td><td>0.84</td><td>0.82</td></tr><tr><td>Divert-SF</td><td>23.70 (3.70)</td><td>0.72</td><td>0.60</td><td>23.65 (3.63)</td><td>0.77</td><td>0.82</td></tr><tr><td>Worsen-SF</td><td>14.20 (4.67)</td><td>0.80</td><td>0.60</td><td>11.54 (3.92)</td><td>0.79</td><td>0.82</td></tr><tr><td>Inauthentic-SF</td><td>18.05 (4.18)</td><td>0.78</td><td>0.69</td><td>17.23 (4.09)</td><td>0.72</td><td>0.75</td></tr><tr><td>Conceal-SF</td><td>20.03 (4.50)</td><td>0.79</td><td>0.63</td><td>20.85 (4.74)</td><td>0.82</td><td>0.83</td></tr><tr><td>Enhance-VSF</td><td>15.83 (2.55)</td><td>0.80</td><td>0.50</td><td>16.91 (2.22)</td><td>0.82</td><td>0.78</td></tr><tr><td>Divert-VSF</td><td>15.79 (2.71)</td><td>0.66</td><td>0.63</td><td>15.53 (2.62)</td><td>0.70</td><td>0.78</td></tr><tr><td>Worsen-VSF</td><td>9.79 (3.26)</td><td>0.72</td><td>0.55</td><td>8.21 (2.89)</td><td>0.72</td><td>0.83</td></tr><tr><td>Inauthentic-VSF</td><td>11.77 (3.02)</td><td>0.77</td><td>0.65</td><td>11.45 (3.09)</td><td>0.74</td><td>0.68</td></tr><tr><td>Conceal-VSF</td><td>13.64 (3.29)</td><td>0.79</td><td>0.61</td><td>14.46 (3.43)</td><td>0.80</td><td>0.72</td></tr><tr><td>H</td><td>31.58 (6.16)</td><td>0.73</td><td></td><td>33.32 (6.42)</td><td>0.73</td><td></td></tr><tr><td>E</td><td>34.21 (6.34)</td><td>0.75</td><td></td><td>34.57 (6.45)</td><td>0.75</td><td></td></tr><tr><td>X</td><td>32.59 (6.86)</td><td>0.83</td><td></td><td>31.60 (7.56)</td><td>0.85</td><td></td></tr><tr><td>A</td><td>31.33 (6.50)</td><td>0.79</td><td></td><td>33.17 (6.87)</td><td>0.82</td><td></td></tr><tr><td>C</td><td>35.67 (6.45)</td><td>0.81</td><td></td><td>33.86 (6.86)</td><td>0.82</td><td></td></tr><tr><td>O</td><td>32.12 (6.76)</td><td>0.78</td><td></td><td>34.96 (6.64)</td><td>0.76</td><td></td></tr><tr><td>SEA</td><td>20.08 (5.06)</td><td>0.89</td><td></td><td>19.22 (4.85)</td><td>0.84</td><td></td></tr><tr><td>OEA</td><td>21.56 (4.28)</td><td>0.84</td><td></td><td>21.32 (4.19)</td><td>0.85</td><td></td></tr><tr><td>UOE</td><td>21.20 (4.78)</td><td>0.84</td><td></td><td>20.05 (4.52)</td><td>0.77</td><td></td></tr><tr><td>ROE</td><td>19.13 (5.76)</td><td>0.90</td><td></td><td>18.50 (4.72)</td><td>0.82</td><td></td></tr><tr><td>TEIQue-SF total score</td><td>141.78 (21.43)</td><td>0.87</td><td></td><td></td><td></td><td></td></tr><tr><td>Emotion Management</td><td></td><td></td><td></td><td>41.21 (7.24)</td><td>0.73</td><td></td></tr><tr><td>Relationship Skills</td><td></td><td></td><td></td><td>49.70 (6.86)</td><td>0.69</td><td></td></tr><tr><td>Social Competence</td><td></td><td></td><td></td><td>50.26 (10.32)</td><td>0.85</td><td></td></tr><tr><td>Empathy</td><td></td><td></td><td></td><td>47.31 (7.48)</td><td>0.80</td><td></td></tr><tr><td>Extrinsic Affect Improving</td><td>23.45 (3.56)</td><td>0.86</td><td>0.64</td><td>22.40 (4.44)</td><td>0.84</td><td></td></tr><tr><td>Extrinsic Affect Worsening</td><td>5.83 (2.49)</td><td>0.80</td><td>0.47</td><td>4.55 (1.86)</td><td>0.75</td><td></td></tr><tr><td>Intrinsic Affect Improving</td><td>20.08 (4.92)</td><td>0.84</td><td>0.61</td><td>19.52 (4.85)</td><td>0.79</td><td></td></tr><tr><td>Intrinsic Affect Worsening</td><td>9.48 (4.03)</td><td>0.89</td><td>0.62</td><td>8.99 (3.70)</td><td>0.85</td><td></td></tr><tr><td>PA</td><td>34.21 (7.60)</td><td>0.89</td><td>0.70</td><td>32.02 (7.09)</td><td>0.86</td><td></td></tr><tr><td>NA</td><td>23.41 (7.75)</td><td>0.87</td><td>0.55</td><td>26.00 (7.56)</td><td>0.85</td><td></td></tr><tr><td>Life Satisfaction</td><td>24.39 (6.59)</td><td>0.89</td><td>0.76</td><td>23.42 (6.55)</td><td>0.86</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Categorical</td><td>Control</td><td>Cases</td><td>OR (95% CI)</td><td>Chi-Square/Fisher</td></tr><tr><td>Excessive maternal weight gain (>30 lbs)</td><td>62/119 (52.1%)</td><td>31/44 (70.5%)</td><td>2.2 (1.05–4.6)</td><td>0.0356</td></tr><tr><td>Persistent fetal head malpresentation</td><td>15/128 (11.7%)</td><td>14/52 (26.9%)</td><td>2.8 (1.23–6.28)</td><td>0.0119</td></tr><tr><td>Gestational diabetes</td><td>6/123 (4.9%)</td><td>9/52 (17.3%)</td><td>4.1 (1.37–2.15)</td><td>0.0073</td></tr><tr><td>Maternal obesity at the beginning of pregnancy</td><td>29/119 (24.3%)</td><td>10/44 (22.7%)</td><td>0.9 (0.4–2.07)</td><td>0.8273</td></tr><tr><td>Maternal obesity at end of pregnancy</td><td>59/122 (48.4%)</td><td>27/47 (57.4%)</td><td>1.4 (0.73–0.84)</td><td>0.2897</td></tr><tr><td>Oxytocin administration</td><td>78/131 (59.5%)</td><td>41/52 (78.9%)</td><td>2.5 (1.19–5.37)</td><td>0.0135</td></tr><tr><td>Tachysystole</td><td>38/87 (43.7%)</td><td>37/50 (74%)</td><td>3.7 (1.71–7.85)</td><td>0.0006</td></tr><tr><td>Occiput anterior delivery position</td><td>106/129 (82.2%)</td><td>25/52 (48.1%)</td><td>4.9773</td><td>0.0001</td></tr><tr><td>Epidural administered</td><td>117/131 (89.3%)</td><td>50/52 (96.2%)</td><td>3 (0.66–13.65)</td><td>0.2434</td></tr><tr><td>Infant clavicle fracture</td><td>0/130 (0%)</td><td>5/52 (9.6%)</td><td>30.2 (1.64–557.01) </td><td>0.0033 </td></tr><tr><td>Infant humerus fracture</td><td>0/130 (0%)</td><td>2/52 (3.9%)</td><td>12.9 (0–273.83) </td><td>0.1610 </td></tr><tr><td>History of difﬁcult delivery</td><td>5/80 (6.3%)</td><td>3/27 (11.1%)</td><td>1.9 (0.42–8.43)</td><td>0.4133</td></tr><tr><td>History of fetal malpresentation</td><td>1/82 (1.2%)</td><td>1/27 (3.7%)</td><td>3.1 (0.19–51.58)</td><td>0.4358</td></tr><tr><td>Macrosomia</td><td>0/131 (0%)</td><td>4/52 (7.7%)</td><td>24.4 (1.29–461.7) *</td><td>0.0120</td></tr><tr><td>Pre-eclampsia</td><td>12/127 (9.5%)</td><td>1/52 (1.9%)</td><td>0.2 (0.02–1.48)</td><td>0.1123</td></tr><tr><td>Prostaglandin administration</td><td>19/126 (15.1%)</td><td>5/52 (9.6%)</td><td>0.6 (0.21–1.7)</td><td>0.4698</td></tr><tr><td>Shoulder Dystocia</td><td>3/132 (2.2%)</td><td>33/51 (64.7%)</td><td>78.8 (21.9–283.72)</td><td><0.0001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Variables</td><td>Mean</td><td>Median</td><td>Std. Deviation</td><td>25 Percentiles</td><td>75 Percentiles</td><td>Min</td><td>Max</td></tr><tr><td colspan="8">Dependent Variable</td></tr><tr><td>Log of IPO Net Proceeds</td><td>1.51</td><td>1.52</td><td>0.34</td><td>1.27</td><td>1.73</td><td>0.39</td><td>2.32</td></tr><tr><td colspan="8">Explanatory Variables</td></tr><tr><td>Healthcare</td><td>0.16</td><td>0.00</td><td>0.83</td><td>0.00</td><td>0.00</td><td>0.00</td><td>7.00</td></tr><tr><td>Genomic</td><td>0.21</td><td>0.00</td><td>0.79</td><td>0.00</td><td>0.00</td><td>0.00</td><td>6.00</td></tr><tr><td>Biotechnology</td><td>1.37</td><td>1.00</td><td>1.37</td><td>0.00</td><td>2.00</td><td>0.00</td><td>6.00</td></tr><tr><td>Regulatory</td><td>0.90</td><td>1.00</td><td>0.99</td><td>0.00</td><td>1.00</td><td>0.00</td><td>4.00</td></tr><tr><td colspan="8">Control Variables</td></tr><tr><td>Log of Number of Employees</td><td>2.11</td><td>2.00</td><td>0.63</td><td>1.73</td><td>2.42</td><td>0.00</td><td>3.97</td></tr><tr><td>Log of Number of Shares Locked Up</td><td>4.52</td><td>6.67</td><td>3.32</td><td>0.00</td><td>7.09</td><td>0.00</td><td>7.71</td></tr><tr><td>Log of Underwriter Reputation</td><td>0.86</td><td>0.91</td><td>0.17</td><td>0.85</td><td>0.96</td><td>0.04</td><td>0.96</td></tr><tr><td>Gross Spread</td><td>0.09</td><td>0.09</td><td>0.03</td><td>0.07</td><td>0.10</td><td>0.00</td><td>0.20</td></tr><tr><td>Hot Issue</td><td>0.35</td><td>0.00</td><td>0.48</td><td>0.00</td><td>1.00</td><td>0.00</td><td>1.00</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Samples Code</td><td>Characteristics</td><td>Merchandising</td></tr><tr><td>M1</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M2</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M3</td><td>Italy 100% (Sicily-Apulia)</td><td>packed</td></tr><tr><td>M4</td><td>EVOO-Extracted from Mediterranean Olives-Packed in Italy</td><td>packed</td></tr><tr><td>M5</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M6</td><td>Italy 100% (Sicily)</td><td>packed</td></tr><tr><td>M7</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M8</td><td>EVOO Product of Italy</td><td>packed</td></tr><tr><td>M9</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M10</td><td>Italy 100%</td><td>unpacked</td></tr><tr><td>M11</td><td>Italy 100%</td><td>packed</td></tr><tr><td>M12</td><td>Italy 100%</td><td>unpacked</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td rowspan="2">I Group n = 28</td><td rowspan="2">II Group n = 23</td><td rowspan="2">III Group n = 22</td><td rowspan="2">IV Group n = 22</td><td rowspan="2">Statistical signiﬁcance between groups</td></tr><tr><td>PC 20</td><td>IL-1β (pg/ml)</td><td>598±210</td><td>562±183</td><td>606±197</td><td>659±302</td><td>n.s</td></tr><tr><td rowspan="2">LPS</td><td>IL-6 (pg/ml)</td><td>807±219</td><td>730±87</td><td>797±84</td><td>946±41</td><td>n.s</td></tr><tr><td>TNFα (pg/ml)</td><td>770±391</td><td>387±259</td><td>444±44</td><td>954±79</td><td>n.s</td></tr><tr><td>PC 100</td><td>IL-1β (pg/ml)</td><td>710±210</td><td>597±95</td><td>434±45</td><td>702±220</td><td>I vs III; p<0.03</td></tr><tr><td rowspan="8">LPS</td><td>IL-6 (pg/ml)</td><td>824±188</td><td>670±77.3</td><td>795±48</td><td>934±44</td><td>n.s</td></tr><tr><td>TNFα (pg/ml)</td><td>831±378</td><td>420±379</td><td>596±423</td><td>966±28</td><td>n.s</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs III; p<0.001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs IV; p<0.0001</td></tr><tr><td>IL-1β (pg/ml)</td><td>1 399±85</td><td>1270±80.7</td><td>992±89</td><td>685±27.0</td><td>II vs III; p<0.0004</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II vs IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>III vs IV; p<0.0002</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs II; p<0.0002</td></tr><tr><td rowspan="6">LPS (C)</td><td>IL-6 (pg/ml)</td><td>1218±127.7</td><td>899±73.9</td><td>781.3±91.8</td><td>646±59.0</td><td>I vs III, IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II versus IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>I vs III, IV; p< 0.0001</td></tr><tr><td>TNFα (pg/ml)</td><td>2 336.2±342</td><td>2075±164.4</td><td>1265±86.7</td><td>852.6±74.0</td><td>II vs III; p<0.0003</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>II vs IV; p<0.0001</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>III vs IV; p<0.04</td></tr><tr><td rowspan="3">PC100 (C)</td><td>IL-1β (pg/ml)</td><td><1</td><td><1</td><td><2</td><td><3</td><td></td></tr><tr><td>IL-6 (pg/ml)</td><td><2</td><td><2</td><td><3</td><td><3</td><td></td></tr><tr><td>TNFα (pg/ml)</td><td><20</td><td><10</td><td><20</td><td><4</td><td></td></tr><tr><td rowspan="3">Cells (C)</td><td>IL-1β (pg/ml)</td><td><2</td><td><2</td><td><2</td><td><2</td><td></td></tr><tr><td>IL-6 (pg/ml)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TNFα (pg/ml)</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Group</td><td colspan="2">Testis</td><td colspan="2">Ovary</td><td colspan="2">Testis-IP</td></tr><tr><td>miRs#</td><td>mirs#</td><td>miRs#</td><td>mirs#</td><td>miRs#</td><td>mirs#</td></tr><tr><td>gp1aa</td><td>238</td><td>169</td><td>341</td><td>212</td><td>195</td><td>157</td></tr><tr><td>gp1bb</td><td>18</td><td>12</td><td>32</td><td>22</td><td>20</td><td>13</td></tr><tr><td>gp2ac</td><td>11</td><td>11</td><td>28</td><td>26</td><td>4</td><td>4</td></tr><tr><td>gp2bd</td><td>69</td><td>53</td><td>122</td><td>111</td><td>66</td><td>64</td></tr><tr><td>gp3ae</td><td>220</td><td>192</td><td>490</td><td>397</td><td>282</td><td>251</td></tr><tr><td>gp3bf</td><td>375</td><td>340</td><td>261</td><td>218</td><td>93</td><td>84</td></tr><tr><td>gp4ag</td><td>951</td><td>844</td><td>1868</td><td>1735</td><td>2525</td><td>2415</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Age group (year)</td><td>Total no.</td><td>Positive no. (%)</td></tr><tr><td><0.5</td><td>92</td><td>86 (93.5)</td></tr><tr><td>0.5–1</td><td>94</td><td>69 (73.4)</td></tr><tr><td>2</td><td>94</td><td>78 (83.0)</td></tr><tr><td>3</td><td>94</td><td>77 (81.9)</td></tr><tr><td>4</td><td>93</td><td>75 (80.6)</td></tr><tr><td>5</td><td>91</td><td>75 (82.4)</td></tr><tr><td>6</td><td>90</td><td>77 (85.6)</td></tr><tr><td>7</td><td>94</td><td>77 (81.9)</td></tr><tr><td>8</td><td>95</td><td>76 (80.0)</td></tr><tr><td>Total</td><td>837</td><td>690 (82.4)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Substance</td><td>GothiaTek® ML</td><td>Average level 2009</td></tr><tr><td>Nitrite</td><td>7.0 ppm</td><td>2.0 ppm</td></tr><tr><td>TSNAs (total)</td><td>10.0 ppm</td><td>1.6 ppm</td></tr><tr><td>N-Nitrosodimethylamine (NDMA)</td><td>10.0 ppb</td><td>0.7 ppb</td></tr><tr><td>Benzo(a)pyrene (B(a)P)</td><td>20.0 ppb</td><td>1.1 ppb</td></tr><tr><td>Lead</td><td>2.0 ppm</td><td>0.3 ppm</td></tr><tr><td>Cadmium</td><td>1 ppm</td><td>0.6 ppm</td></tr><tr><td>Arsenic</td><td>0.5 ppm</td><td>0.1 ppm</td></tr><tr><td>Nickel</td><td>4.5 ppm</td><td>1.3 ppm</td></tr><tr><td>Chromium</td><td>3.0 ppm</td><td>0.8 ppm</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Line</td><td>Cells/mm2</td><td>P (line)</td><td>P (type)</td><td>Cell layers</td><td>P (line)</td><td>P (type)</td></tr><tr><td>Wild type</td><td>6.192</td><td></td><td></td><td>27.53</td><td></td><td></td></tr><tr><td>SlARF9-OE-4</td><td>5.676</td><td>ns</td><td rowspan="2">ns</td><td>24.39</td><td></td><td rowspan="2"></td></tr><tr><td>SlARF9-OE-5</td><td>5.395</td><td>ns</td><td>23.96</td><td></td></tr><tr><td>SlARF9-RNAi-1</td><td>7.391</td><td>ns</td><td rowspan="4"></td><td>36.03</td><td></td><td rowspan="4"></td></tr><tr><td>SlARF9-RNAi-6</td><td>7.307</td><td>ns</td><td>32.85</td><td></td></tr><tr><td>SlARF9-RNAi-9</td><td>7.241</td><td>ns</td><td>34.40</td><td></td></tr><tr><td>SlARF9-RNAi-12</td><td>9.755</td><td></td><td>34.13</td><td>*</td></tr><tr><td>Maximum SED</td><td>1.1514</td><td></td><td></td><td>2.034</td><td></td><td></td></tr><tr><td>Degrees of freedom</td><td>49</td><td></td><td></td><td>50</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Biomarker</td><td>RR</td><td>95 % CI</td><td>Hedges’g</td><td>95% CrI</td><td>PPPV</td><td>Rank</td></tr><tr><td>AVC</td><td>1.19</td><td>1.05–1.36</td><td>0.08</td><td>0.01 to 0.13</td><td>0.010</td><td>2</td></tr><tr><td>Midwall ﬁbrosis</td><td>2.88</td><td>1.12–7.39</td><td>0.11</td><td>−0.34 to 0.67</td><td>0.456</td><td>4</td></tr><tr><td>LGE%</td><td>1.05</td><td>1.01–1.10</td><td>0.016</td><td>0.01 to 0.02</td><td><0.0001</td><td>1</td></tr><tr><td>ECV</td><td>1.68</td><td>1.17–2.41</td><td>0.15</td><td>−0.06 to 0.44</td><td>0.134</td><td>3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Group</td><td colspan="3">Resistive Index before sildenafil</td><td colspan="3">Resistive Index after sildenafil</td></tr><tr><td>Control</td><td>Breath hold</td><td>Hyperventilation</td><td>Control</td><td>Breath hold</td><td>Hyperventilation</td></tr><tr><td>Normal</td><td>0.56 ± 0.02</td><td>0.51 ± 0.02</td><td>0.7 ± 0.03</td><td>0.58 ± 0.02</td><td>0.49 ± 0.02</td><td>0.7 ± 0.02</td></tr><tr><td>DM</td><td>0.6 ± 0.02</td><td>0.53 ± .02</td><td>0.71 ± 0.02</td><td>0.6 ± .015</td><td>0.53 ± .02</td><td>0.72 ± .018</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Diagnostic criteria</td><td colspan="2">Total (5959)</td><td colspan="2">Male (2451)</td><td colspan="2">Female (3508)</td><td rowspan="2">χ2</td><td rowspan="2">P</td></tr><tr><td></td><td>Prevalence</td><td>Prevalence rate</td><td>Prevalence</td><td>Prevalence rate</td><td>Prevalence</td><td>Prevalence rate</td></tr><tr><td>Overweight or obese</td><td>CDS</td><td>1685</td><td>28.28%</td><td>747</td><td>30.48%</td><td>938</td><td>26.74%</td><td>9.89</td><td><0.01</td></tr><tr><td>Central obesity</td><td>IDF/ ATPⅢ</td><td>2249</td><td>37.74%</td><td>609</td><td>24.85%</td><td>1640</td><td>46.75%</td><td>294.01</td><td><0.01</td></tr><tr><td>Hypertriglyceridemia</td><td>IDF/ ATPⅢ</td><td>1432</td><td>24.03%</td><td>655</td><td>26.72%</td><td>777</td><td>22.15%</td><td>16.48</td><td><0.01</td></tr><tr><td rowspan="2">Reduced HDL-C</td><td>IDF</td><td>2071</td><td>34.75%</td><td>618</td><td>25.21%</td><td>1453</td><td>41.42%</td><td>167.62</td><td><0.01</td></tr><tr><td>ATPⅢ</td><td>2117</td><td>35.53%</td><td>618</td><td>25.21%</td><td>1499</td><td>42.73%</td><td>193.88</td><td><0.01</td></tr><tr><td rowspan="2">Elevated blood pressure</td><td>IDF/ ATPⅢ</td><td>2483</td><td>41.67%</td><td>1154</td><td>47.08%</td><td>1329</td><td>37.88%</td><td>51.26</td><td><0.01</td></tr><tr><td>CDS</td><td>1656</td><td>27.79%</td><td>744</td><td>30.35%</td><td>912</td><td>26.00%</td><td>14.01</td><td><0.01</td></tr><tr><td rowspan="3">Hyperglycemia</td><td>IDF</td><td>1918</td><td>32.19%</td><td>834</td><td>34.03%</td><td>1084</td><td>30.90%</td><td>6.31</td><td>0.01</td></tr><tr><td>ATPⅢ</td><td>1912</td><td>32.09%</td><td>833</td><td>33.99%</td><td>1079</td><td>30.76%</td><td>6.74</td><td>0.01</td></tr><tr><td>CDS</td><td>1346</td><td>22.59%</td><td>591</td><td>24.11%</td><td>755</td><td>21.52%</td><td>5.73</td><td>0.02</td></tr><tr><td>Dyslipidemia</td><td>CDS</td><td>1524</td><td>25.57%</td><td>670</td><td>27.34%</td><td>854</td><td>24.34%</td><td>6.74</td><td>0.01</td></tr><tr><td rowspan="3">MS</td><td>IDF</td><td>1327</td><td>22.27%</td><td>412</td><td>16.81%</td><td>915</td><td>26.08%</td><td>71.69</td><td><0.01</td></tr><tr><td>ATPⅢ</td><td>1670</td><td>28.02%</td><td>594</td><td>24.24%</td><td>1076</td><td>30.67%</td><td>29.65</td><td><0.01</td></tr><tr><td>CDS</td><td>698</td><td>11.71%</td><td>320</td><td>13.06%</td><td>378</td><td>10.78%</td><td>7.26</td><td>0.01</td></tr><tr><td rowspan="3">MS**</td><td>IDF</td><td>—</td><td>19.85%</td><td>—</td><td>16.98%</td><td>—</td><td>22.11%</td><td>—</td><td>—</td></tr><tr><td>ATPⅢ</td><td>—</td><td>24.77%</td><td>—</td><td>23.86%</td><td>—</td><td>25.76%</td><td>—</td><td>—</td></tr><tr><td>CDS</td><td>—</td><td>9.95%</td><td>—</td><td>12.31%</td><td>—</td><td>8.50%</td><td>—</td><td>—</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Characteristics</td><td>Frequency</td><td>Percentage</td></tr><tr><td colspan="3">Age</td></tr><tr><td>10–14</td><td>109</td><td>20.2</td></tr><tr><td>15–19</td><td>429</td><td>79.4</td></tr><tr><td>20–24</td><td>2</td><td>0.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Sex</td></tr><tr><td>Male</td><td>213</td><td>39.4</td></tr><tr><td>Female</td><td>327</td><td>60.6</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Ethnic group</td></tr><tr><td>Yoruba</td><td>468</td><td>86.7</td></tr><tr><td>Igbo</td><td>47</td><td>8.7</td></tr><tr><td>Hausa</td><td>10</td><td>1.9</td></tr><tr><td>Others</td><td>15</td><td>2.8</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Class</td></tr><tr><td>SSS 1</td><td>128</td><td>23.7</td></tr><tr><td>SSS 2</td><td>253</td><td>46.9</td></tr><tr><td>SSS 3</td><td>159</td><td>29.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">School type</td></tr><tr><td>Public</td><td>482</td><td>89.3</td></tr><tr><td>Private</td><td>58</td><td>10.7</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Religion</td></tr><tr><td>Christianity</td><td>511</td><td>94.6</td></tr><tr><td>Islam</td><td>29</td><td>5.4</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr><tr><td colspan="3">Ethnicity</td></tr><tr><td>Yoruba</td><td>468</td><td>86.7</td></tr><tr><td>Ibo</td><td>47</td><td>8.7</td></tr><tr><td>Hausa</td><td>10</td><td>1.9</td></tr><tr><td>Others</td><td>15</td><td>2.8</td></tr><tr><td>Total</td><td>540</td><td>100.0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Dimension of performance</td><td colspan="3">Number of written concerns/comments</td></tr><tr><td></td><td>First cycle</td><td>Second cycle</td><td>Third cycle</td></tr><tr><td>1</td><td>Communication with patients and their families</td><td>Five</td><td>Two</td><td>Zero</td></tr><tr><td>2</td><td>Courtesy and professionalism</td><td>Nine</td><td>Zero</td><td>Two</td></tr><tr><td>3</td><td>Temper</td><td>Four</td><td>Three</td><td>One</td></tr><tr><td>4</td><td>Approachability</td><td>Six</td><td>One</td><td>Zero</td></tr><tr><td>5</td><td>Responsiveness to concerns</td><td>Five</td><td>Zero</td><td>Zero</td></tr><tr><td>6</td><td>Non-clinical quality of care</td><td>Six</td><td>Zero</td><td>Zero</td></tr><tr><td>7</td><td>Overall Management of ED patients</td><td>Fifteen</td><td>One</td><td>Three</td></tr><tr><td>8</td><td>Initiative and responsibility in conflict resolution</td><td>Nine</td><td>One</td><td>One</td></tr><tr><td>9</td><td>Availability in ED</td><td>Six</td><td>Zero</td><td>One</td></tr><tr><td>10</td><td>Engaging the nurses in plan of care</td><td>Seven</td><td>Zero</td><td>One</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Reads (M)</td><td>Data (MB)</td><td>Alignment (%)</td><td>Coverage (%)</td><td>Depth</td></tr><tr><td>MO-1</td><td>3.05</td><td>0.27</td><td>91.39</td><td>93.57</td><td>135.92</td></tr><tr><td>FA-1</td><td>2.37</td><td>0.21</td><td>88.77</td><td>95.30</td><td>104.15</td></tr><tr><td>FT-1</td><td>2.71</td><td>0.24</td><td>89.05</td><td>93.23</td><td>124.62</td></tr><tr><td>MP-1</td><td>128.89</td><td>11.59</td><td>93.58</td><td>95.63</td><td>203.21</td></tr><tr><td>MP-1(Duo-index)</td><td>128.89</td><td>11.59</td><td>93.58</td><td>95.66</td><td>279.91</td></tr><tr><td>MO-2</td><td>30.35</td><td>2.73</td><td>92.10</td><td>98.36</td><td>174.87</td></tr><tr><td>FA-2</td><td>22.09</td><td>1.99</td><td>92.90</td><td>97.14</td><td>135.81</td></tr><tr><td>FT-2</td><td>33.92</td><td>3.05</td><td>89.36</td><td>98.51</td><td>176.90</td></tr><tr><td>MP-2</td><td>141.91</td><td>12.78</td><td>95.34</td><td>98.61</td><td>62.28</td></tr><tr><td>MO-3</td><td>30.83</td><td>2.77</td><td>93.14</td><td>98.36</td><td>131.22</td></tr><tr><td>FA-3</td><td>33.04</td><td>2.97</td><td>93.31</td><td>97.43</td><td>148.44</td></tr><tr><td>FT-3</td><td>22.66</td><td>2.04</td><td>92.99</td><td>98.32</td><td>104.64</td></tr><tr><td>MP-3</td><td>145.86</td><td>13.12</td><td>95.28</td><td>98.68</td><td>44.75</td></tr><tr><td>MO-4</td><td>39.81</td><td>3.58</td><td>91.82</td><td>98.67</td><td>226.32</td></tr><tr><td>FA-4</td><td>28.02</td><td>2.52</td><td>92.19</td><td>97.30</td><td>176.12</td></tr><tr><td>FT-4</td><td>28.75</td><td>2.59</td><td>89.97</td><td>97.34</td><td>117.40</td></tr><tr><td>MP-4</td><td>188.27</td><td>16.94</td><td>89.16</td><td>97.56</td><td>93.81</td></tr><tr><td>MO-5</td><td>34.61</td><td>3.46</td><td>94.65</td><td>98.61</td><td>174.67</td></tr><tr><td>FA-5</td><td>43.09</td><td>4.31</td><td>94.20</td><td>97.27</td><td>180.79</td></tr><tr><td>FT-5</td><td>41.39</td><td>4.14</td><td>91.54</td><td>97.46</td><td>176.58</td></tr><tr><td>MP-5</td><td>134.99</td><td>12.14</td><td>95.24</td><td>97.11</td><td>28.91</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Comparison</td><td>Hazard ratio for death</td><td>95% CI</td><td>p-value</td></tr><tr><td>(Adjuvant treated, miR-21 negative) vs. rest</td><td>0.316</td><td>0.166–0.600</td><td>0.0004</td></tr><tr><td>CXCR3 status: positive vs. negative</td><td>4.177</td><td>1.775–9.831</td><td>0.0011</td></tr><tr><td>AJCC stage: IIB vs. IIA</td><td>2.092</td><td>1.078–4.058</td><td>0.0290</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td></td><td>Initial range</td><td>Case 1</td><td>Case 2</td><td>Case 3</td><td>Case 4</td><td>Case 5</td></tr><tr><td colspan="2">aon</td><td>(0.001, 0.04)</td><td>0.019</td><td>0.020</td><td>0.028</td><td>0.024</td><td>0.021</td></tr><tr><td colspan="2">aoff</td><td>(100, 1,000)</td><td>211</td><td>348</td><td>309</td><td>460</td><td>206</td></tr><tr><td rowspan="2">Ck</td><td>xi > 0</td><td>(0, 2,100)</td><td>1,544</td><td>1,735</td><td>1,885</td><td>2,085</td><td>2,015</td></tr><tr><td>xi < 0</td><td>(0, 2,100)</td><td>264</td><td>1,345</td><td>1,166</td><td>1,113</td><td>529</td></tr><tr><td rowspan="2">kd</td><td>xi > 0</td><td>(0, 400)</td><td>293</td><td>343</td><td>280</td><td>190</td><td>247</td></tr><tr><td>xi < 0</td><td>(0, 400)</td><td>195</td><td>74</td><td>51</td><td>290</td><td>267</td></tr><tr><td rowspan="4">kdb</td><td>xi > 0</td><td>(0, 50)</td><td>26</td><td>49</td><td>47</td><td>42</td><td>36</td></tr><tr><td>xi < 0</td><td>(0, 50)</td><td>47</td><td>19</td><td>28</td><td>18</td><td>19</td></tr><tr><td>kplus</td><td>(0, 100)</td><td>54</td><td>50</td><td>40</td><td>72</td><td>35</td></tr><tr><td>kminus</td><td>(0, 20)</td><td>12</td><td>14</td><td>19</td><td>18</td><td>13</td></tr><tr><td colspan="2">�/element (strain)</td><td>N/A</td><td>0.077</td><td>0.078</td><td>0.055</td><td>0.080</td><td>0.076</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Database</td><td>common carp hits</td><td>Unique protein</td><td>% of total unique proteins</td></tr><tr><td>NR</td><td>28,055</td><td>19,165</td><td></td></tr><tr><td colspan="4">Refseq/Ensembl</td></tr><tr><td>Zebrafish</td><td>27,693</td><td>14,554</td><td>53.4% of 27,271</td></tr><tr><td>Medaka</td><td>24,501</td><td>12,471</td><td>50.6% of 24,661</td></tr><tr><td>Tetraodon</td><td>24,371</td><td>12,536</td><td>54.2% of 23,118</td></tr><tr><td>Three-spined stickleback</td><td>25,025</td><td>13,147</td><td>47.7% of 27,576</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Medium</td><td>icorr (μA cm−2)</td><td>Ecorr (mV)</td><td>βa (mV/dec)</td><td>βc (mV/dec)</td></tr><tr><td>Sterile</td><td>0.087</td><td>− 472</td><td>286.4</td><td>− 237.8</td></tr><tr><td>P. aeruginosa inoculated</td><td>0.328</td><td>− 277</td><td>121.2</td><td>− 153.6</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Village/Strata</td><td colspan="2">Examined for nodules (REMO)</td><td rowspan="2">Nodules No. positive (%)</td><td colspan="3">OV16 tests</td></tr><tr><td>N</td><td>Median age (IQR)</td><td>Number screened (%)</td><td>Positive percentage (95% CI)</td><td>χ2-test (P-value)δ</td></tr><tr><td colspan="7">Village</td></tr><tr><td>Matumbala</td><td>35</td><td>38.5 (28.0–47.0)</td><td>1 (2.9)</td><td>34 (97.1)</td><td>32.3 (15.8–48.9)</td><td></td></tr><tr><td>Vigoi</td><td>54</td><td>43.8 (33.5–55.5)</td><td>1 (1.9)</td><td>53 (98.1)</td><td>62.3 (48.8–75.8)</td><td>7.41 (0.006)</td></tr><tr><td>Mdindo</td><td>54</td><td>43.2 (30.8–53.5)</td><td>3 (5.6)</td><td>50 (92.6)</td><td>80.0 (68.5–91.5)</td><td>19.26 ( < 0.001)</td></tr><tr><td>Msogezi</td><td>72</td><td>35.7 (28.6–50.2)</td><td>0 (0)</td><td>69 (95.8)</td><td>73.9 (63.3–84.5)</td><td>16.42 (< 0.001)</td></tr><tr><td colspan="7">Strata</td></tr><tr><td>Suburban</td><td>126</td><td>42.5 (31.9–53.6)</td><td>2 (1.6)</td><td>119 (94.4)</td><td>50.6 (39.9–61.3)</td><td></td></tr><tr><td>Rural</td><td>89</td><td>39.0 (28.9–51.9)</td><td>3 (3.4)</td><td>87 (97.6)</td><td>76.5 (68.7–84.2)</td><td>14.9 (< 0.001)</td></tr><tr><td>Total/Average</td><td>215</td><td>40.2 (29.6–52.9)</td><td>5 (2.3)</td><td>206 (95.8)</td><td>65.5 (59.0–72.1)</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Length (μm)</td><td>Diameter (μm)</td></tr><tr><td>Proboscis</td><td>L1 = 1560 (n = 8)</td><td>D1 = 25</td></tr><tr><td>Pharynx</td><td>L2 = 200 (n = 4)</td><td>D2 = 25</td></tr><tr><td>Pharyngeal valve (closed)</td><td>l2 = 20</td><td>d2 = 5</td></tr><tr><td>Esophagus</td><td>L3 = 100</td><td>D3 = 50</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Indicator</td><td>Short name</td><td>Units/ Range</td><td>Associated population feature</td><td>Description</td></tr><tr><td>Centre of Gravity</td><td>CG</td><td>Degree</td><td>Location</td><td>Mean location of the population</td></tr><tr><td>Number of Patches</td><td>NP</td><td>>0</td><td>Patchiness</td><td>Patchiness, biomass hotspots</td></tr><tr><td>Inertia</td><td>I</td><td>nmi2</td><td>Dispersion</td><td>Dispersion of the individuals around the GC of the population</td></tr><tr><td>Isotropy</td><td>I</td><td>0 to 1</td><td>Dispersion</td><td>Elongation of the population</td></tr><tr><td>Positive Area</td><td>PA</td><td>nmi2</td><td>Occupation</td><td>Area of presence</td></tr><tr><td>Spreading Area</td><td>SA</td><td>nmi2</td><td>Aggregation</td><td>Area occupied by the population accounting for density values</td></tr><tr><td>Equivalent Area</td><td>EA</td><td>nmi2</td><td>Aggregation</td><td>Individual-based measure of the area occupied by the stock</td></tr><tr><td>Global Index of Collocation</td><td>GIC</td><td>0 to 1</td><td>Overlap</td><td>Overlapping degree of two populations</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Response: Predictor</td><td colspan="4">Probability of reproduction (0,1)</td><td></td><td colspan="4">Reproductive success (N offspring)</td><td></td></tr><tr><td rowspan="2">Estimate</td><td colspan="2">95% CI</td><td rowspan="2">z</td><td></td><td rowspan="2">Estimate</td><td colspan="2">95% CI</td><td rowspan="2">z</td><td></td></tr><tr><td>lower</td><td>upper</td><td></td><td>lower</td><td>upper</td><td></td></tr><tr><td>Intercept</td><td>-0.068</td><td>-0.596</td><td>0.461</td><td>-0.17</td><td></td><td>-0.403</td><td>-0.762</td><td>-0.044</td><td>-2.41</td><td></td></tr><tr><td>Trap effort (TE)</td><td>0.167</td><td>-0.196</td><td>0.530</td><td>0.94</td><td></td><td>0.106</td><td>-0.114</td><td>0.326</td><td>0.93</td><td></td></tr><tr><td>Maternal age (mmage)</td><td>2.278</td><td>-0.599</td><td>5.154</td><td>2.17</td><td></td><td>1.228</td><td>-0.366</td><td>2.822</td><td>2.01</td><td></td></tr><tr><td>mmage2</td><td>-0.642</td><td>-1.206</td><td>-0.079</td><td>-2.44</td><td></td><td>-0.335</td><td>-0.638</td><td>-0.031</td><td>-2.27</td><td></td></tr><tr><td>rain</td><td>-0.513</td><td>-0.889</td><td>-0.136</td><td>-2.71</td><td></td><td>-0.324</td><td>-0.551</td><td>-0.097</td><td>-2.86</td><td></td></tr><tr><td>RPY</td><td>0.084</td><td>-0.690</td><td>0.857</td><td></td><td></td><td>-0.048</td><td>-0.501</td><td>0.405</td><td></td><td></td></tr><tr><td>TQ4</td><td>0.746</td><td>0.290</td><td>1.201</td><td>3.26</td><td></td><td>0.338</td><td>0.021</td><td>0.656</td><td>2.42</td><td></td></tr><tr><td>maxage</td><td>-0.075</td><td>-0.736</td><td>0.586</td><td></td><td></td><td>0.111</td><td>-0.277</td><td>0.499</td><td></td><td></td></tr><tr><td>mmage × rain</td><td>-0.112</td><td>-0.653</td><td>0.429</td><td></td><td></td><td>-0.031</td><td>-0.351</td><td>0.288</td><td></td><td></td></tr><tr><td>mmage × RPY</td><td>-0.624</td><td>-1.591</td><td>0.344</td><td></td><td></td><td>-0.457</td><td>-1.049</td><td>0.135</td><td></td><td></td></tr><tr><td>mmage × TQ4</td><td>0.660</td><td>0.094</td><td>1.226</td><td>2.34</td><td></td><td>0.286</td><td>-0.056</td><td>0.627</td><td>1.60</td><td></td></tr><tr><td>mmage × maxage</td><td>-0.578</td><td>-1.301</td><td>0.144</td><td></td><td></td><td>-0.262</td><td>-0.723</td><td>0.199</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>1QF6</td><td>BaThrRS</td></tr><tr><td>Cys334</td><td>Cys343</td></tr><tr><td>Arg363</td><td>Arg372</td></tr><tr><td>Glu365</td><td>Glu374</td></tr><tr><td>Met374</td><td>Met383</td></tr><tr><td>Arg375</td><td>Arg384</td></tr><tr><td>Val376</td><td>Val385</td></tr><tr><td>Phe379</td><td>Phe388</td></tr><tr><td>Gln381</td><td>Gln390</td></tr><tr><td>His385</td><td>His394</td></tr><tr><td>Gln479</td><td>Gln493</td></tr><tr><td>Cys480</td><td>Cys494</td></tr><tr><td>Thr482</td><td>Thr496</td></tr><tr><td>His511</td><td>His525</td></tr><tr><td>Gly516</td><td>Gly530</td></tr><tr><td>Ser517</td><td>Ser531</td></tr><tr><td>Arg520</td><td>Arg534</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Subcategory</td><td colspan="2">Farmers</td><td colspan="2">Advisors</td><td colspan="2">Technicians</td><td colspan="2">Veterinarians</td></tr><tr><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td><td>Mean</td><td>Range</td></tr><tr><td>Reproduction or number of lambs or kids born</td><td>9.5</td><td>5–10</td><td>8.4</td><td>6–10</td><td>7.7</td><td>0–10</td><td>8.2</td><td>0–10</td></tr><tr><td>Number of sheep sold per year</td><td>8.2</td><td>4–10</td><td>7.0</td><td>5–9</td><td>6.4</td><td>0–10</td><td>6.9</td><td>0–10</td></tr><tr><td>Number of goats sold per year</td><td>8.2</td><td>4–10</td><td>6.2</td><td>59</td><td>5.9</td><td>0–10</td><td>6.0</td><td>0–10</td></tr><tr><td>Amount of wool sold per year</td><td>8.3</td><td>2–10</td><td>8.3</td><td>6–10</td><td>7.5</td><td>0–10</td><td>6.7</td><td>0–10</td></tr><tr><td>Quality of wool sold</td><td>8.5</td><td>3–10</td><td>8.1</td><td>6–10</td><td>7.2</td><td>0–10</td><td>6.7</td><td>0–10</td></tr><tr><td>Others (specify income source)</td><td>0.0</td><td>0–0</td><td>1.9</td><td>0–10</td><td>0.4</td><td>0–8</td><td>0.0</td><td>0–0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>C27H32O</td><td>F000 = 4040</td></tr><tr><td>Mr = 372.53</td><td>Dx = 1.111 Mg m−3</td></tr><tr><td>Monoclinic, C2/c</td><td>Mo Kα radiation λ = 0.71073 Å</td></tr><tr><td>Hall symbol: -C 2yc</td><td>Cell parameters from 2156 reflections</td></tr><tr><td>a = 41.246 (7) Å</td><td>θ = 5.3–40.8º</td></tr><tr><td>b = 6.2930 (10) Å</td><td>µ = 0.07 mm−1</td></tr><tr><td>c = 43.001 (7) Å</td><td>T = 293 (2) K</td></tr><tr><td>β = 94.243 (4)º</td><td>Prism, yellow</td></tr><tr><td>V = 11131 (3) Å3</td><td>0.50 × 0.41 × 0.18 mm</td></tr><tr><td>Z = 20</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="2">Gender</td></tr><tr><td>(i) Male</td><td>51</td></tr><tr><td>(ii) Female</td><td>29</td></tr><tr><td>Age</td><td>47.65 (SD = 7.1)</td></tr><tr><td colspan="2">Ethnicity</td></tr><tr><td>(i) Black, non-Hispanic</td><td>77</td></tr><tr><td>(ii) Hispanic</td><td>2</td></tr><tr><td>(iii) White</td><td>1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Characteristic</td><td></td><td colspan="2">Study Cohort</td></tr><tr><td></td><td>N</td><td>%</td></tr><tr><td>Total</td><td></td><td>8,711</td><td>100</td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td>3,733</td><td>42.9</td></tr><tr><td>Female</td><td>4,978</td><td>57.1</td></tr><tr><td>Age (years)</td><td>Mean (SD)</td><td>65.9</td><td>10.5</td></tr><tr><td rowspan="5">Age category (years)</td><td>45–54</td><td>1,474</td><td>16.9</td></tr><tr><td>55–64</td><td>2,780</td><td>31.9</td></tr><tr><td>65–74</td><td>2,573</td><td>29.5</td></tr><tr><td>75–84</td><td>1,583</td><td>18.2</td></tr><tr><td>≥85</td><td>302</td><td>3.5</td></tr><tr><td rowspan="3">SES</td><td>High</td><td>1,651</td><td>19.2</td></tr><tr><td>Intermediate</td><td>3,597</td><td>41.9</td></tr><tr><td>Low</td><td>3,346</td><td>38.9</td></tr><tr><td>BMI (kg/m²)</td><td>Mean (SD)</td><td>27.1</td><td>4.1</td></tr><tr><td rowspan="3">Smoking</td><td>Current</td><td>1,734</td><td>20.2</td></tr><tr><td>Former</td><td>4,288</td><td>49.9</td></tr><tr><td>Never</td><td>2,570</td><td>29.9</td></tr><tr><td>Diabetes Status</td><td></td><td>952</td><td>10.9</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Location2</td><td>size (kb)</td><td>classification</td><td>genes in the region1</td></tr><tr><td>Ger1</td><td>chr10 12719281–13144281</td><td>425</td><td>coding, imprinted, disease related</td><td>Phactr2 (phosphatase and actin regulator 2 isoform A), Plagl1 (pleiomorphic adenoma gene-like 1), Zac1 (zinc finger protein)</td></tr><tr><td>Ger2</td><td>chr14 35,222,025–35,451,7633</td><td>230</td><td>coding, disease related</td><td>Bmpr1a (bone morphogenetic protein receptor type-1A), Ldb3 (LIM domain-binding protein 3 isoform), Opn4 (melanopsin isoform 1)</td></tr><tr><td>Ger3</td><td>chr17 11,520,278–12,071,811</td><td>550</td><td>coding, disease related</td><td>Park2 (parkinson protein 2 - E3 ubiquitin-protein ligase parkin)</td></tr><tr><td>Fra1</td><td>chr12 59,560,813–59,710,943</td><td>150</td><td>non-coding</td><td>center of 680 kb non-coding region</td></tr><tr><td>Fra2</td><td>chr15 38,059,935–38,210,538</td><td>150</td><td>coding</td><td>Odf1, main protein of sperm tail outer dense fibers</td></tr><tr><td>Cze1</td><td>chr3 112,689,523–115,078,986</td><td>2,390</td><td>coding, disease related</td><td>Amy2b (amylase 2b isoform 1), Amy2a5 (pancreatic alpha- amylase), Amy1 (alpha-amylase 1), Col11a1 (collagen alpha-1(XI) chain), Olfm3 (olfactomedin 3)</td></tr><tr><td>Cze2</td><td>chr7 29571436–30171436</td><td>600</td><td>coding</td><td>ca 35 partially overlapping genes</td></tr><tr><td>Cze3</td><td>chr8 6013855–6933855</td><td>920</td><td>non-coding</td><td>center of an approx 3 Mb non- coding region</td></tr><tr><td>Kaz1</td><td>chr14 109933747–111553747</td><td>1,620</td><td>coding (mostly non-coding)</td><td>Slitrk6 (SLIT and NTRK-like protein 6)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>EV</td><td>Concentration (particles/mL)</td><td>Size (nm)</td></tr><tr><td rowspan="2">HS.5</td><td rowspan="2">3,29 × 1011 ± 2,4 × 1010</td><td>Mean – 125.6</td></tr><tr><td>SD – 49.8</td></tr><tr><td rowspan="2">hTERT</td><td rowspan="2">7,64 × 1011 ± 4,62 × 1010</td><td>Mean – 159,7</td></tr><tr><td>SD – 130,4</td></tr><tr><td rowspan="2">K562</td><td rowspan="2">3,36 × 1011 ± 5,05 × 1010</td><td>Mean – 122</td></tr><tr><td>SD – 65,9</td></tr><tr><td rowspan="2">hMSC</td><td rowspan="2">6,40 × 1011 ± 1 × 1010</td><td>Mean – 136,6</td></tr><tr><td>SD – 86,8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Motif No.</td><td>Consensus sequences</td></tr><tr><td>1</td><td>KCGDQAQLSCCNKATYAQDVTDIDEFILAGTLKNLIGGGSG{T, S}EGLGLF{D, N}Q</td></tr><tr><td>2</td><td>{D, G}L{V, G}{G, N}Q{K, S}C{K, S}{Q, A}{Q, N}{I, T}{V, A}CCQN{S, N}{P{F, S}{D, N}{G, A}</td></tr><tr><td>3</td><td>{S, Q}{Q, C}{C, S}{N, Q}{T, G}{G, Q}{T, S}{L, V, A}{Q, K}CCNS</td></tr><tr><td>4</td><td>VQS{A, S}S{S, D, N}PX{V, A}{A, G}{G, L}LLGLLG{I, V}V{L, V}G</td></tr><tr><td>5</td><td>L{V, I}{G, N}LTC{S, T}PI{S, T}V</td></tr><tr><td>6</td><td>SX{T, V}A{A, L}VLALAA{A, L}{A, L}{A, V}{A, V}AXPXPX</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>n</td><td>%</td></tr><tr><td colspan="3">Predominant site of gastric lymphoma</td></tr><tr><td>Corpus</td><td>28</td><td>35</td></tr><tr><td>Antrum</td><td>26</td><td>33</td></tr><tr><td>Cardia</td><td>7</td><td>9</td></tr><tr><td>Fundus</td><td>2</td><td>3</td></tr><tr><td>Multiple site</td><td>5</td><td>6</td></tr><tr><td>Unknown</td><td>11</td><td>14</td></tr><tr><td colspan="3">Symptoms</td></tr><tr><td>Abdominal pain and dyspepsia</td><td>55</td><td>70</td></tr><tr><td>Weight loss, fever, night sweat</td><td>42</td><td>53</td></tr><tr><td>Nausea and vomiting</td><td>13</td><td>17</td></tr><tr><td>Weakness</td><td>11</td><td>14</td></tr><tr><td>Gastrointestinal bleeding</td><td>8</td><td>10</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Type of response provided</td><td>Number (22 total)a</td><td>Percentage of total</td></tr><tr><td>Favorable</td><td>11</td><td>50 %</td></tr><tr><td>Neutral</td><td>1</td><td>4.5 %</td></tr><tr><td>Unfavorable</td><td>2</td><td>9.1 %</td></tr><tr><td>Both favorable and unfavorable</td><td>6</td><td>27.3 %</td></tr><tr><td>Prefer not to answer</td><td>2</td><td>9.1 %</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="5">Men (n = 68)</td><td colspan="5">Women (n = 71)</td></tr><tr><td></td><td colspan="2">Crude intake</td><td colspan="3">Energy-adjusted intake</td><td colspan="2">Crude intake</td><td colspan="3">Energy-adjusted intake</td></tr><tr><td></td><td>CC</td><td>95% conﬁdence interval</td><td>CC</td><td>95% conﬁdence interval</td><td>De- attenuated CC</td><td>CC</td><td>95% conﬁdence interval</td><td>CC</td><td>95% conﬁdence interval</td><td>De- attenuated CC</td></tr><tr><td>Protein</td><td>0.35</td><td>(0.12, 0.54)</td><td>0.54</td><td>(0.35, 0.69)</td><td>0.67</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.39</td><td>(0.18, 0.57)</td><td>0.47</td></tr><tr><td>Isoleucine</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.59</td><td>(0.41, 0.73)</td><td>0.75</td><td>0.58</td><td>(0.40, 0.71)</td><td>0.43</td><td>(0.22, 0.60)</td><td>0.52</td></tr><tr><td>Leucine</td><td>0.38</td><td>(0.15, 0.56)</td><td>0.58</td><td>(0.39, 0.72)</td><td>0.73</td><td>0.58</td><td>(0.40, 0.71)</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.46</td></tr><tr><td>Lysine</td><td>0.37</td><td>(0.14, 0.56)</td><td>0.57</td><td>(0.38, 0.71)</td><td>0.73</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.42</td><td>(0.20, 0.59)</td><td>0.52</td></tr><tr><td>Methionine</td><td>0.36</td><td>(0.13, 0.55)</td><td>0.54</td><td>(0.34, 0.69)</td><td>0.69</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.39</td><td>(0.18, 0.58)</td><td>0.49</td></tr><tr><td>Phenylalanine</td><td>0.40</td><td>(0.18, 0.58)</td><td>0.59</td><td>(0.41, 0.72)</td><td>0.73</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.42</td><td>(0.21, 0.60)</td><td>0.52</td></tr><tr><td>Threonine</td><td>0.36</td><td>(0.13, 0.55)</td><td>0.56</td><td>(0.37, 0.70)</td><td>0.70</td><td>0.56</td><td>(0.38, 0.70)</td><td>0.43</td><td>(0.21, 0.60)</td><td>0.52</td></tr><tr><td>Tryptophan</td><td>0.40</td><td>(0.18, 0.58)</td><td>0.61</td><td>(0.43, 0.74)</td><td>0.74</td><td>0.60</td><td>(0.43, 0.73)</td><td>0.44</td><td>(0.23, 0.61)</td><td>0.54</td></tr><tr><td>Valine</td><td>0.39</td><td>(0.17, 0.57)</td><td>0.59</td><td>(0.41, 0.73)</td><td>0.73</td><td>0.58</td><td>(0.40, 0.72)</td><td>0.42</td><td>(0.20, 0.59)</td><td>0.50</td></tr><tr><td>Histidine</td><td>0.32</td><td>(0.09, 0.52)</td><td>0.40</td><td>(0.18, 0.59)</td><td>0.60</td><td>0.63</td><td>(0.47, 0.76)</td><td>0.46</td><td>(0.26, 0.63)</td><td>0.61</td></tr><tr><td>Arginine</td><td>0.44</td><td>(0.22, 0.61)</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.69</td><td>0.49</td><td>(0.29, 0.65)</td><td>0.38</td><td>(0.17, 0.57)</td><td>0.48</td></tr><tr><td>Cystine</td><td>0.45</td><td>(0.23, 0.62)</td><td>0.51</td><td>(0.31, 0.67)</td><td>0.60</td><td>0.51</td><td>(0.31, 0.66)</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.45</td></tr><tr><td>Tyrosine</td><td>0.40</td><td>(0.17, 0.58)</td><td>0.58</td><td>(0.39, 0.72)</td><td>0.72</td><td>0.62</td><td>(0.45, 0.74)</td><td>0.46</td><td>(0.25, 0.63)</td><td>0.57</td></tr><tr><td>Alanine</td><td>0.39</td><td>(0.17, 0.58)</td><td>0.61</td><td>(0.43, 0.74)</td><td>0.75</td><td>0.53</td><td>(0.33, 0.68)</td><td>0.39</td><td>(0.17, 0.57)</td><td>0.47</td></tr><tr><td>Aspartic acid</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.65</td><td>(0.49, 0.77)</td><td>0.78</td><td>0.54</td><td>(0.35, 0.69)</td><td>0.43</td><td>(0.22, 0.60)</td><td>0.52</td></tr><tr><td>Glutamic acid</td><td>0.30</td><td>(0.07, 0.50)</td><td>0.56</td><td>(0.37, 0.71)</td><td>0.72</td><td>0.51</td><td>(0.31, 0.66)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.43</td></tr><tr><td>Glycine</td><td>0.38</td><td>(0.16, 0.57)</td><td>0.48</td><td>(0.27, 0.64)</td><td>0.61</td><td>0.53</td><td>(0.33, 0.68)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.42</td></tr><tr><td>Proline</td><td>0.28</td><td>(0.05, 0.49)</td><td>0.57</td><td>(0.39, 0.71)</td><td>0.75</td><td>0.55</td><td>(0.36, 0.69)</td><td>0.35</td><td>(0.13, 0.54)</td><td>0.42</td></tr><tr><td>Serine</td><td>0.37</td><td>(0.15, 0.56)</td><td>0.55</td><td>(0.36, 0.70)</td><td>0.67</td><td>0.53</td><td>(0.34, 0.68)</td><td>0.36</td><td>(0.13, 0.54)</td><td>0.43</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>References</td><td>Pts. (N)</td><td>Age of treated GHD patients (years)</td><td>GHD testing</td><td>Study design</td><td>GH dose/ day*</td><td>Follow-up</td><td>Parameters</td><td>Key results</td></tr><tr><td>High et al. (16)</td><td>12 treated/ 11 controls</td><td>36.1 ± 10</td><td>Glucagon stimulation test</td><td>Open, prospective, randomized study</td><td>0.6 mg (or uptitrated)</td><td>12 months</td><td>Cognition: neuropsych. battery</td><td>Improvements in Dominant Hand Finger Tapping Test, WAIS III–PSI, CVLT II, WCST (executive functioning)</td></tr><tr><td>Maric et al. (19)</td><td>4 treated/ 2 controls (≥3 yrs after TBI)</td><td>39.3 ± 11</td><td>GHRH + GH releasing peptide-6</td><td>Open, prospective, study</td><td>0.3 mg (males), 0.4 mg (females)</td><td>6 months</td><td>Cognition: semi-structured interviews, SCL-90-R, ZDI, neuropsych. battery</td><td>Improvements in cognition, particularly of memory, and psychiatric functioning; worsening of memory and symptoms in 3 SCL dimensions after discontinuing GH therapy for 12 months (n = 3)</td></tr><tr><td>Reimunde et al. (17)</td><td>11/19 GHD, 8/19 controls w/o GHD</td><td>53.4 ± 17.4</td><td>GHRH-arginine</td><td>Open, prospective study, placebo-controlled study</td><td>1 mg</td><td>3 months</td><td>Cognition WAIS test</td><td>GHD: significant improvements in understanding, digits, numbers, incomplete figures, similarities, vocabulary, verbal and total IQ; GHD vs. controls: significant improvements in similarities, vocabulary, verbal and total IQ</td></tr><tr><td>Moreau et al. (15)</td><td>23 (27 controls)</td><td>37.9 ± 11.7</td><td>ITT or GHRH-arginine</td><td>Open, prospective, controlled study</td><td>0.2–0.6 mg</td><td>12 months</td><td>Cognition, HrQoL, ADL</td><td>Significant cognitive improvements, in particular for the ROCF, and in 2/6 QoL domains (personal, functional); greatest improvements if lower pre-treatment performance; modest correlation with ADL</td></tr><tr><td>Devesa et al. (20)</td><td>5/13 GHD (2.5 months−11 years after TBI)</td><td>24.6 ± 9.6</td><td>GHRH-arginine</td><td>Open, prospective study</td><td>0.8–1 mg/ 5 days/week, resting 15 days every 2 months</td><td>max. 8 months</td><td>Cognition, motor symptoms</td><td>Significant improvements in all patients; cognitive improvements appeared earlier and were more important than motor improvements; visual performance ameliorated in a patient with amaurosis</td></tr><tr><td>Gardner et al. (18)</td><td>161</td><td>42.6 [40.8; 44.5]</td><td>ITT or glucagon stimulation or GHRH-arginine or IGF-1 SDS</td><td>Retrospective database analysis</td><td>0.37 mg (95% CI, 0.35, 0.40)</td><td>8 years</td><td>HrQoL: QoL-AGHDA</td><td>Significant improvement of QoL-AGHDA score was sustained over 8 years; normalization of socialization after 1 year, self-confidence and tenseness after 6 years; no normalization of tiredness and memory</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Substrate and coatings</td><td>AZ91D</td><td>Ni-P</td><td>Ni-P-Al2O3 (1.7%)</td><td>Ni-P-Al2O3 (3.6%)</td><td>Ni-P-Al2O3 (4.2%)</td></tr><tr><td>icorr (A/cm2)</td><td>1.4 × 10−4</td><td>3.1 × 10−6</td><td>1.6 × 10−6</td><td>4.5 × 10−7</td><td>1.0 × 10−6</td></tr><tr><td>Ecorr (V)</td><td>− 1.46</td><td>− 0.51</td><td>− 0.47</td><td>− 0.35</td><td>− 0.41</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>N</td><td>Frequency%</td></tr><tr><td colspan="3">Exon 1 allele</td></tr><tr><td>A normal</td><td>587</td><td>80</td></tr><tr><td>B(A>G)</td><td>3</td><td>0.4</td></tr><tr><td>C(G>A)</td><td>141</td><td>20</td></tr><tr><td>D(C>T)</td><td>1</td><td>0.1</td></tr><tr><td colspan="3">Promoter alleles</td></tr><tr><td>-550H</td><td>38</td><td>5</td></tr><tr><td>-550L</td><td>694</td><td>95</td></tr><tr><td>-221X</td><td>134</td><td>18</td></tr><tr><td>-221Y</td><td>598</td><td>82</td></tr><tr><td>+4P</td><td>343</td><td>47</td></tr><tr><td>+4Q</td><td>389</td><td>53</td></tr><tr><td colspan="3">MBL2 Exon 1 genotype</td></tr><tr><td>AA wild-type</td><td>233</td><td>64</td></tr><tr><td>AB (A>G)</td><td>3</td><td>0.8</td></tr><tr><td>AC(G>A)</td><td>117</td><td>32</td></tr><tr><td>AD (C>T)</td><td>1</td><td>0.2</td></tr><tr><td>CC (C>T)</td><td>12</td><td>3</td></tr><tr><td colspan="3">Promoter region genotypes</td></tr><tr><td>-550HH</td><td>1</td><td>0.3</td></tr><tr><td>-550HL</td><td>37</td><td>10.1</td></tr><tr><td>-550LL</td><td>328</td><td>89.6</td></tr><tr><td>-221YY</td><td>242</td><td>66.1</td></tr><tr><td>-221XY</td><td>112</td><td>30.0</td></tr><tr><td>-221XX</td><td>12</td><td>3.2</td></tr><tr><td>+4PP</td><td>74</td><td>20.2</td></tr><tr><td>+4QQ</td><td>97</td><td>26.5</td></tr><tr><td>+4PQ</td><td>195</td><td>53.3</td></tr><tr><td colspan="3">MBL2 Haplotypes</td></tr><tr><td>1. MBL2LYPA</td><td>260</td><td>35.5</td></tr><tr><td>2. MBL2LYQA</td><td>183</td><td>25.0</td></tr><tr><td>3. MBL2LYQC</td><td>108</td><td>14.6</td></tr><tr><td>4. MBL2LXPA</td><td>58</td><td>7.9</td></tr><tr><td>5. MBL2LXQA</td><td>45</td><td>6.1</td></tr><tr><td>6. MBL2HYPA</td><td>41</td><td>5.6</td></tr><tr><td>7. MBL2LXQC</td><td>31</td><td>4.2</td></tr><tr><td>8. MBL2LXPC</td><td>2</td><td>0.3</td></tr><tr><td>9. MBL2LYQB</td><td>2</td><td>0.3</td></tr><tr><td>10. MBL2HYPD</td><td>1</td><td>0.1</td></tr><tr><td>11. MBL2*LYPB</td><td>1</td><td>0.1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>LTG (n = 30)</td><td>VPA (n = 30)</td><td>Control (n = 30)</td></tr><tr><td>Age (year)a</td><td>27.2±8.4</td><td>24.4±8.9</td><td>26.1±3.9</td></tr><tr><td>Gender (female;male)</td><td>15;15</td><td>15;15</td><td>15;15</td></tr><tr><td>Duration of AED therapy (month)b</td><td>17(6,30)</td><td>22.5(12.25,59.5)</td><td></td></tr><tr><td>Dosage of AED (mg/day)b</td><td>112.5(100,181.25)</td><td>750(625,1000)</td><td></td></tr><tr><td>AED concentration (μg/ml)a</td><td>2.89±1.33</td><td>64.22±29.52</td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Case ID</td><td>Age (Years)</td><td>Sex</td><td>Cause of Death</td><td>Smoking *</td><td>Classification</td></tr><tr><td>ME0503</td><td>54</td><td>Male</td><td>Cardiac arrest</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0501</td><td>69</td><td>Female</td><td>Head trauma</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0105</td><td>78</td><td>Male</td><td>Cardiac arrest</td><td>Unknown</td><td>Control</td></tr><tr><td>ME0505</td><td>59</td><td>Female</td><td>Cardiovascular</td><td>Unknown</td><td>Control</td></tr><tr><td>ELM0065</td><td>77</td><td>Male</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0038</td><td>65</td><td>Female</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0056</td><td>61</td><td>Male</td><td>NA</td><td>No</td><td>AAA</td></tr><tr><td>ELM0060</td><td>77</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr><tr><td>ELM0041</td><td>62</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr><tr><td>ELM0063</td><td>71</td><td>Male</td><td>NA</td><td>Yes</td><td>AAA</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Strain</td><td>Period of isolation</td><td>Source</td><td>References</td></tr><tr><td>1</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>2</td><td>2009–2010</td><td>Ground, Farm E</td><td>Polifroni et al., 2012</td></tr><tr><td>3</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>4</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>5</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>6</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>7</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>8</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>9</td><td>1995–1996</td><td>Calf</td><td>Blanco et al., 2004</td></tr><tr><td>10</td><td>2002–2009</td><td>Human with diarrhea</td><td>Rivero et al., 2010</td></tr><tr><td>11</td><td>2002–2009</td><td>Human with diarrhea</td><td>Rivero et al., 2010</td></tr><tr><td>12</td><td>2009</td><td>Milk-fed calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>13</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>14</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>15</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>16</td><td>2010</td><td>Newborn calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>17</td><td>2009–2010</td><td>Cow, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>18</td><td>2009</td><td>Milk-fed calf, Farm E</td><td>Fernández et al., 2012</td></tr><tr><td>19</td><td>2010</td><td>Newborn calf, Farm A</td><td>Fernández et al., 2012</td></tr><tr><td>20</td><td>2010</td><td>Newborn calf, Farm B</td><td>Fernández et al., 2012</td></tr><tr><td>21</td><td>2010</td><td>Newborn calf, Farm B</td><td>Fernández et al., 2012</td></tr><tr><td>22</td><td>2009</td><td>Growing calf, Farm D</td><td>Fernández et al., 2012</td></tr><tr><td>23</td><td>2010</td><td>Human with diarrhea</td><td>This study</td></tr><tr><td>24</td><td>2009</td><td>Human with diarrhea</td><td>This study</td></tr><tr><td>25</td><td>2009</td><td>Cow</td><td>This study</td></tr><tr><td>26</td><td>2013</td><td>Beef</td><td>This study</td></tr><tr><td>27</td><td>2013</td><td>Beef</td><td>This study</td></tr><tr><td>28</td><td>2013</td><td>Ground meat</td><td>This study</td></tr><tr><td>29</td><td>2009</td><td>Calf feed, Farm E</td><td>This study</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="4">Liver 21 days</td></tr><tr><td>Fatty acid</td><td>Corn oil diet</td><td>Canola diet</td><td>p value</td></tr><tr><td>18:2 LA</td><td>17.35 ± 1.22</td><td>12.10 ± 0.90</td><td><0.0001</td></tr><tr><td>18:1+18:3 ALA</td><td>9.59 ± 2.16</td><td>20.29 ± 2.04</td><td><0.0001</td></tr><tr><td>20:4 AA</td><td>18.40 ± 1.60</td><td>10.08 ± 0.57</td><td><0.0001</td></tr><tr><td>20:5 EPA</td><td>0.09 ± 0.02</td><td>1.39 ± 0.20</td><td><0.0001</td></tr><tr><td>22:6 DHA</td><td>5.04 ± 0.81</td><td>11.22 ± 0.46</td><td><0.0001</td></tr><tr><td>22:5 DPA</td><td>0.64 ± 0.08</td><td>0.53 ± 0.06</td><td>0.023</td></tr><tr><td colspan="4">Liver 130 days</td></tr><tr><td>18:2 LA</td><td>23.96 ± 2.74</td><td>22.91 ± 0.93</td><td>0.5565</td></tr><tr><td>18:1+18:3 ALA</td><td>18.19 ± 2.47</td><td>24.14 ± 1.01</td><td>0.0289</td></tr><tr><td>20:4 AA</td><td>13.82 ± 0.46</td><td>10.33 ± 0.49</td><td>0.0041</td></tr><tr><td>20:5 EPA</td><td>0.045 ± 0.04</td><td>0.10 ± 0.04</td><td>0.2382</td></tr><tr><td>22:6 DHA</td><td>5.37 ± 0.49</td><td>3.83 ± 0.17</td><td>0.0127</td></tr><tr><td>22:5 DPA</td><td>0.315 ± 0.04</td><td>0.24 ± 0.03</td><td>0.0817</td></tr><tr><td colspan="4">Mammary gland 21 days</td></tr><tr><td>18:2 LA</td><td>26.25 ± 1.32</td><td>6.74 ± 1.99</td><td>0.0000</td></tr><tr><td>18:1+18:3 ALA</td><td>29.26 ± 0.70</td><td>50.99 ± 1.98</td><td>0.0000</td></tr><tr><td>20:4 AA</td><td>0.67 ± 0.12</td><td>0.31 ± 0.11</td><td>0.0043</td></tr><tr><td>20:5 EPA</td><td>0.06 ± 0.01</td><td>0.08 ± 0.05</td><td>0.4050</td></tr><tr><td>22:6 DHA</td><td>0.08 ± 0.02</td><td>0.02 ± 0.01</td><td>0.0008</td></tr><tr><td>22:5 DPA</td><td>0.01 ± 0.01</td><td>0.06 ± 0.03</td><td>0.0124</td></tr><tr><td colspan="4">Mammary gland 130 days</td></tr><tr><td>18:2 LA</td><td>37.15 ± 0.78</td><td>35.77 ± 2.30</td><td>0.2879</td></tr><tr><td>18:1+18:3 ALA</td><td>0.40 ± 0.01</td><td>0.38 ± 0.03</td><td>0.1996</td></tr><tr><td>20:4 AA</td><td>0.13 ± 0.01</td><td>0.11 ± 0.03</td><td>0.3218</td></tr><tr><td>20:5 EPA</td><td>0.02 ± 0.01</td><td>0.00 ± 0.00</td><td>0.0000</td></tr><tr><td>22:6 DHA</td><td>0.01 ± 0.00</td><td>0.01 ± 0.01</td><td>0.2415</td></tr><tr><td>22:5 DPA</td><td>0.02 ± 0.00</td><td>0.00 ± 0.00</td><td>0.0000</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Independent variable</td><td>F for set</td><td>R2</td><td>t for predictors</td><td>df</td><td>Semipartial correlation (sr)</td><td>P</td></tr><tr><td>1</td><td>.179</td><td>.002</td><td></td><td>2,160</td><td></td><td>.836</td></tr><tr><td>Age</td><td></td><td></td><td>2.109</td><td></td><td>2.009</td><td>.913</td></tr><tr><td>Gender</td><td></td><td></td><td>.591</td><td></td><td>.047</td><td>.555</td></tr><tr><td>2</td><td>34.008</td><td>.463</td><td></td><td>4,158</td><td></td><td>.001</td></tr><tr><td>Depression</td><td></td><td></td><td>8.443</td><td></td><td>.492</td><td>.001</td></tr><tr><td>Autistic traits</td><td></td><td></td><td>4.745</td><td></td><td>.277</td><td>.001</td></tr><tr><td>3</td><td>28.904</td><td>.479</td><td></td><td>5,157</td><td></td><td>.001</td></tr><tr><td>Autistic traits 3 depression</td><td></td><td></td><td>22.241</td><td></td><td>2.129</td><td>.026</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Hes6</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>93</td><td>252</td><td>1534</td><td>2.74E-014</td><td>[26, 38]</td></tr><tr><td>Uterus</td><td>39</td><td>94</td><td>1692</td><td>3.24E-008</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>12</td><td>27</td><td>1759</td><td>0.00043528</td><td>-</td></tr><tr><td>Rectum</td><td>12</td><td>32</td><td>1754</td><td>0.00303994</td><td>-</td></tr><tr><td>Hes6/DDC</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>197</td><td>252</td><td>1534</td><td>0</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>21</td><td>27</td><td>1759</td><td>1.42E-009</td><td>-</td></tr><tr><td>Rectum</td><td>23</td><td>32</td><td>1754</td><td>5.03E-009</td><td>-</td></tr><tr><td>Liver</td><td>24</td><td>38</td><td>1748</td><td>1.65E-007</td><td>-</td></tr><tr><td>Kidney</td><td>75</td><td>214</td><td>1572</td><td>0.00040486</td><td>-</td></tr><tr><td>Stomach</td><td>5</td><td>8</td><td>1778</td><td>0.00476289</td><td>-</td></tr><tr><td>Hes6/CHGA</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Colon</td><td>89</td><td>252</td><td>1534</td><td>0</td><td>-</td></tr><tr><td>Uterus</td><td>42</td><td>94</td><td>1692</td><td>6.80E-013</td><td>-</td></tr><tr><td>Endometrium</td><td>30</td><td>71</td><td>1715</td><td>6.50E-009</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>13</td><td>27</td><td>1759</td><td>1.02E-005</td><td>-</td></tr><tr><td>Rectum</td><td>13</td><td>32</td><td>1754</td><td>0.00011383</td><td>-</td></tr><tr><td>Stomach</td><td>4</td><td>8</td><td>1778</td><td>0.00324489</td><td>-</td></tr><tr><td>NTS</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Lung</td><td>36</td><td>108</td><td>1678</td><td>1.29E-010</td><td>[39]</td></tr><tr><td>Ovary</td><td>32</td><td>170</td><td>1616</td><td>0.00143643</td><td>[40]</td></tr><tr><td>Small intestine</td><td>3</td><td>6</td><td>1780</td><td>0.00226141</td><td>[41]</td></tr><tr><td>Ascl1</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Breast</td><td>40</td><td>317</td><td>1469</td><td>8.27E-008</td><td>-</td></tr><tr><td>Lung</td><td>20</td><td>108</td><td>1678</td><td>3.76E-007</td><td>[42, 43]</td></tr><tr><td>Ascl1/Hes6/NTS/DDC</td><td>tumour. hits</td><td>Fgr</td><td>Bgr</td><td>p. value</td><td>Reference</td></tr><tr><td>Lung</td><td>15</td><td>108</td><td>1678</td><td>3.79E-006</td><td>-</td></tr><tr><td>Rectosigmoid</td><td>4</td><td>27</td><td>1759</td><td>0.00421239</td><td>-</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Factor</td><td>Meditation practitioners∗</td></tr><tr><td>Number of responses</td><td>343</td></tr><tr><td>% Male</td><td>39.6</td></tr><tr><td>Mean age and age range</td><td>44, (SD 13.4), range 18 yrs to 82 yrs</td></tr><tr><td>% Caucasian</td><td>77.2</td></tr><tr><td>% Asian</td><td>21.9</td></tr><tr><td>% Single/never married/divorced/widow</td><td>27</td></tr><tr><td>% Married/de facto</td><td>73</td></tr><tr><td>High school, highest level</td><td>25.9</td></tr><tr><td>Undergraduate, highest level</td><td>49.4</td></tr><tr><td>Postgraduate, highest level</td><td>21.2</td></tr><tr><td>No history of mental illness</td><td>87.9</td></tr><tr><td>History of minor mental illness</td><td>10.4</td></tr><tr><td>History of major mental illness</td><td>1.7</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">Variables</td><td colspan="2">TdIF1 expression</td><td rowspan="2">Total</td><td rowspan="2">Χ2</td><td rowspan="2">P value</td></tr><tr><td></td><td>High</td><td>Low</td></tr><tr><td rowspan="3">Age (year)</td><td></td><td></td><td></td><td></td><td>1.298</td><td>0.254</td></tr><tr><td>≤60</td><td>24</td><td>17</td><td>41</td><td></td><td></td></tr><tr><td>>60</td><td>35</td><td>15</td><td>50</td><td></td><td></td></tr><tr><td rowspan="3">Sex</td><td></td><td></td><td></td><td></td><td>1.298</td><td>0.254</td></tr><tr><td>Female</td><td>24</td><td>17</td><td>41</td><td></td><td></td></tr><tr><td>Male</td><td>35</td><td>15</td><td>50</td><td></td><td></td></tr><tr><td rowspan="4">TNM stage</td><td></td><td></td><td></td><td></td><td>3.613</td><td>0.057</td></tr><tr><td>I/II</td><td>24</td><td>21</td><td>45</td><td></td><td></td></tr><tr><td>III/IV</td><td>30</td><td>11</td><td>41</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td>5</td><td></td><td></td></tr><tr><td rowspan="4">T stage</td><td></td><td></td><td></td><td></td><td>5.129</td><td>0.024*</td></tr><tr><td>N0</td><td>20</td><td>18</td><td>38</td><td></td><td></td></tr><tr><td>N1/N2/N3</td><td>28</td><td>8</td><td>36</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td>17</td><td></td><td></td></tr><tr><td rowspan="4">M stage</td><td></td><td></td><td></td><td></td><td>0.558</td><td>0.455</td></tr><tr><td>M0</td><td>57</td><td>32</td><td>89</td><td></td><td></td></tr><tr><td>M1</td><td>1</td><td>0</td><td>1</td><td></td><td></td></tr><tr><td>null</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Error rate (%)</td><td>Raw reads</td><td>Clean reads</td><td>Ave overall mapping rate to virus</td><td>Ave overall mapping rate to host</td></tr><tr><td colspan="6">RNA-seq</td></tr><tr><td>dcl1-9_M</td><td>0.03</td><td>47155365</td><td>46712485</td><td>0.00%</td><td>78.33%</td></tr><tr><td>dcl1-9_T</td><td>0.03</td><td>47105814</td><td>47086893</td><td>1.73%</td><td>80.17%</td></tr><tr><td>WT_M</td><td>0.03</td><td>47249649</td><td>47027652</td><td>0.19%</td><td>86.60%</td></tr><tr><td>WT_T</td><td>0.03</td><td>46493706</td><td>46186167</td><td>7.19%</td><td>85.73%</td></tr><tr><td colspan="6">sRNA-seq</td></tr><tr><td>dcl1-9_M</td><td>0.01</td><td>23404642</td><td>22422124</td><td>0.54%</td><td>63.12%</td></tr><tr><td>dcl1-9_T</td><td>0.01</td><td>22075148</td><td>21033182</td><td>52.63%</td><td>52.27%</td></tr><tr><td>WT_M</td><td>0.01</td><td>22873226</td><td>22026042</td><td>0.19%</td><td>58.76%</td></tr><tr><td>WT_T</td><td>0.01</td><td>22645661</td><td>21997229</td><td>87.46%</td><td>22.37%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>SNP id</td><td>Position</td><td>MAFa</td><td>Odds ratiob</td><td>P-valueb</td><td>PC1c</td><td>PC2c</td></tr><tr><td>rs1394371</td><td>76511524</td><td>0.32</td><td>1.110685</td><td>7.34E-02</td><td>0.238102</td><td>0.289431</td></tr><tr><td>rs12903150</td><td>76511700</td><td>0.22</td><td>0.916667</td><td>1.89E-01</td><td>20.22088</td><td>0.066403</td></tr><tr><td>rs12899131</td><td>76513940</td><td>0.38</td><td>0.973222</td><td>6.27E-01</td><td>20.36255</td><td>0.013854</td></tr><tr><td>rs2656069</td><td>76532762</td><td>0.23</td><td>0.760253</td><td>7.67E-05</td><td>0.110054</td><td>20.40066</td></tr><tr><td>rs13180</td><td>76576543</td><td>0.39</td><td>0.873685</td><td>1.75E-02</td><td>20.08845</td><td>20.374</td></tr><tr><td>rs3743079</td><td>76578116</td><td>0.17</td><td>1.075484</td><td>3.13E-01</td><td>20.2273</td><td>20.05414</td></tr><tr><td>rs3885951</td><td>76612972</td><td>0.12</td><td>1.279568</td><td>2.30E-03</td><td>0.158959</td><td>0.186958</td></tr><tr><td>rs2036534</td><td>76614003</td><td>0.24</td><td>0.698668</td><td>1.23E-07</td><td>0.120671</td><td>20.42301</td></tr><tr><td>rs2292117</td><td>76621744</td><td>0.36</td><td>0.908155</td><td>8.78E-02</td><td>20.39076</td><td>0.034655</td></tr><tr><td>rs680244</td><td>76658343</td><td>0.37</td><td>0.911216</td><td>1.03E-01</td><td>20.39566</td><td>0.037326</td></tr><tr><td>rs578776</td><td>76675455</td><td>0.29</td><td>0.738028</td><td>1.45E-06</td><td>0.085806</td><td>20.39304</td></tr><tr><td>rs12914385</td><td>76685778</td><td>0.41</td><td>1.416705</td><td>3.68E-10</td><td>0.258519</td><td>0.31863</td></tr><tr><td>rs1948</td><td>76704454</td><td>0.3</td><td>0.878962</td><td>3.10E-02</td><td>20.36327</td><td>0.013799</td></tr><tr><td>rs11636753</td><td>76716001</td><td>0.35</td><td>0.89959</td><td>6.74E-02</td><td>20.35628</td><td>0.025404</td></tr><tr><td>rs12441998</td><td>76716427</td><td>0.24</td><td>0.725298</td><td>2.24E-06</td><td>0.096535</td><td>20.36738</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Safety margin</td><td>Total prediction accuracy</td><td>Class 1 (< 25% activity)</td><td>Class 2 (> 25% activity)</td><td>Unknown</td><td>MCC</td></tr><tr><td>0</td><td>76.6</td><td>78.7</td><td>73.6</td><td>0</td><td>0.52</td></tr><tr><td>5</td><td>78.3</td><td>80.4</td><td>75.3</td><td>11.4</td><td>0.55</td></tr><tr><td>10</td><td>80.2</td><td>83.4</td><td>75.8</td><td>23.3</td><td>0.59</td></tr><tr><td>15</td><td>82.6</td><td>85.6</td><td>78.3</td><td>34.9</td><td>0.64</td></tr><tr><td>20</td><td>85.5</td><td>89.1</td><td>80.5</td><td>46.0</td><td>0.70</td></tr><tr><td>25</td><td>87.6</td><td>91.1</td><td>82.6</td><td>54.9</td><td>0.74</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Country</td><td rowspan="3">Locality</td><td rowspan="3">Coordinates (Lat; Long)</td><td rowspan="3">Source</td><td colspan="2">N</td><td rowspan="3">Molecular form</td><td colspan="6">2L arrangements and 2L PCR genotypes</td></tr><tr><td rowspan="2">Ag</td><td rowspan="2">Aa</td><td colspan="2">2L+a/2L+a</td><td colspan="2">2La/2L+a</td><td rowspan="2">2La/2La 492/492</td><td rowspan="2">HWE: χ2; P values</td></tr><tr><td>207/207</td><td>207/687</td><td>207/492</td><td>687/492</td></tr><tr><td>Cameroon</td><td>Loum</td><td>-4.100; 11.500</td><td>Colony</td><td>30</td><td>0</td><td>M</td><td>0</td><td>0</td><td>16</td><td>0</td><td>14</td><td>P = 0.6</td></tr><tr><td>Mali</td><td>Banambani</td><td>-8.050; 12.800</td><td>Colony</td><td>30</td><td>0</td><td>M</td><td>1</td><td>0</td><td>12</td><td>0</td><td>17</td><td>P = 0.9</td></tr><tr><td>Kenya</td><td>Kisumu</td><td>-0.583; 34.466</td><td>Colony</td><td>37</td><td>0</td><td>S</td><td>6</td><td>0</td><td>22</td><td>0</td><td>9</td><td>P = 0.9</td></tr><tr><td>Tanzania</td><td>Njage</td><td>-8.133; 36.683</td><td>Colony</td><td>79</td><td>0</td><td>S</td><td>2</td><td>3</td><td>23</td><td>37</td><td>14</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Lupiro</td><td>-8.377 36.667</td><td>Field</td><td>45</td><td>101</td><td>S</td><td>10</td><td>1</td><td>7</td><td>8</td><td>19</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Mkamba</td><td>-8.033; 37.767</td><td>Field</td><td>51</td><td>23</td><td>S</td><td>18</td><td>0</td><td>1</td><td>2</td><td>30</td><td>P < 0.001</td></tr><tr><td>Tanzania</td><td>Mikeregemb e</td><td>-8.036; 37.967</td><td>Field</td><td>1</td><td>138</td><td>S</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Ukindu</td><td>-8.277; 36.667</td><td>Field</td><td>0</td><td>76</td><td>N/A</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Malinyi</td><td>-8.933; 36.133</td><td>Field</td><td>1</td><td>122</td><td>S</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>-</td></tr><tr><td>Tanzania</td><td>Ilonga</td><td>-9.067; 36.855</td><td>Field</td><td>15</td><td>15</td><td>S</td><td>3</td><td>0</td><td>3</td><td>2</td><td>7</td><td>P = 0.5</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Factor</td><td colspan="2">mRNA expression</td><td colspan="2">Protein localization</td></tr><tr><td>Oocytes</td><td>Ovary</td><td>Oocyte</td><td>Ovary</td></tr><tr><td>Oct-4</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>Figα</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>NoBox</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>TAFII 105</td><td>—</td><td>+++</td><td>n/d</td><td>n/d</td></tr><tr><td>FOXL2</td><td>+</td><td>+++</td><td>—</td><td>+++</td></tr><tr><td>Oogenesin 1</td><td>+++</td><td>—</td><td>+++</td><td>—</td></tr><tr><td>Sox 3</td><td>+</td><td>++</td><td>—</td><td>—</td></tr><tr><td>Obox 1,2,3,4,5,6</td><td>++</td><td>—</td><td>n/d</td><td>n/d</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Testing set</td><td>ACC(%)</td><td>SN(%)</td><td>Spec(%)</td><td>PPV(%)</td><td>NPV(%)</td><td>F1(%)</td><td>MCC(%)</td></tr><tr><td>1</td><td>95.41</td><td>93.15</td><td>97.60</td><td>97.46</td><td>93.54</td><td>92.26</td><td>90.88</td></tr><tr><td>2</td><td>94.99</td><td>92.03</td><td>97.82</td><td>97.57</td><td>92.80</td><td>94.72</td><td>90.11</td></tr><tr><td>3</td><td>94.28</td><td>92.31</td><td>96.29</td><td>96.23</td><td>92.44</td><td>94.23</td><td>88.64</td></tr><tr><td>4</td><td>94.95</td><td>92.69</td><td>97.22</td><td>97.10</td><td>92.97</td><td>94.84</td><td>89.99</td></tr><tr><td>5</td><td>95.40</td><td>93.15</td><td>97.60</td><td>97.46</td><td>93.54</td><td>95.26</td><td>90.88</td></tr><tr><td>Average</td><td>95.01±0.46</td><td>92.67±0.5</td><td>97.31±0.61</td><td>97.16±0.55</td><td>93.06±0.48</td><td>94.26±1.18</td><td>90.1±0.92</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>conformer</td><td>E 1 (a) [kJ/mol]</td><td>E 1 (b) [kJ/mol]</td><td>conformer</td><td>E 2 (a) [kJ/mol]</td><td>E 2 (b) [kJ/mol]</td></tr><tr><td>g+ g+</td><td>7.7</td><td>0.3</td><td>g− g−</td><td>9.8</td><td>0</td></tr><tr><td>g+ t</td><td>4.7</td><td>0.8</td><td>g− t</td><td>5.3</td><td>1.4</td></tr><tr><td>t t</td><td>0</td><td>0</td><td>t t</td><td>0</td><td>0.1</td></tr><tr><td>g+ g−</td><td>13.3</td><td>3.2</td><td>g− g+</td><td>16.4</td><td>3.6</td></tr><tr><td>g− t</td><td>9.6</td><td>2.5</td><td>g+ t</td><td>10.8</td><td>1.8</td></tr><tr><td>g− g−</td><td>18.2</td><td>3.4</td><td>g+ g+</td><td>22.5</td><td>6.8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Gene</td><td>Ka</td><td>Ks</td><td>Ka/Ks</td></tr><tr><td>nd6</td><td>0.056</td><td>1.248</td><td>0.045</td></tr><tr><td>atp6</td><td>0.040</td><td>0.598</td><td>0.067</td></tr><tr><td>atp8</td><td>0.162</td><td>0.557</td><td>0.290</td></tr><tr><td>cox1</td><td>0.009</td><td>0.866</td><td>0.010</td></tr><tr><td>cox2</td><td>0.024</td><td>1.123</td><td>0.021</td></tr><tr><td>cox3</td><td>0.026</td><td>1.601</td><td>0.016</td></tr><tr><td>cytb</td><td>0.051</td><td>1.271</td><td>0.040</td></tr><tr><td>nd1</td><td>0.023</td><td>1.847</td><td>0.012</td></tr><tr><td>nd2</td><td>0.043</td><td>0.665</td><td>0.064</td></tr><tr><td>nd3</td><td>0.063</td><td>0.929</td><td>0.068</td></tr><tr><td>nd4</td><td>0.028</td><td>1.008</td><td>0.028</td></tr><tr><td>nd4l</td><td>0.040</td><td>0.874</td><td>0.046</td></tr><tr><td>nd5</td><td>0.056</td><td>1.123</td><td>0.050</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">T0</td><td colspan="2">T1</td><td colspan="2">T2</td></tr><tr><td></td><td>Mean</td><td>S.D.</td><td>Mean</td><td>S.D.</td><td>Mean</td><td>S.D.</td></tr><tr><td>A-angle(group A)</td><td>20.63</td><td>5.98</td><td>22.93</td><td>7.16</td><td>20.80</td><td>6.72</td></tr><tr><td>A-angle(group B)</td><td>18.13</td><td>8.09</td><td>20.33</td><td>7.87</td><td>18.23</td><td>7.71</td></tr><tr><td>Total</td><td>19.38</td><td>7.11</td><td>21.63</td><td>7.51</td><td>19.52</td><td>7.23</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Name</td><td>Definition</td></tr><tr><td>TAF1 [GenBank:NP004597.2]</td><td>TBP-associated factor 1 isoform 1</td></tr><tr><td>ATF2 [GenBank:NP001871.2]</td><td>activating transcription factor 2</td></tr><tr><td>GTF2B [GenBank:NP001505.1]</td><td>general transcription factor IIB</td></tr><tr><td>CCND1 [GenBank:NP444284.1]</td><td>cyclin D1</td></tr><tr><td>STAT1 [GenBank:NP009330.1]</td><td>signal transducer and activator of transcription 1 isoform alpha</td></tr><tr><td>TBP [GenBank:NP003185.1]</td><td>TATA box binding protein</td></tr><tr><td>CDKN1A [GenBank:NP000380.1]</td><td>cyclin-dependent kinase inhibitor 1A</td></tr><tr><td>CEBPB [GenBank:NP005185.2]</td><td>CCAAT/enhancer binding protein beta</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Catechins</td><td>Tea Leaves a</td><td>Tea Flowers b</td></tr><tr><td>EGCG</td><td>6.81–8.58</td><td>0.27–1.97</td></tr><tr><td>ECG</td><td>1.11–2.07</td><td>0.21–0.85</td></tr><tr><td>EGC</td><td>1.15–1.58</td><td>0.03–1.96</td></tr><tr><td>EC</td><td>0.50–0.69</td><td>0.04–0.41</td></tr><tr><td>C</td><td>0.02–0.11</td><td>0.00–0.31</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="5">Caregivers of patients with</td></tr><tr><td></td><td rowspan="3">Eating Disordersa (n=251) Mean C-index</td><td rowspan="3">Depressionb (n=252) Mean C-index</td><td rowspan="3">Schizophreniaa (n=151) Mean C-index*</td><td rowspan="3">P-value</td></tr><tr><td colspan="5">IE Q-EU scales</td></tr><tr><td>Tension</td><td>0.18 (0.19)b,c</td><td>0.17 (0.21)c,ab,ac,a</td><td>0.11 (0.17)b,ab,c</td><td>0.0002</td></tr><tr><td>Supervision</td><td>0.10 (0.19)c</td><td>0.07 (0.14)</td><td>0.06 (0.15)a</td><td>0.06</td></tr><tr><td>Worrying</td><td>0.56 (0.29)b,c</td><td>0.32 (0.31)a</td><td>0.37 (0.31)a</td><td><0.0001</td></tr><tr><td>Urging</td><td>0.21 (0.17)b,c</td><td>0.16 (0.20)a</td><td>0.21 (0.25)a</td><td><0.0001</td></tr><tr><td>Total score</td><td>0.26 (0.15)b,c</td><td>0.17 (0.16)a</td><td>0.18 (0.17)a</td><td><0.0001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Autism Group</td><td>Neurotypical Group</td></tr><tr><td>Total Participants</td><td>55</td><td>44</td></tr><tr><td>Male</td><td>49 (89%)</td><td>39 (89%)</td></tr><tr><td>Female</td><td>6 (11%)</td><td>5(11%)</td></tr><tr><td>Age (years)</td><td>10.0 +/- 3.1</td><td>11.0 +/- 3.1</td></tr><tr><td>Diagnosis</td><td>85% autism, 4% PDD/ NOS, 11% Asperger’s</td><td>In good mental and physical health</td></tr><tr><td>Medications</td><td>55% no medications 29% psycho- pharmaceuticals - primarily risperidone and clonidine; 9% on CNS stimulants (primarily Concerta); 4% on anti-convulsants 5% on GI medications; 7% on asthma/allergy medicine; 2% on insulin</td><td>89% no medications; 9% on anti-inflammatories (asthma/allergies); 2% on anti-incontinence medication</td></tr><tr><td>Special Diets</td><td>84% on regular diet; 3 gluten-free, casein-free diet; 1 gluten-free; 3 reduced dairy/gluten; 2 low sugar</td><td>1 child on dairy-free diet</td></tr><tr><td>Nutritional Supplements</td><td>1 on fish oil; 2 on melatonin</td><td>none</td></tr><tr><td>PDD-BI (modified autism composite)</td><td>-63 +/- 54</td><td>n/a</td></tr><tr><td>ATEC</td><td>64 +/- 25</td><td>n/a</td></tr><tr><td>SAS</td><td>4.9 +/- 2.4</td><td>n/a</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Parameters</td><td>Meaning</td><td>Value</td><td>Unit</td><td>Reference</td></tr><tr><td>π</td><td>Bee daily birth rate</td><td>2500</td><td>bees × day−1</td><td>[13]</td></tr><tr><td>δ</td><td>Maturation rate</td><td>0.05</td><td>day−1</td><td>[13]</td></tr><tr><td>H</td><td>Generic hygienic behavior</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>Hi</td><td>Hygienic behavior towards infested brood</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>g</td><td>Grooming</td><td>-</td><td>day−1</td><td>-</td></tr><tr><td>μ</td><td>Mortality rate</td><td>0.04</td><td>day−1</td><td>[14]</td></tr><tr><td>γ</td><td>Mite induced mortality</td><td>10−7</td><td>day−1</td><td>[11]</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">No. of the at-risk area (full name of the area)</td><td>P1 (2012–2013 and 2013–2014) Culture</td><td>P2 (2015–2016 and 2016–2017) PCR</td></tr><tr><td colspan="2">Apparent prevalence (No. of infected wild</td></tr><tr><td>rates [95% CI] boar/no. analyzed)</td><td>1 (Brotonne-Mauny forest)</td><td>1.5% [0.6–3.2%] (6/401)</td></tr><tr><td>1.3% [0.4–2.9%] (5/394)</td><td>2 (Côte-d’Or)</td><td>3.1% [1.7–5.1%] (15/483)</td></tr><tr><td>2.2% [1.0–4.2%] (9/404)</td><td>3 (Dordogne/Charente/ Charente-Maritime/Haute- Vienne/Corrèze/Gironde)</td><td>4.1% [2.4–6.4%] (17/419)</td></tr><tr><td>2.7% [1.7–4.1%] (21/770)</td><td>4 (Dordogne/Lot)</td><td>4.3% [1.9–8.2%] (8/188)</td></tr><tr><td>3.2% [1.6–5.7%] (11/341)</td><td>5 (Béarn)</td><td>2.1% [0.9–4.2%] (8/373)</td></tr><tr><td>4.4% [2.4–7.4%] (13/295)</td><td>9 (Lot-et-Garonne)</td><td>/</td></tr><tr><td>4.2% [1.6–8.9%] (6/143)</td><td>11 (Ariège/Haute-Garonne)</td><td>/</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Kdr mutation status</td><td colspan="4">2010</td><td colspan="4">2011</td></tr><tr><td rowspan="2">LLIN only arm n (%)</td><td rowspan="2">IRS-LLIN arm n (%)</td><td rowspan="2">OR (95% CI) (adjusted for clustering)</td><td rowspan="2">p value</td><td rowspan="2">LLIN only arm n (%)</td><td rowspan="2">IRS-LLIN arm n (%)</td><td rowspan="2">OR (95% CI) (adjusted for clustering)</td><td rowspan="2">p value</td></tr><tr><td>Wild type</td><td>1761 (70.3%)</td><td>1015 (58.5%)</td><td></td><td></td><td>461 (53.9%)</td><td>250 (39.6%)</td><td></td><td></td></tr><tr><td>Any Vgsc‑1014 muta‑ tion</td><td>695 (27.7%)</td><td>693 (39.9%)</td><td>1.54 (1.07–2.22)</td><td>0.02</td><td>370 (43.2%)</td><td>344 (54.4%)</td><td>2.26 (1.24–4.11)</td><td>0.01</td></tr><tr><td>Heterozygous Vgsc‑ 1014F</td><td>70 (2.8%)</td><td>103 (5.9%)</td><td>2.17 (1.28–3.68)</td><td>0.004</td><td>34 (4.0%)</td><td>31 (4.9%)</td><td>1.32 (0.75–2.33)</td><td>0.34</td></tr><tr><td>Homozygous Vgsc‑ 1014F</td><td>167 (6.7%)</td><td>290 (16.7%)</td><td>2.24 (1.12–4.49)</td><td>0.02</td><td>169 (19.7%)</td><td>196 (31.0%)</td><td>2.52 (1.20–5.29)</td><td>0.01</td></tr><tr><td>Heterozygous Vgsc‑ 1014S</td><td>412 (16.4%)</td><td>262 (15.1%)</td><td>0.86 (0.67–1.11)</td><td>0.26</td><td>149 (17.4%)</td><td>95 (15.0%)</td><td>0.71 (0.41–1.23)</td><td>0.22</td></tr><tr><td>Homozygous Vgsc‑ 1014S</td><td>46 (1.8%)</td><td>38 (2.2%)</td><td>1.09 (0.60–1.99)</td><td>0.78</td><td>18 (2.1%)</td><td>22 (3.5%)</td><td>1.34 (0.53–3.36)</td><td>0.54</td></tr><tr><td>N</td><td>2506</td><td>1736</td><td></td><td></td><td>856</td><td>632</td><td></td><td></td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Median</td><td>Mean</td><td>Range</td></tr><tr><td>Age (years)</td><td>77</td><td>76.5</td><td>53-95</td></tr><tr><td>Follow-up period (months)</td><td>49</td><td>52.0</td><td>12-143</td></tr><tr><td>PSA level at diagnosis (ng/mL)</td><td>15</td><td>28.9</td><td>1.4-200</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Label</td><td>Size (Mb)</td><td>Topology</td><td>INSDC identifier</td><td>RefSeq ID</td></tr><tr><td>Chromosome 1</td><td>2.74</td><td>circular</td><td>CP001365.1</td><td>NC012029.1</td></tr><tr><td>Chromosome 2 (pHL500)</td><td>0.53</td><td>circular</td><td>CP001366.1</td><td>NC012028.1</td></tr><tr><td>Plasmid (pHL400)</td><td>0.43</td><td>circular</td><td>CP001367.1</td><td>NC012030.1</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Variable</td><td rowspan="2">Patients, n/n</td><td rowspan="2">Patients with Variable when Increased ECFCs Frequency is Present, n</td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td>Unadjusted Odds Ratio for Increased ECFCs Frequency (95% CI)</td><td>P value</td><td>Adjusted Odds Ratio for Increased ECFCs Frequency (95% CI)</td><td>P value</td></tr><tr><td>Female sex</td><td>102/214</td><td>29</td><td>2.24 (1.09–4.69)</td><td>0.026</td><td></td><td></td></tr><tr><td>Age lower than 50 years</td><td>99/214</td><td>17</td><td>2.72 (1.28–5.68)</td><td>0.008</td><td></td><td></td></tr><tr><td>Diagnosis of prefibrotic myelofibrosis</td><td>56/214</td><td>21</td><td>2.84 (1.36–5.81)</td><td>0.005</td><td></td><td></td></tr><tr><td>Phenotype of non-active disease</td><td>27/214</td><td>13</td><td>4.67 (1.81–11.94)</td><td>0.001</td><td>4.43 (1.45–13.49)</td><td>0.008</td></tr><tr><td>History of splanchnic vein thrombosis</td><td>35/214</td><td>20</td><td>7.63 (3.34–17.91)</td><td>,0.001</td><td>6.61 (2.54–17.16)</td><td>,0.001</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Inhibitor</td><td>Other name(s)</td><td>IC50/Ki</td><td>IC50/Ki for PARP-1</td><td>IC50/Ki for PARP-2</td><td>Trial status</td><td>Type of cancer(s)</td></tr><tr><td>Olaparib</td><td>AZD2281 KU0059436</td><td>IC50</td><td>5 nM</td><td>1 nM</td><td>Phase I/II singly or combination</td><td>Breast, ovarian, colorectal, solid tumors, pancreatic, prostate, carcinoma of esophagus, head and neck squamous cells carcinoma, gastric, NSCLC, brain, CNS, Ewing’s sarcoma, uterine, fallopian tube, etc.</td></tr><tr><td>Veliparib</td><td>ABT-888</td><td>Ki</td><td>5.2 nM</td><td>2.9 nM</td><td>Phase I/II singly or combination</td><td>Breast, colorectal, GBM, melanoma, solid tumors, pancreatic, fallopian tube, peritoneal cavity, pancreatic, brain, CNS, lymphoma, multiple myeloma, etc.</td></tr><tr><td>Rucaparib</td><td>AG014699 PF01367338</td><td>Ki</td><td>1.4 nM</td><td>–</td><td>Phase I combined with chemotherapy/phase II singly in BRCA associated status</td><td>Breast, ovarian, solid tumors (also diabetes mellitus)</td></tr><tr><td>INO-1001</td><td>–</td><td>IC50</td><td>50 nM</td><td>–</td><td>Phase I/II</td><td>Cardiovascular disease/combination with TMZ in melanoma</td></tr><tr><td>MK-4827</td><td>–</td><td>IC50</td><td>3.8 nM</td><td>2.1 nM</td><td>Phase I singly or with chemotherapy/phase II</td><td>Ovarian, solid tumors, glioblastoma multiform, melanoma, lymphoma, chronic lymphocytic leukemia, T-cell-pro-lymphocytic leukemia</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>Least-squares matrix: full</td><td>H-atom parameters constrained</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.038</td><td>w = 1/[σ2(Fo 2) + (0.0379P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>wR(F2) = 0.084</td><td>(Δ/σ)max = 0.001</td></tr><tr><td>S = 0.84</td><td>Δρmax = 0.28 e Å−3</td></tr><tr><td>4303 reflections</td><td>Δρmin = −0.30 e Å−3</td></tr><tr><td>229 parameters</td><td>Extinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4</td></tr><tr><td>1 restraint</td><td>Extinction coefficient: 0.046 (2)</td></tr><tr><td>Primary atom site location: structure-invariant direct methods</td><td>Absolute structure: Flack (1983), 1878 Friedel pairs</td></tr><tr><td>Secondary atom site location: difference Fourier map</td><td>Flack parameter: 0.05 (7)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Mesh</td><td># of fly genes</td><td># of fly genes with human ortholog(s)</td><td># of fly genes shared disease categories with their human ortholog</td><td>% fly genes with human ortholog(s)</td><td>% fly genes shared disease categories with their human ortholog</td></tr><tr><td>Neoplasms</td><td>681</td><td>636</td><td>592</td><td>93%</td><td>93%</td></tr><tr><td>Pathological Conditions, Signs and Symptoms</td><td>2105</td><td>1713</td><td>1566</td><td>81%</td><td>91%</td></tr><tr><td>Nervous System Diseases</td><td>1179</td><td>1004</td><td>878</td><td>85%</td><td>87%</td></tr><tr><td>Digestive System Diseases</td><td>105</td><td>94</td><td>81</td><td>90%</td><td>86%</td></tr><tr><td>Otorhinolaryngologic Diseases</td><td>18</td><td>14</td><td>12</td><td>78%</td><td>86%</td></tr><tr><td>Mental Disorders</td><td>470</td><td>448</td><td>378</td><td>95%</td><td>84%</td></tr><tr><td>Congenital, Hereditary, and Neonatal Diseases and Abnormalities</td><td>1234</td><td>1100</td><td>900</td><td>89%</td><td>82%</td></tr><tr><td>Cardiovascular Diseases</td><td>139</td><td>126</td><td>103</td><td>91%</td><td>82%</td></tr><tr><td>Stomatognathic Diseases</td><td>20</td><td>20</td><td>16</td><td>100%</td><td>80%</td></tr><tr><td>Skin and Connective Tissue Diseases</td><td>148</td><td>123</td><td>98</td><td>83%</td><td>80%</td></tr><tr><td>Immune System Diseases</td><td>112</td><td>84</td><td>64</td><td>75%</td><td>76%</td></tr><tr><td>Respiratory Tract Diseases</td><td>8</td><td>8</td><td>6</td><td>100%</td><td>75%</td></tr><tr><td>Disorders of Environmental Origin</td><td>760</td><td>642</td><td>466</td><td>84%</td><td>73%</td></tr><tr><td>Hemic and Lymphatic Diseases</td><td>100</td><td>96</td><td>69</td><td>96%</td><td>72%</td></tr><tr><td>Endocrine System Diseases</td><td>163</td><td>144</td><td>103</td><td>88%</td><td>72%</td></tr><tr><td>Nutritional and Metabolic Diseases</td><td>577</td><td>452</td><td>310</td><td>78%</td><td>69%</td></tr><tr><td>Female Urogenital Diseases and Pregnancy Complications</td><td>558</td><td>413</td><td>276</td><td>74%</td><td>67%</td></tr><tr><td>Virus Diseases</td><td>38</td><td>32</td><td>21</td><td>84%</td><td>66%</td></tr><tr><td>Musculoskeletal Diseases</td><td>211</td><td>165</td><td>106</td><td>78%</td><td>64%</td></tr><tr><td>Male Urogenital Diseases</td><td>468</td><td>355</td><td>221</td><td>76%</td><td>62%</td></tr><tr><td>Bacterial Infections and Mycoses</td><td>325</td><td>233</td><td>99</td><td>72%</td><td>42%</td></tr><tr><td>Eye Diseases</td><td>699</td><td>590</td><td>221</td><td>84%</td><td>37%</td></tr><tr><td>Parasitic Diseases</td><td>229</td><td>187</td><td>21</td><td>82%</td><td>11%</td></tr><tr><td>All Categories</td><td>3557</td><td>2739</td><td>2283</td><td>77%</td><td>83%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Genotypes qGL3aqGL7</td><td colspan="4">qGW5aqGW9b</td></tr><tr><td>NNNN</td><td>NNCC</td><td>CCNN</td><td>CCCC</td></tr><tr><td>NNNN</td><td>3.36</td><td>3.43</td><td>3.64</td><td>3.86</td></tr><tr><td>NNCC</td><td>2.83</td><td>2.89</td><td>3.06</td><td>3.25</td></tr><tr><td>CCNN</td><td>2.48</td><td>2.53</td><td>2.68</td><td>2.84</td></tr><tr><td>CCCC</td><td>2.26</td><td>2.30</td><td>2.44</td><td>2.59</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Rank</td><td colspan="2">FD</td><td colspan="2">XS</td><td colspan="2">QH</td><td colspan="2">Total</td></tr><tr><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td><td>Gene</td><td>CV ± SD</td></tr><tr><td>1</td><td>PP2A</td><td>1.42 ± 0.34</td><td>UBC</td><td>0.60 ± 0.10</td><td>CYP</td><td>1.70 ± 0.50</td><td>UBC</td><td>2.03 ± 0.48</td></tr><tr><td>2</td><td>α-TUB</td><td>1.96 ± 0.45</td><td>GAPDH</td><td>1.00 ± 0.20</td><td>UBC</td><td>2.40 ± 0.60</td><td>EF-1α</td><td>2.22 ± 0.52</td></tr><tr><td>3</td><td>TIP41</td><td>1.75 ± 0.45</td><td>TIP41</td><td>1.00 ± 0.30</td><td>EF-1α</td><td>2.60 ± 0.60</td><td>TIP41</td><td>2.16 ± 0.56</td></tr><tr><td>4</td><td>GAPDH</td><td>2.25± 0.48</td><td>PP2A</td><td>1.50 ± 0.40</td><td>TIP41</td><td>2.30 ± 0.60</td><td>CYP</td><td>2.37 ± 0.62</td></tr><tr><td>5</td><td>UBC</td><td>2.28 ± 0.53</td><td>EF-1α</td><td>1.70 ± 0.40</td><td>α-TUB</td><td>3.10 ± 0.80</td><td>PP2A</td><td>2.64 ± 0.66</td></tr><tr><td>6</td><td>ACTIN</td><td>2.04± 0.53</td><td>ACTIN</td><td>2.10 ± 0.60</td><td>GAPDH</td><td>3.50 ± 0.80</td><td>GAPDH</td><td>3.34 ± 0.74</td></tr><tr><td>7</td><td>EF-1α</td><td>2.46 ± 0.58</td><td>α-TUB</td><td>2.40 ± 0.60</td><td>β-TUB</td><td>3.30 ± 0.80</td><td>α-TUB</td><td>3.55 ± 0.85</td></tr><tr><td>8</td><td>CYP</td><td>2.77 ± 0.71</td><td>CYP</td><td>2.20 ± 0.60</td><td>PP2A</td><td>3.30 ± 0.80</td><td>ACTIN</td><td>3.17 ± 0.85</td></tr><tr><td>9</td><td>SAMS</td><td>3.67 ± 0.76</td><td>β-TUB</td><td>2.60 ± 0.70</td><td>ACTIN</td><td>3.70 ± 1.00</td><td>β-TUB</td><td>3.53 ± 0.86</td></tr><tr><td>10</td><td>β-TUB</td><td>3.84 ± 0.90</td><td>SAMS</td><td>3.20 ± 0.70</td><td>SAMS</td><td>5.70 ± 1.20</td><td>SAMS</td><td>4.37 ± 0.91</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Modality</td><td>Model</td><td>Test sample(s)</td><td>Axon Dice similarity</td><td>Myelin Dice similarity</td><td>Pixel-wise accuracy</td><td>Sensitivity</td><td>Precision</td></tr><tr><td rowspan="3">SEM</td><td rowspan="3">Trained on rat samples</td><td>Rat 1</td><td>0.9089</td><td>0.8193</td><td>0.8510</td><td>0.9699</td><td>0.8468</td></tr><tr><td>Rat 2</td><td>0.9244</td><td>0.8389</td><td>0.8822</td><td>0.9876</td><td>0.7987</td></tr><tr><td>Human</td><td>0.8089</td><td>0.7629</td><td>0.8114</td><td>0.9300</td><td>0.7306</td></tr><tr><td rowspan="2">TEM</td><td rowspan="2">Trained on mice samples</td><td>Mice</td><td>0.9493</td><td>0.8552</td><td>0.9451</td><td>0.9597</td><td>0.9647</td></tr><tr><td>Macaque</td><td>0.9069</td><td>0.7519</td><td>0.8438</td><td>0.9429</td><td>0.8129</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Bimatoprost 0.03%, 2.5 mL</td><td>Bimatoprost 0.03%, 5.0 mL ($ per 2.5 mL)</td><td>Latanoprost 0.005%, 2.5 mL</td><td>Travoprost 0.004%, 2.5 mL</td></tr><tr><td>Walgreens</td><td>$54.99</td><td>$52.50</td><td>$53.99</td><td>--</td></tr><tr><td>Park Pharmacy</td><td>$51.95</td><td>$50.98</td><td>$49.95</td><td>$49.95</td></tr><tr><td>WalMart</td><td>$51.46</td><td>$51.89</td><td>$40.98</td><td>$48.62</td></tr><tr><td>Winn Dixie</td><td>$44.50</td><td>$44.50</td><td>$46.00</td><td>$47.00</td></tr><tr><td>K-Mart</td><td>$56.97</td><td>$51.99</td><td>$49.99</td><td>$53.97</td></tr><tr><td>Target</td><td>$56.39</td><td>$51.35</td><td>$41.99</td><td>$53.69</td></tr><tr><td>DrugStore.Com</td><td>$50.10</td><td>$50.10</td><td>$46.90</td><td>$47.40</td></tr><tr><td>Average</td><td>$52.34</td><td>$50.47</td><td>$47.11</td><td>$50.11</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Primary atom site location: structure-invariant direct methods</td></tr><tr><td>Least-squares matrix: full</td><td>Secondary atom site location: difference Fourier map</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.041</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>wR(F2) = 0.140</td><td>H-atom parameters constrained</td></tr><tr><td>S = 1.11</td><td>w = 1/[σ2(Fo 2) + (0.0893P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>15185 reflections</td><td>(Δ/σ)max < 0.001</td></tr><tr><td>582 parameters</td><td>Δρmax = 0.83 e Å−3</td></tr><tr><td>1 restraint</td><td>Δρmin = −0.88 e Å−3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td rowspan="2">COG ID</td><td rowspan="2">Estimated No. of truly existing CDSs</td><td colspan="2">Read Counts</td></tr><tr><td></td><td>By BLAST</td><td>By RPS-BLAST</td></tr><tr><td rowspan="3">Step 1</td><td>COG0454</td><td>0</td><td>362</td><td>0</td></tr><tr><td>COG0500</td><td>2</td><td>658</td><td>0</td></tr><tr><td>COG0477</td><td>0</td><td>2283</td><td>85</td></tr><tr><td rowspan="2">Step 2</td><td>COG0457</td><td>0</td><td>101</td><td>0</td></tr><tr><td>COG0639</td><td>2</td><td>58</td><td>0</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Electron donor</td><td rowspan="3">Concentration (mM)</td><td colspan="4">Specific activity (U mg21)a</td></tr><tr><td colspan="2">FepB</td><td colspan="2">HRP</td></tr><tr><td>pH 3.3</td><td>pH 4.7</td><td>pH 3.3</td><td>pH 4.7</td></tr><tr><td>Catechol</td><td>10</td><td>0.3060.04</td><td>nd</td><td>179.165.0</td><td>413.1635.6</td></tr><tr><td>ABTS</td><td>1.5</td><td>39.466.3</td><td>0.7060.05</td><td>1.3260.12</td><td>42066.6</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">Ocln</td><td colspan="2">ZO-1</td><td colspan="2">Cldn-1</td><td colspan="2">Cldn-4</td></tr><tr><td></td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td><td>Pos</td><td>Neg</td></tr><tr><td colspan="9">Tumor grading</td></tr><tr><td>I</td><td>57.1%</td><td>25.9%</td><td>27.3%</td><td>25.0%</td><td>32.5%</td><td>50%</td><td>20.8%</td><td>40%</td></tr><tr><td>II</td><td>28.6%</td><td>40.7%</td><td>45.4%</td><td>37.5%</td><td>42.5%</td><td>25%</td><td>50%</td><td>20%</td></tr><tr><td>III</td><td>14.3%</td><td>33.4%</td><td>27.3%</td><td>37.5%</td><td>25%</td><td>25%</td><td>29.2%</td><td>40%</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td colspan="8">A) Toxicogenomics study</td></tr><tr><td rowspan="2">GO category</td><td rowspan="2">Original Annotation</td><td rowspan="2">Non redundant Annotations</td><td colspan="3">SELECTIONS</td><td rowspan="2">STEM</td><td rowspan="2">Pair-wise</td></tr><tr><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td></tr><tr><td>BP</td><td>1828</td><td>967</td><td>7</td><td>33</td><td>15</td><td></td><td></td></tr><tr><td>MF</td><td>992</td><td>534</td><td>8</td><td>15</td><td>20</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>398</td><td>243</td><td>0</td><td>10</td><td>8</td><td></td><td></td></tr><tr><td></td><td>total</td><td>15</td><td>58</td><td>43</td><td>0</td><td>49</td></tr><tr><td colspan="8">B) Potato Stress study</td></tr><tr><td></td><td></td><td></td><td colspan="3">SELECTIONS</td><td></td><td></td></tr><tr><td>GO category</td><td>Original Annotation</td><td>Non redundant Annotations</td><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td><td>STEM</td><td>Pair-wise</td></tr><tr><td>BP</td><td>2444</td><td>780</td><td>23</td><td>258</td><td>116</td><td></td><td></td></tr><tr><td>MF</td><td>943</td><td>431</td><td>21</td><td>141</td><td>29</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>369</td><td>203</td><td>14</td><td>48</td><td>46</td><td></td><td></td></tr><tr><td></td><td>total</td><td>58</td><td>447</td><td>191</td><td>0</td><td>46</td></tr><tr><td colspan="8">C) Arabidopsis IAA study</td></tr><tr><td></td><td></td><td></td><td colspan="3">SELECTIONS</td><td></td><td></td></tr><tr><td>GO category</td><td>Original Annotation</td><td>Non redundant Annotations</td><td>maSigFun</td><td>PCA-maSigFun</td><td>ASCA-Functional</td><td>STEM</td><td>Pair-wise</td></tr><tr><td>BP</td><td>2640</td><td>1120</td><td>3</td><td>60</td><td>201</td><td></td><td></td></tr><tr><td>MF</td><td>1769</td><td>694</td><td>8</td><td>24</td><td>45</td><td></td><td></td></tr><tr><td rowspan="2">CC</td><td>499</td><td>260</td><td>0</td><td>8</td><td>61</td><td></td><td></td></tr><tr><td></td><td>total</td><td>11</td><td>92</td><td>307</td><td>46</td><td>284</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Plasmid</td><td>Size (bp)</td><td>Characteristics</td><td>Reference</td></tr><tr><td>pCD256</td><td>4790</td><td>pUC19 containing origin from p256, AmpR, CmR</td><td>[19]</td></tr><tr><td>pCDWV01</td><td>3514</td><td>pUC19 containing origin from pWV01, AmpR, CmR</td><td>[19]</td></tr><tr><td>pCD256_hTFF1</td><td>5362</td><td>pCD256 containing hTFF1 expression cassette</td><td></td></tr><tr><td>pCD256ΔEc</td><td>1690</td><td>pCD256 lacking E. coli sequences</td><td rowspan="2">this study</td></tr><tr><td>pCD256ΔEc_hTFF1</td><td>2302</td><td>pCD256ΔEc containing hTFF1 expression cassette</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Sample</td><td>Counts Prior Filtering</td><td>Counts after Filtering</td></tr><tr><td>Blank</td><td>3824</td><td>NA</td></tr><tr><td>FI3</td><td>78,903</td><td>78,881</td></tr><tr><td>FI9</td><td>24,956</td><td>24,495</td></tr><tr><td>FI12</td><td>56,971</td><td>56,846</td></tr><tr><td>NASD3</td><td>32,086</td><td>14,768</td></tr><tr><td>NASD14</td><td>44,255</td><td>24,740</td></tr><tr><td>NASD22</td><td>60,266</td><td>55,727</td></tr><tr><td>NASD27</td><td>24,633</td><td>13,392</td></tr><tr><td>NASD29</td><td>101,517</td><td>100,028</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Acetylase/ Deacetylase</td><td>Loss/Gain of function</td><td>Physiological roles</td><td>References</td></tr><tr><td>CBP</td><td>Loss</td><td>Increased insulin sensitivity and glucose tolerance</td><td>Yamauchi et al. (2002)</td></tr><tr><td>CBP/p300</td><td>Loss</td><td>Improved insulin sensitivity with reduction in body mass Decreased glucose production</td><td>Bedford et al. (2011) He et al. (2012)</td></tr><tr><td>p300</td><td>Gain</td><td>Impaired insulin sensitivity and glucose tolerance</td><td>Bricambert et al. (2010)</td></tr><tr><td rowspan="2">SIRT1</td><td>Loss</td><td>Impaired insulin sensitivity and glucose tolerance Increased fatty liver development</td><td>Chalkiadaki and Guarente (2012) Xu et al. (2010)</td></tr><tr><td>Gain</td><td>Improved insulin sensitivity and glucose tolerance</td><td>Banks et al. (2008), Li et al. (2011)</td></tr><tr><td>HDAC3</td><td>Loss</td><td>Improved insulin sensitivity and glucose tolerance, despite of increased lipid accumulation</td><td>Sun et al. (2012)</td></tr><tr><td>Class IIa HDAC</td><td>Loss</td><td>Improved glucose tolerance by inhibiting gluconeogenesis</td><td>Mihaylova et al. (2011)</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Time/group</td><td>3h</td><td>24h</td><td>72h</td></tr><tr><td>100%CL</td><td>10.13 (0.89)Bab</td><td>8.7 (0.45)Cab</td><td>7.35 (0.08)Aa</td></tr><tr><td>100%PG</td><td>10.19 (0.4)Ab</td><td>9.44 (0.72)Ac</td><td>7.4 (0.09)Bab</td></tr><tr><td>50% CL+50% PG</td><td>8.54 (0.63)Ac</td><td>8.54 (0.14)Aa</td><td>7.39 (0.22)Bab</td></tr><tr><td>80% CL+20% PG</td><td>9.42 (0.51)Aa</td><td>9.08 (0.16)Abc</td><td>7.56 (0.2)Bb</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Clinical parameter</td><td>Negative Tau expression</td><td>Positive Tau expression</td><td>p value</td></tr><tr><td colspan="4">Age</td></tr><tr><td>o < 65</td><td>16</td><td>44</td><td rowspan="2">p= ,8496</td></tr><tr><td>o ≥ 65</td><td>4</td><td>10</td></tr><tr><td colspan="4">FIGO stage at diagnosis</td></tr><tr><td>o Early (I,II)</td><td>7</td><td>10</td><td rowspan="2">p= ,1345</td></tr><tr><td>o Advanced (III,IV)</td><td>13</td><td>44</td></tr><tr><td colspan="4">Histopathologic cell type</td></tr><tr><td>o Serous</td><td>8</td><td>29</td><td rowspan="2">p= ,2951</td></tr><tr><td>o others</td><td>12</td><td>25</td></tr><tr><td colspan="4">Performance status (ECOG)</td></tr><tr><td>o 0-1</td><td>19</td><td>50</td><td rowspan="2">p= ,8768</td></tr><tr><td>o 2</td><td>1</td><td>4</td></tr><tr><td colspan="4">Tumor grade</td></tr><tr><td>o G1,G2</td><td>12</td><td>19</td><td rowspan="2">p= ,0547</td></tr><tr><td>o G3, unknown</td><td>8</td><td>35</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="3">Age (years)</td><td>Min</td><td>18</td></tr><tr><td>Mean</td><td>52</td></tr><tr><td>Max</td><td>83</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>81 (21.5 %)</td></tr><tr><td>Female</td><td>296 (78.5 %)</td></tr><tr><td rowspan="3">Disease duration (years)</td><td>Min</td><td>0.3</td></tr><tr><td>Mean</td><td>7.3</td></tr><tr><td>Max</td><td>39.7</td></tr><tr><td rowspan="3">DAS28-CRP score</td><td>Min</td><td>3.6</td></tr><tr><td>Mean</td><td>5.9</td></tr><tr><td>Max</td><td>7.9</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Refinement on F2</td><td>Primary atom site location: structure-invariant direct methods</td></tr><tr><td>Least-squares matrix: full</td><td>Secondary atom site location: difference Fourier map</td></tr><tr><td>R[F2 > 2σ(F2)] = 0.051</td><td>Hydrogen site location: inferred from neighbouring sites</td></tr><tr><td>wR(F2) = 0.167</td><td>H-atom parameters constrained</td></tr><tr><td>S = 1.05</td><td>w = 1/[σ2(Fo 2) + (0.0656P)2] where P = (Fo 2 + 2Fc 2)/3</td></tr><tr><td>5479 reflections</td><td>(Δ/σ)max = 0.001</td></tr><tr><td>290 parameters</td><td>Δρmax = 1.26 e Å−3</td></tr><tr><td>42 restraints</td><td>Δρmin = −1.31 e Å−3</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Generator</td><td>Power (MW)</td></tr><tr><td>1</td><td>110.802</td></tr><tr><td>2</td><td>110.800</td></tr><tr><td>3</td><td>97.400</td></tr><tr><td>4</td><td>179.733</td></tr><tr><td>5</td><td>87.800</td></tr><tr><td>6</td><td>140.000</td></tr><tr><td>7</td><td>259.600</td></tr><tr><td>8</td><td>284.601</td></tr><tr><td>9</td><td>284.599</td></tr><tr><td>10</td><td>130.000</td></tr><tr><td>11</td><td>94.000</td></tr><tr><td>12</td><td>94.001</td></tr><tr><td>13</td><td>214.760</td></tr><tr><td>14</td><td>394.279</td></tr><tr><td>15</td><td>394.279</td></tr><tr><td>16</td><td>394.278</td></tr><tr><td>17</td><td>489.280</td></tr><tr><td>18</td><td>489.279</td></tr><tr><td>19</td><td>511.279</td></tr><tr><td>20</td><td>511.279</td></tr><tr><td>21</td><td>523.280</td></tr><tr><td>22</td><td>523.279</td></tr><tr><td>23</td><td>523.278</td></tr><tr><td>24</td><td>523.279</td></tr><tr><td>25</td><td>523.279</td></tr><tr><td>26</td><td>523.280</td></tr><tr><td>27</td><td>10.000</td></tr><tr><td>28</td><td>10.000</td></tr><tr><td>29</td><td>10.000</td></tr><tr><td>30</td><td>87.800</td></tr><tr><td>31</td><td>189.999</td></tr><tr><td>32</td><td>190.000</td></tr><tr><td>33</td><td>190.000</td></tr><tr><td>34</td><td>164.800</td></tr><tr><td>35</td><td>199.996</td></tr><tr><td>36</td><td>194.401</td></tr><tr><td>37</td><td>110.000</td></tr><tr><td>38</td><td>110.000</td></tr><tr><td>39</td><td>110.000</td></tr><tr><td>40</td><td>511.279</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Group</td><td>Pooled Effect Estimate 95% CI</td><td>I2%</td><td>Number of Observations</td></tr><tr><td>All citations</td><td>1.65 (1.47, 1.85)</td><td>89.9</td><td>51</td></tr><tr><td>Case-control citations</td><td>1.70 (1.42, 2.03)</td><td>88.7</td><td>37</td></tr><tr><td>Cohort citations</td><td>1.64 (1.30, 2.08)</td><td>87.8</td><td>14</td></tr><tr><td>Asia</td><td>3.26(1.91, 5.58)</td><td>0.0</td><td>3</td></tr><tr><td>Canada</td><td>1.22 (1.09, 1.37)</td><td>82.1</td><td>14</td></tr><tr><td>Europe</td><td>1.90 (1.35, 2.66)</td><td>75.5</td><td>10</td></tr><tr><td>USA</td><td>1.70 (1.41, 2.04)</td><td>73.3</td><td>24</td></tr><tr><td>Studies reported adjusted effect estimates</td><td>1.78 (1.56, 2.02)</td><td>92.2</td><td>37</td></tr><tr><td>Studies reported unadjusted effect estimates</td><td>1.27 (0.93, 1.71)</td><td>59.4</td><td>14</td></tr><tr><td>PPI ascertainment method (Chart){</td><td>1.89 (1.45, 2.45)</td><td>93.6</td><td>20</td></tr><tr><td>PPI ascertainment method (Interview){</td><td>1.17 (0.91, 1.51)</td><td>79.0</td><td>8</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Pathogen</td><td colspan="4">Geographical location</td><td colspan="2">Sepsis severitya,b</td><td colspan="3">Clinical diagnosis</td><td rowspan="2">Overall urosepsis</td></tr><tr><td>Europe n (%)</td><td>Asia n (%)</td><td>Africa n (%)</td><td>Americas n (%)</td><td>Simple urosepsis n (%)</td><td>Severe urosepsis and uroseptic shock n (%)</td><td>MAGI n (%)</td><td>Pyelone- phritis n (%)</td><td>Cystitis n (%)</td></tr><tr><td colspan="11">Gram negative</td></tr><tr><td>E. coli</td><td>127 (41 %)</td><td>34 (52 %)</td><td>8 (38 %)</td><td>5 (50 %)</td><td>121 (46.9 %)</td><td>29 (37.2 %)</td><td>77 (37 %)</td><td>190 (45 %)</td><td>240 (43 %)</td><td>174 (43 %)</td></tr><tr><td>Klebsiella spp.</td><td>25 (8 %)</td><td>8 (11 %)</td><td>6 (29 %)</td><td>3 (30 %)</td><td>24 (9.3 %)</td><td>9 (11.5 %)</td><td>17 (8 %)</td><td>54 (13 %)</td><td>73 (13 %)</td><td>42 (10 %)</td></tr><tr><td>P. aeruginosa</td><td>39 (13 %)</td><td>3 (5 %)</td><td>0</td><td>0</td><td>24 (9.3 %)</td><td>11 (14. %1)</td><td>25 (12 %)</td><td>34 (8 %)</td><td>48 (9 %)</td><td>42 (10 %)</td></tr><tr><td>Enterobacter spp.</td><td>19 (6 %)</td><td>2 (3 %)</td><td>0</td><td>2 (20 %)</td><td>14 (5.4 %)</td><td>6 (7.7 %)</td><td>13 (6 %)</td><td>20 (5 %)</td><td>42 (7 %)</td><td>23 (6 %)</td></tr><tr><td>Proteus spp.</td><td>14 (4 %)</td><td>0</td><td>2 (10 %)</td><td>0</td><td>7 (2.7)</td><td>4 (5.1)</td><td>7 (3 %)</td><td>27 (6 %)</td><td>34 (6 %)</td><td>16 (4 %)</td></tr><tr><td>Acinetobacter spp.</td><td>2 (1 %)</td><td>5 (8 %)</td><td>0</td><td></td><td>3 (1.2 %)</td><td>3 (3.8 %)</td><td>1 (1 %)</td><td>6 (1 %)</td><td>9 (2 %)</td><td>7 (2 %)</td></tr><tr><td>Citrobacter spp.</td><td>3 (1 %)</td><td>1 (2 %)</td><td>0</td><td>0</td><td>2 (0.8 %)</td><td>0</td><td>2 (1 %)</td><td>7 (2 %)</td><td>8 (1 %)</td><td>4 (1 %)</td></tr><tr><td colspan="11">Gram positive</td></tr><tr><td>Enterococcus.</td><td>37 (12 %)</td><td>5 (8 %)</td><td>4 (19 %)</td><td>0</td><td>27 (10.5 %)</td><td>9 (11.5 %)</td><td>23 (11 %)</td><td>41 (10 %)</td><td>55 (10 %)</td><td>46 (11 %)</td></tr><tr><td>S. aureus</td><td>12 (4 %)</td><td>3 (5 %)</td><td>0</td><td>0</td><td>12 (4.7 %)</td><td>2 (2.6 %)</td><td>7 (3 %)</td><td>7 (2 %)</td><td>18 (3 %)</td><td>15 (4 %)</td></tr><tr><td>CoNS</td><td>8 (3 %)</td><td>1 (2 %)</td><td>0</td><td>0</td><td>7 (2.7 %)</td><td>0</td><td>11 (5 %)</td><td>6 (1 %)</td><td>9 (2 %)</td><td>9 (2 %)</td></tr><tr><td>Other gram (+) cocci</td><td>4 (1 %)</td><td>0</td><td>1 (5 %)</td><td>0</td><td>3 (1.2)</td><td>0 (0.0)</td><td>4 (2 %)</td><td>0</td><td>4 (1 %)</td><td>5 (1 %)</td></tr><tr><td>Other bacteria</td><td>13 (4 %)</td><td>0</td><td>0</td><td>0</td><td>9 (3.5 %)</td><td>3 (3.8 %)</td><td>18 (9 %)</td><td>21 (5 %)</td><td>17 (3 %)</td><td>13 (3 %)</td></tr><tr><td>Fungi</td><td>8 (3 %)</td><td>4 (6 %)</td><td>0</td><td>0</td><td>5 (1.9 %)</td><td>2 (2.6 %)</td><td>2 (1 %)</td><td>14 (3 %)</td><td>7 (1 %)</td><td>12 (3 %)</td></tr><tr><td>Total</td><td>311</td><td>66</td><td>21</td><td>10</td><td>258</td><td>78</td><td>207</td><td>427</td><td>564</td><td>408</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td>Partial Correlation Coefficient</td><td>t Value</td><td>Significance</td></tr><tr><td colspan="4">Dependent variable: Pimax</td></tr><tr><td>cACE activity</td><td>0.262</td><td>2.899</td><td>0.0045</td></tr><tr><td>Weight at measurement</td><td>0.244</td><td>2.697</td><td>0.0081</td></tr><tr><td>ACE genotypes</td><td></td><td>0.317</td><td>0.752</td></tr><tr><td>Postmenstrual age</td><td></td><td>0.283</td><td>0.778</td></tr><tr><td>Gender</td><td></td><td>0.077</td><td>0.939</td></tr><tr><td>Duration of mechanicalventilation</td><td></td><td>1.451</td><td>0.150</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>miRNA ID</td><td>Control Average</td><td>FM Average</td><td>Ratio C/FM Average</td></tr><tr><td>hsa-miR-223-3p</td><td>66736.98</td><td>10577.74</td><td>6.31</td></tr><tr><td>hsa-miR-451a</td><td>4830.07</td><td>358.62</td><td>13.47</td></tr><tr><td>hsa-miR-338-3p</td><td>374.20</td><td>32.22</td><td>11.62</td></tr><tr><td>hsa-miR-143-3p</td><td>506.26</td><td>45.42</td><td>11.15</td></tr><tr><td>hsa-miR-145-5p</td><td>546.05</td><td>52.58</td><td>10.39</td></tr><tr><td>hsa-miR-21-5p</td><td>5470.04</td><td>1409.50</td><td>3.88</td></tr><tr><td>hsa-miR-1908-5p</td><td>762.60</td><td>660.45</td><td>1.15</td></tr><tr><td>hsa-miR-1260b</td><td>23676.19</td><td>17356.79</td><td>1.36</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Laxative type</td><td>Examples</td><td>Proposed mode of action</td><td>Potential limitations</td></tr><tr><td>Dietary ﬁber/bulking agents</td><td>Wheat bran Psyllium seed husk Methylcellulose</td><td>Luminal water binding increases stool bulk and reduces consistency</td><td>Flatulence and abdominal distension Stool impaction (rarely) Not recommended in frail, immobile, or palliative care patients</td></tr><tr><td colspan="4">Osmotic laxatives</td></tr><tr><td>Undigestible disaccharides and sugar alcohols</td><td>Lactulose Sorbitol</td><td>Luminal water binding by creating an osmotic gradient</td><td>Bloating, ﬂatulence</td></tr><tr><td>Synthetic macromolecules</td><td>PEG Polycarbophil</td><td>Luminal water binding</td><td>Bloating</td></tr><tr><td>Salinic laxatives</td><td>Magnesium hydroxide (e.g., milk of magnesia) Magnesium citrate Magnesium sulfate Sodium phosfate</td><td>Luminal water binding Increases ﬂuid excretion</td><td>Electrolyte imbalance (must be used with caution in patients with compromised renal or cardiac function)</td></tr><tr><td colspan="4">Stimulant laxatives</td></tr><tr><td>Diphenylmethane derivatives</td><td>Bisacodyl, sodium picosulfate</td><td>Act locally to stimulate colonic motility, decrease water absorption from large intestine</td><td>Abdominal discomfort and cramps</td></tr><tr><td>Anthraquinones</td><td>Senna, aloe, cascara</td><td>Act locally to stimulate colonic motility, decrease water absorption from large intestine</td><td>Abdominal discomfort and cramps</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td></td><td colspan="2">Intervention Group (n = 212)</td><td colspan="4">Control Group (n = 217)</td></tr><tr><td></td><td>At Admission</td><td>At Discharge</td><td>p-Value b</td><td>At Admission</td><td>At Discharge</td><td>p-Value b</td></tr><tr><td>Anticholinergic drugs, n (%)</td><td>15 (7.1)</td><td>7 (3.3)</td><td>0.005</td><td>12 (5.5)</td><td>9 (4.1)</td><td>0.083</td></tr><tr><td>Propiomazine, n (%)</td><td>6 (2.8)</td><td>5 (2.4)</td><td>0.317</td><td>6 (2.8)</td><td>6 (2.8)</td><td>-</td></tr><tr><td>Tramadol, n (%)</td><td>4 (1.9)</td><td>3 (1.4)</td><td>0.317</td><td>5 (2.3)</td><td>4 (1.8)</td><td>0.317</td></tr><tr><td>Long-acting benzodiazepines, n (%)</td><td>1 (0.5)</td><td>1 (0.5)</td><td>-</td><td>6 (2.8)</td><td>6 (2.8)</td><td>-</td></tr><tr><td>Antipsychotic drug use, n (%)</td><td>16 (7.5)</td><td>16 (7.5)</td><td>-</td><td>12 (5.5)</td><td>13 (6.0)</td><td>0.317</td></tr><tr><td>NSAID, n (%)</td><td>7 (3.3)</td><td>2 (0.9)</td><td>0.025</td><td>11 (5.1)</td><td>9 (4.1)</td><td>0.157</td></tr><tr><td>Potentially inappropriate medication a, n (%)</td><td>43 (20.3)</td><td>30 (14.2)</td><td>0.002</td><td>45 (20.7)</td><td>40 (18.4)</td><td>0.025</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td>Likely</td><td>Possible</td></tr><tr><td>Diﬀuse cutaneous subtype</td><td rowspan="5">Anti-topoisomerase antibodies</td></tr><tr><td>Anti-centromere antibodies</td></tr><tr><td>Current smoking</td></tr><tr><td>Anti-beta2-glycoprotein I antibodies</td></tr><tr><td>Anti-granzyme B antibodies</td></tr></tbody></table> <\|md_end\|>
	<\|im_start\|>user <image> <\|im_end\|> <\|md_start\|> <table><tbody><tr><td rowspan="2">Characteristics</td><td rowspan="2">All patients (n = 763)</td><td rowspan="2">MACE (n = 254)</td><td rowspan="2">No MACE (n = 509)</td><td rowspan="2">P value</td></tr><tr><td>Age in years, μ (σ)</td><td>60.49 (13.33)</td><td>61.75 (11.86)</td><td>59.86 (13.97)</td><td>0.001</td></tr><tr><td>Men</td><td>496 (64.9)</td><td>185 (72.8)</td><td>310 (60.9)</td><td>0.001</td></tr><tr><td>Race</td><td></td><td></td><td></td><td>0.647</td></tr><tr><td>Chinese</td><td>489 (64.1)</td><td>168 (66.1)</td><td>321 (63.1)</td><td></td></tr><tr><td>Malay</td><td>144 (18.9)</td><td>47 (18.5)</td><td>97 (19.1)</td><td></td></tr><tr><td>Indian</td><td>106 (13.9)</td><td>30 (11.8)</td><td>76 (14.9)</td><td></td></tr><tr><td>Other</td><td>24 (3.1)</td><td>9 (3.5)</td><td>15 (2.9)</td><td></td></tr><tr><td colspan="5">Medical history</td></tr><tr><td>IHD</td><td>336 (44.0)</td><td>115 (45.3)</td><td>221 (43.4)</td><td>0.643</td></tr><tr><td>DM</td><td>275 (36.0)</td><td>113 (44.5)</td><td>162 (31.8)</td><td>0.001</td></tr><tr><td>Hypertension</td><td>492 (64.5)</td><td>173 (68.1)</td><td>319 (62.7)</td><td>0.149</td></tr><tr><td>Hyperlipidemia</td><td>456 (59.8)</td><td>148 (58.3)</td><td>308 (60.5)</td><td>0.584</td></tr><tr><td>Previous stroke</td><td>60 (7.9)</td><td>19 (7.5)</td><td>41 (8.1)</td><td>0.887</td></tr><tr><td>Cancer</td><td>32 (4.2)</td><td>8 (3.1)</td><td>24 (4.7)</td><td>0.345</td></tr><tr><td>Respiratory disease</td><td>31 (4.1)</td><td>4 (1.6)</td><td>27 (5.3)</td><td>0.012</td></tr><tr><td>Renal disease</td><td>96 (12.6)</td><td>34 (13.4)</td><td>62 (12.2)</td><td>0.644</td></tr><tr><td>CHF</td><td>39 (5.1)</td><td>10 (3.9)</td><td>29 (5.7)</td><td>0.383</td></tr><tr><td>Previous PCI</td><td>175 (22.9)</td><td>64 (25.2)</td><td>111 (21.8)</td><td>0.315</td></tr><tr><td>Previous CABG</td><td>70 (9.2)</td><td>25 (9.8)</td><td>45 (8.8)</td><td>0.690</td></tr><tr><td>Previous MI</td><td>114 (14.9)</td><td>41 (16.1)</td><td>73 (14.3)</td><td>0.519</td></tr><tr><td>Disposition from ED</td><td></td><td></td><td></td><td><0.001</td></tr><tr><td>Admission to GW</td><td>354 (46.4)</td><td>96 (37.8)</td><td>258 (50.7)</td><td></td></tr><tr><td>Admission to ICW</td><td>176 (23.1)</td><td>141 (55.5)</td><td>35 (6.9)</td><td></td></tr><tr><td>No admission</td><td>233 (30.5)</td><td>17 (6.7)</td><td>216 (42.4)</td><td></td></tr></tbody></table> <\|md_end\|>